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DAMPs   Damage associated Molecular patterns.   
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MALDI-MS Matrix-assisted laser desorption/ionization- Mass 
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MET   Mesenchymal epithelial transition. 
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Abstract: 
  
Cancers are amongst the leading cause of morbidity and 
mortality today. Besides the tremendous amount of research, it 
still appears to be a long way till we can fully understand the 
pathology and find its cure. Scientists are still striving to find 
out the precise pathogenesis, factors leading to progression and 
the mechanisms of spread of cancers. The ultimate objective is 
to find out how these can be prevented and treated. Many 
molecules are a focus of attention in this regard and CD24 is 
amongst them. CD24 is normally present on haematopoietic 
cells and embryonal epithelial cells but the expression is 
generally lost with cellular maturity and differentiation. 
Upregulation of CD24 has been documented in a large variety 
of cancers, besides non-malignant pathologies. In the recent 
literature, CD24 has been linked to significant cancer associated 
properies such as proliferation, metastasis and cancer stem 
cells. It is an interesting molecule with a very small protein core 
decorated with heavy glycosylation. The pattern and 
composition of CD24 glycosylation also varies within different 
tissues. This study attempted to explore the molecule a bit 
further regarding its structure, functions, molecular interactions 
and possible downstream signalling partners. 
The first part of the project was to evaluate the possible effects 
of CD24 in mediating cellular response to DAMPs (Damage 
Associated Molecular Patterns) in colorectal cancer cell lines. 
Malignancies have increased CD24 levels and there is increased 
tissue damage and necrosis thereby release of DAMPs (Damage 
Associated Molecular Patterns) in their microenvironment. The 
effects of CD24 on modulation of DAMPs response were 
analysed by exposing cells to autologous DAMPs and performing 
functional assays (migration and proliferation assays). 
 Abstract.  
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The results of wound healing assay showed significant inhibition 
of colorectal cell migration by DAMPs but this was independent 
of CD24 status. Furthermore, transwell assays also showed 
significantly reduced directional motility, independent of CD24 
status, in cells exposed to autologous DAMPs. The study also 
tested the effects of DAMPs on cellular proliferation in three 
colorectal cancer cell lines using Presto Blue assay. The results 
indicated a significant increase in cellular proliferation when 
exposed to DAMPs, irrespective of the CD24 status of the cell 
line. We proposed thereby that in colorectal cancer cells, CD24 
does not appear to modulate cellular response to DAMPs unlike 
seen in immune cells. Nevertheless, DAMPs did show effects on 
autologous cell migration and proliferation. However it is 
acknowledged that the arguments can be strengthened by the 
use of purified DAMPs to demonstrate similar results and also 
by showing abrogation of effects after addition of anti-DAMPs 
antibodies to our functional assays. 
Another interesting aspect of CD24 is its localisation in the cell 
membrane. It is attached to the cell membrane via GPI anchor 
and resides in lipid rafts. Interestingly, it has no cytoplasmic or 
transmembrane domains that are used by most signalling 
molecules. It is unclear how CD24 molecule mediates diverse 
cellular properties and molecular responses in the absence of 
traditional signalling domains. 
The second part of this study was aimed at exploring some of 
the potential signalling partners and their functional relevance 
if any to CD24. The study explored Cten and CD24 interactions, 
as both molecules are proposed to be mediators of increased 
cellular motility. CD24 and Cten were also observed to have 
some common downstream signalling targets. In addition, the 
expression levels of both molecules also presented similar 
trends amid different cancer cell lines. 
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The above observations led us to contemplate if the two 
molecules have mutual signalling and functional relationship. 
We observed that CD24 up regulation led to increased 
levels of Cten protein, whereas, knock down of CD24 resulted 
in down regulation of Cten protein. Also the results of our 
functional studies showed that the knockdown of Cten in co-
transfection experiments abrogated the increased cell motility 
by CD24. Based on these observations we proposed that CD24 
appears to modulate Cten levels and this regulation has 
significant functional relevance as well. The Co-
immunoprecipitation experiments indicated that these two 
molecules did not seem to have physical interaction with each 
other, suggesting the possibility that the regulation of Cten by 
CD24 may be arbitrated by intermediate molecules. 
Similarly, we also investigated the molecular relationship 
between CD24, ILK and FAK using co-transfection technique. 
The results revealed enhanced cell migration through the 
membrane by CD24 but it was reduced after the knock down of 
both ILK and FAK. These findings provide further insight that 
not only these molecules are being regulated by CD24 as 
proposed by many recent studies but are also functionally 
relevant. The current study proposed that the increased cancer 
cell motility demonstrated by CD24 may well be mediated 
through FAK and ILK in addition to Cten. The argument needs 
further validation as the confirmation of successful transfection 
and expression levels by western blots are missing in this study. 
This is recognised as a limitation. 
Being heavily glycosylated CD24 is considered a mucin- like 
molecule and many studies point towards the possibility of its 
functional diversity to be related to these sugars. But to  date 
not much is known about this aspect of CD24. Hence, the third 
part of our study was aimed at finding the functional and 
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signalling significance of these sugar binding sites. CD24 has 
both O and N-sugar binding sites. While the molecule has 
multiple O-glycosylation sites, there are only two potential sites 
for N-glycosylation. Employing the fact that for CD24 molecule 
to be N-glycosylated, asparagine is a must and should be 
present in a specific sequence. We aimed at replacing the 
asparagine by glutamine, hence disabling the site to be 
decorated by N-sugars in CD24. We designed to mutate these 
N-glycosylation sites using Phusion-site directed mutagenesis 
kit. The procedure uses mutant primers in a PCR-based 
methodology to create the desired mutation. Once successful 
the next step of the study was to use this mutant CD24 in 
further experiments to explore the signalling and functional 
significance of these sugars in CD24 molecule. However, the 
results of our gene sequencing experiments showed that the 
attempt at generating the required clones was not successful 
and needed retrial. This step could not be carried out due to 
time limitation. 
In summary, it can be said the study aimed at exploring novel 
aspects of CD24 biology from three different perspectives with 
some exciting new facts and findings. Though these are 
undermined by a number of limitations that can be rectified as 
discussed in the thesis and would generate stronger and 
publishable contribution to the current understanding of CD24 
biology.  
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General over view of CD24: 
 
CD24 is also known as Heat Stable antigen (HSA) and was first 
discovered in mice by Springer et al in 1978. Mouse CD24 gene 
was cloned in 1990 and the human analogue of the gene was 
discovered a year later. Initially, it was thought to be a marker 
of immune cells but in the recent years, a whole multitude of 
potential roles have been attributed to this molecule. These 
encompass roles in immunity, inflammation, auto immunity, 
tumour metastasis and progression. CD24 is also proposed to 
be a marker of cancer stem cells in recent literature. This 
stemness potential may confer features like resistance to 
chemotherapy and hence linking CD24 with poorer prognosis in 
a wide spectrum of haematological and solid tumours. There is 
yet much to explore about this tiny molecule, in order to 
understand the diversity presented by the literature regarding 
its potential roles.  
Interesting aspects of CD24 biology include: 
 Gene structure  
 Protein structure  
 Extensive glycosylation 
 Location in lipid rafts  
 Ligands of CD24  
Genome of CD24: 
 
Mouse CD24 gene cloned in 1990 was found at Chromosome 10 
and very similar sequences were also observed at chromosome 
number 8 and 14. However, the copy at chromosome 10 is 
regarded as the true gene as the other two sites lack introns 
and do not express the protein. 
Human CD24 gene has a similar situation and its location has 
been a debate. There are highly homologous sequences in the 
human genome namely at chromosome 1p (CD24L1),  
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chromosome 15q21-q22 (CD24L2), chromosome 20q11.21 
(CD24L3) and chromosome Yq11 (CD24L4) and chromosome6 
(1). In the case of chromosome 15, it is considered as a 
pseudogene as the ATG start codon is replaced by a GTG codon. 
Looking up Yq11 reveals that it is theoretically capable of 
producing a protein; however, it is deficient in the TATA box 
which is present in the CD24 promoter on chromosome 6(2). As 
the level of CD24 expression does not show any gender 
difference between males and females, copy present on Y 
chromosome may also be taken as a pseudogene. This leaves 
most researchers to conclude that chromosomal 6q21 copy to 
be the true gene location for CD24(1).  
CD24 m-RNA: 
 
CD24 mRNA comprises 2179 base pairs, its ORF (open reading 
frame) has just 243 base pairs starting from 111 till 353 (see 
Appendix i /Appendix ii). CD24 has a particularly long 3´ UTR 
region (1.8 kilo-bases) that provides capping and stability to the 
CD24 mRNA. Deletions of this 3´ UTR have been linked to 
unstable mRNA and a higher risk of developing systemic Lupus 
erythematosus (SLE) and Multiple sclerosis (MS) (3). Another 
important feature of the CD24 mRNA is the presence of a 
regulator region from position -446 till -840 relative to the start 
codon (ATG). This is a binding site for TCF/LEF (transcription        
factors) and link the regulation of this gene by the Wnt canonical 
pathway, the signal transduction pathway also known as  Wnt/β-
catenin Pathway (4). 
Protein structure: 
 
Human CD24 gene is translated into 80 amino acids  but the 
mature peptide is just 31 amino acids (5),(6). It has an N-
terminal signal peptide directing CD24 to the cell surface and 
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later gets removed in the endoplasmic reticulum; this signal 
peptide comprises of 26 amino acids. 
Present at the C-terminal,  is a  23 amino acids sequence that 
starts  at position 59 , it represents a pro-peptide and is called 
GPI-displaced tail (5). It helps in the binding of the GPI anchor 
to the C-terminal of CD24 protein and it is sliced off 
subsequently leaving the mature peptide hanging on the cell 
membrane through a GPI anchor Figure 1. 
 
 
 
Figure 1: Simplified cartoon of CD24 protein. 
 
CD24 undergoes extensive post translational modifications and 
in addition to the ones described above, there is extensive 
glycosylation. The molecular weight of CD24 ranges from 30 to 
70 kDa (5), most of its weight and the variability of weight is 
due to extensive and variable N- and O-linked glycosylation in 
different tissues and cells. CD24 has 16 potential O- and two 
potential N glycosylation sites (7), Figure 2. 
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Figure 2: Simplified diagram showing extensive glycosylation sites of CD24(8). 
 
The glycosylation renders CD24 similarity to a mucin. The 
pattern of glycosylation of CD24 is highly variable and differs 
significantly between cell types and tissues (9, 10). In general, 
studies using MALDI-MS techniques to analyse glycosylation 
patterns of CD24 show that the N-glycosylation pattern of CD24 
is  less complex in the majority of cases when expressed in cell 
lines compared to the expression in brain, independent of 
whether the cell line is of murine or human origin(11, 12). 
Several studies have provided proof that at least some functions 
of CD24 are dependent on its glycosylation.  The process takes 
place in endoplasmic reticulum and Golgi and will be discussed 
in more detail in the chapter on N-glycosylation of CD24. 
Sequence comparison of Murine HSA and Human CD24: 
 
Aigner et al. in 1997 presented in a study the sequence 
comparison of human and mouse CD24. They proposed that 
during evolution the human CD24 molecule has acquired 
additional serine and threonine residues. Making the molecule 
more like a typical mucin (by providing additional glycosylation 
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sites in human CD24) and these might have conferred diverse 
characteristics (12), Figure 3.  
 
 
Figure 3: Primary amino acid sequences for HSA (mouse)  and human CD24(8). 
Potential N-linked glycosylation sites are marked with an asterisk, and potential O-linked 
glycosylation sites are marked with a circle above the amino acid. Putative binding sites for   
P selectin, MoAb CD57, and the CD24-specific MoAbs SWA11 and ML-5 are indicated. The 
shaded area indicates similarities between HSA and CD24 (12). 
Ligands of CD24:  
P-selectin: 
The selectin family features calcium-dependent type-I trans 
membrane glycoproteins with extracellular lectin-like domains 
that interact, for example, with sialylated carbohydrate 
determinants and mucin-like glycoproteins. In mammals, three 
structurally similar family members have been identified: 
E(ndothelium)- selectin, L(eukocyte)- selectin and P(latelet)-
selectin(13). CD24 is thought to function as an adhesion 
molecule. It is known to bind to P-selectin, a protein expressed 
on thrombin-activated platelets and endothelial cells. The 
interaction between HSA/CD24 and P-selectin is mediated by 
either sialyl-Lex or a related sialylated carbohydrate and is 
shown to mediate rolling of breast carcinoma cells (10, 14). 
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L1:  
L1 is a member of the immunoglobulin superfamily (15, 16) and  
also known as LCAM1 and CD171. It is a 200-kDa adhesion 
molecule, with both homophilic and heterophilic characteristics 
expressed by many post-mitotic neurons in the central nervous 
system and also present on the lymphoid cells. According to a 
study, by Kadmon G et al. CD24 acts as a ligand for L1 (16, 17). 
A recent study by Kleene et al. also showed that L1 and CD24 
cooperate with each other in neurite outgrowth and signal 
transduction. They also revealed that binding of CD24 to L1 
depends on α2,3-sialic acid on CD24, which determines the 
CD24 induced and cell type-specific promotion or inhibition of 
neurite outgrowth(18). 
TAG-1 and Contactin: 
 
In addition to α2,3-linked sialic acid and L1 interaction, another 
important sugar present on CD24 molecule  is Lewis x glycan. 
TAG-1 also called Axonin-1, is a cell adhesion molecule and 
Contactin is a lectin like molecule present in the lipid rafts (17). 
They interact with Lewis-X glycan and mediate Lewis–x 
dependent neurite outgrowth of cerebellar and DRG (dorsal 
root ganglion) neurons (19). 
SIGLECS: 
 
Siglecs are quite recently identified. These are Sialic acid 
binding Immunoglobulin like lectins. These are members of the 
Ig superfamily and are expressed on immune cell surfaces 
including B-cells, NK-cells, eosinophils, basophils, thymocytes 
and  T-cells (20). In humans more than 10 types of Siglec- 
molecules have been identified till now. Each of these has a 
distinct yet sometimes overlapping tissue expression and 
interactions and they are believed to play a variety of significant 
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roles. Studies have shown that CD24 is a ligand for Siglec10 in 
humans and Siglec G in mice and this interaction plays a very 
important role regarding the physiological response of cells to 
tissue damage caused by non-pathogenic stimuli (DAMPs)(21). 
This interaction helps to discriminate between Pathogen 
mediated and Damage mediated tissue injury. Even though 
both tissue injuries lead to, Toll like receptor activation, DAMPs-
Siglec and CD24 combination sends inhibitory signals to the 
innate immune system(21).  
Expression of CD24: 
 
In mouse CD24 is found on haematopoietic cell populations 
including erythrocytes, thymocytes, neutrophils, B-cells and T-
cells. As its expression is developmentally regulated, it was 
traditionally used as a marker of differentiation for B and T-cells 
ontogeny(22).  Later it was also found to be expressed during 
the embryonic stages of other tissues including neuronal tissue 
and  certain epithelia(23).  
 
Figure 4: Expression of CD24 found in murine and human cells.(24). 
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In humans, CD24 is not expressed on erythrocytes or 
thymocytes but is highly expressed on progenitor B-cells and 
remains expressed on mature resting B-cells eventually waning 
from the plasma cells (22, 25). Being present on the activated 
B-cells it also acts as a co stimulatory molecule for T-cell clonal 
expansion. On T-cells, expression of CD24 varies with different 
maturation and activation states of T cells (25). Continued 
research has shown even broader expression of CD24 on cells 
and tissues including more hematopoietic cells (eosinophils, 
neutrophils dendritic cells and macrophages), human neuronal 
tissue, muscle cells, gastric parietal cells, pancreatic cells and 
many stem cells (26-28), Figure 4.  
In addition to its expression in normal tissues, CD24 is shown 
to be up regulated in a growing list of inflammatory, 
autoimmune and neoplastic conditions. The list of tumours 
overexpressing CD24 is still growing and already  includes both 
solid and haematological malignancies such as B-cell 
lymphomas, erythroleukemia, gliomas, small cell lung cancer, 
oesophageal squamous cell carcinoma, hepatocellular 
carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, 
urothelial carcinoma, ovarian cancer, breast cancer, gastric 
cancer, prostatic carcinoma and colorectal carcinoma (28-38). 
Role of CD24 in Immune system: 
 
CD24 is expressed on a variety of haemopoietic and immune 
cells.  As a general rule, it is seen much more abundantly on 
the progenitor cells and in more metabolically active cells, with 
a gradual loss from the surface as the cells mature and 
differentiate. CD24 is considered as a B-cell marker and seen 
on very early B-cell progenitors and expression varies with 
stages of differentiation being highly expressed on the 
progenitor cells to totally absent on the plasma cells(7). 
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This indicates a role of CD24 in B-cell development and 
maturation. Several lines of evidence have pointed towards this 
role of CD24 and studies have also observed that CD24-
deficiency resulted in a reduction in late pre-B and immature B-
cell populations in the bone marrow. On activated B cells, CD24 
functions as a T-cell co-stimulator for CD4+ T-cell clonal 
expansion. Research has also shown that cross linking of CD24 
induces apoptosis in B-cell precursors including pre-B and pro-
B ALL( Acute lymphocytic leukemia) cell lines (39).  
Quite similar to B-cells, CD24 is highly expressed on immature 
T cells and expression gets weaker on peripheral T cells, but it 
is found to be upregulated in activated T cells. Li et al. found 
that a functional CD24 gene is essential for optimal homeostatic 
proliferation of T cells in a lymphopenic host (40). Interestingly, 
on the dendritic cells, CD24 is a negative regulator of T-cell 
homeostatic proliferation and thereby prevents fatal damage 
associated with the uncontrolled homeostatic proliferation of   
T-cells in lymphopenic hosts (7).  
Very recently another important role has been attributed to 
CD24  i.e. discriminating between the PAMPs (Pathogen 
associated molecular patterns) and DAMPs (Damage/Danger 
associated molecular patterns) responses by the immune cells 
and it has been shown that the CD24-siglec axis provides the  
negative feedback mechanism for release of inflammatory 
cytokines after non-pathogenic cell injury(21). In addition, 
CD24 is shown by recent research to be the  negative mediator 
of inflammation in sepsis and potentially important  in the 
treatment of sepsis (21, 41).  
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Role of CD24 in neuronal tissue: 
 
Besides immune cells, CD24 has been implicated to play a 
significant role in neuronal development. Keeping its general 
trend of expression being related to immature cells, studies on 
mouse brain have revealed that CD24 is transiently but 
extensively expressed in developing neurons and glial tissue. In 
an adult brain, its expression is lost from the developed neurons 
but still remains present  on immature brain cells, and ciliated 
ependymal cells (42). Kadmon et al. explored the interaction 
between CD24 and L1 in neurons (16, 37). They provided 
evidence that in neuroblastoma N2A cells and cerebellar 
neurons, LI and CD24 interact with one another and there is a 
significant increase in intracellular Ca++ concentration (16). 
Kleene et al. showed that binding of CD24 to L1 depends on its 
glycan chains and sialic acid residues on CD24 are essential for 
the binding to L1. They also showed that trans-interaction takes 
place between both molecules and being present in lipid rafts is 
also an important factor in determining the outcome of these 
interactions  (18),Figure 5. 
 
Figure 5: L1 and CD24 interactions in the brain(18, 43). 
The trans-interaction between the 30- and 33-kDa glycoforms of CD24 and L1 depends on α2,3-
linked sialic acid (NeuAc) residues and being located in lipid rafts region. This trans-interaction 
determines the CD24 induced and cell type-specific promotion or inhibition of neurite 
outgrowth. These CD24 glycoforms could be located either on neurons or glia(18). 
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Role of CD24 in Autoimmune diseases: 
 
In general, autoimmune diseases are thought to be polygenic 
and multiple genes are being associated with each type of 
autoimmune disease, however, few have shown to employ 
direct significant impact and CD24 provides one such example. 
It has been linked to multiple autoimmune diseases including 
Systemic lupus erythematosus (SLE), Multiple sclerosis (MS), 
Autoimmune encephalitis, Rheumatoid arthritis, Crohn’s 
disease and ulcerative colitis to name a few (44, 45).  
Through a detailed pedigree analysis of families with SLE and 
MS, Wang et al. found that a destabilizing dinucleotide deletion 
in the 3' UTR of CD24 mRNA lead to significant protection 
against both MS and SLE (3). Similarly, Zhou et al. found a 
single nucleotide polymorphism of CD24 to be related with the 
risk and progression of MS. They found that CD24 v/v renders 
a >2-fold increase in the relative risk of MS even in the general 
population (P=0.023) with greater disability in familial cases 
(46). A meta-analysis published in 2015 proposed that CD24 
C170T polymorphism might contribute to higher risk 
UC(ulcerative colitis), and the CD24 TG1527del polymorphism 
might be associated with the risk of Crohn’s disease (47, 45). 
Stem cells and cancer stem cells: 
 
Many human tissues undergo rapid and continuous cell 
turnover. One of a good example is  colonic mucosa where, for 
example, the average life span of a mature, differentiated cell 
(for exemple a goblet cell in a crypt of the large intestine) can 
be measured in days or even hours. Under physiological 
conditions, this process is sustained by a small minority of long-
lived cells with extraordinary expansion potential, known as 
stem cells.  
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Stem cells have three main properties: 
1. Differentiation: 
The ability to give rise to a heterogeneous progeny of cells, 
which progressively diversify and specialize according to a 
hierarchical process, constantly replenishing the tissue of 
short-lived, mature elements; 
2. Self-renewal:  
The ability to form new stem cells with identical, intact 
potential for proliferation, expansion, and differentiation, thus 
maintaining the stem cell pool. 
3. Homeostatic control: 
The ability to modulate and balance differentiation and self-
renewal according to environmental stimuli and genetic 
constraints (48).  
In the past few decades, owing to dramatic   improvements in 
techniques of molecular biology, the underlying mechanisms of 
cancers are gradually being uncovered.  There is  evidence that  
many cancers are composed of heterogeneous sub populations 
of tumour cells and these cells differ from each other  not only 
in molecular markers but also in their abilities of growth and 
differentiation (49). 
There are undifferentiated cells which, when xeno-transplanted 
into immunocompromised mice result in the formation of 
tumours which resemble the primary tumour from which they 
were isolated. These cells are called  Cancer stem cells (CSC)  
due to the characteristics of self-renewal and ability to produce 
mature cells through differentiation  just like  normal stem 
cells(50, 51). 
Cancer stem cells (CSC) are thus a small number of cells in a 
tumour with tumour initiation ability and can give rise to 
progeny that then differentiates into mature tumour cells, 
besides their own renewal.  According to this concept, cancers 
Chapter One  Introduction. 
14 
 
are not  mere monoclonal expansions of transformed cells, but  
rather  complex tri -dimensional tissues where cancer cells 
become functionally heterogeneous as a result of differentiation 
(48). 
 These cancer stem cells are getting immense attention due to 
their probable role in tumour formation , metastasis and 
resistance to currently available forms of chemotherapy(50). 
The evidence is increasing regarding each role of cancer stem 
cells (49) (52). It has been proposed now that the current 
chemotherapies only de-bulk the tumour and the stem cells 
are the ones that need eradication in order to prevent tumour 
relapse after treatment  (50, 53), Figure 6. 
 
Figure 6: Cancer stem cells as a cause of tumour re-growth(50). 
In order to develop specific and effective treatment of cancers 
there is need to further uncover the cancer stem cell properties 
including understanding of their signalling mechanisms, their 
interacting molecular partners and thereby developing specific 
targeted therapy. In the recent literature several molecular 
markers have been attributed to  represent stem cells in solid 
tumours, and some of them differ in different tissues(53). 
CD24 positive cells as cancer stem cells: 
Ovarian Cancer: 
Gao et al. in a recent study identified a sub-population enriched 
for ovarian CSCs defined by CD24 phenotype(37). Experiments 
Chapter One  Introduction. 
15 
 
in vitro demonstrated that the CD24+ sub-population 
possessed stem cell-like characteristics of remaining quiescent 
and more chemo resistance compared with CD24− fraction, as 
well as a specific capacity for self-renewal and differentiation. 
 In addition, injection of 5 × 103 CD24+ cells was able to form 
tumour xenografts in nude mice, whereas an equal number of 
CD24− cells remained non-tumorigenic. They  also found that 
CD24+ cells expressed higher mRNA levels of some ‘stemness’ 
genes, including Nestin, β-catenin, Bmi-1, Oct4, Oct3/4, Notch1 
and Notch4 (37). 
Colorectal Carcinoma: 
To further add to the concept of cancer stem cells, a study by 
Vermeulen et al.  used colon cancer undifferentiated stem cells 
and revealed that even a single CSC (cancer stem cell) can 
generate the tumour of origin on xenotransplantation. It was  
also proved that CD24 in addition to CDq133 was the marker of 
cancer stem cell(49). 
Pancreatic Carcinoma: 
Li et al. found that the pancreatic cancer cells with the 
CD44+CD24+ESA+ phenotype (constituting 0.2–0.8% of the 
pancreatic cancer cells) had a 100-fold increased tumorigenic 
potential compared with non-tumorigenic cancer cells. The 
CD44+CD24+ESA+ pancreatic cancer cells showed the stem 
cell properties of self-renewal, the ability to produce 
differentiated progeny, and increased expression of the 
developmental signalling molecule, sonic hedgehog(54). 
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CD24 negative cells as cancer stem cells : 
Prostatic Cancer : 
By using flow cytometry, Hurt et al.  isolated a population of 
CD44+ve and CD24-ve prostate cells and found that they  
display stem cell characteristics as well as gene expression 
patterns that predict overall survival in prostate cancer patients 
(31). 
Breast carcinoma: 
Research showed that, in most human breast cancers, only a 
minority subpopulation of the tumour clone, defined as (CD44+, 
CD24−/low) and representing 11%–35% of the total cancer 
cells, is endowed with the capacity to sustain tumour growth, 
when xeno-grafted in NODSCID mice (48). 
In short CD24 is definitely linked to” stemness”, but whether 
its presence or its absence marks the stem cells is apparently 
different in different carcinomas. 
Roles of CD24 in tumours: 
 
There are more than 20 different types of solid and 
haematological malignancies shown till now to be related with 
CD24 and the list continues to grow. This small molecule has 
been linked to vital cellular events including altered cell 
proliferation, adhesion, invasion in vitro and tumour growth in 
vivo (33, 55-58). CD24 on tumour cells binds to P-selectin on 
endothelial cells and platelets and this interaction has been 
proposed significant for breast cancer cell metastasis (14, 59). 
Similarly, upregulation of CD24 has been shown to promote 
tumour cell invasion by reducing TFI-2 (tissue factor pathway 
inhibitor-2 (55). 
Downregulation of CD24 has been shown to inhibit invasive 
growth, increased apoptosis and results in a better response to 
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chemotherapy in a gastric cancer cell line (60). Expression of 
CD24 has been linked to poor prognosis, recurrence (61) and 
reduced patient survival in pancreatic cancers(34) liver cancer, 
gastric cancer and cervical cancer(36, 62). 
 In non-small cell lung cancer, the CD24 expression is an 
independent marker for the overall survival of cancer 
patients(7). However, our group has shown that CD24 is not a 
prognostic factor in colorectal carcinoma(29). 
CD24  as  therapeutic option: 
 
As described above evidence underpins the significance of CD24 
in several human diseases including a long and growing list of 
tumours. Multiples studies have provided evidence on the 
prognostic and diagnostic role of CD24. There has been some 
progress in the design of novel treatment options targeting 
CD24 and some have found promising results(63). 
In tumours : 
Burkett’s lymphoma is a B-cell neoplasm with a high expression 
of CD24. A study by Suzuki et al.  showed that anti-CD24 
monoclonal antibodies  not only inhibit aggregation  but also 
reduce the growth of these CD24 expressing Burkett’s 
lymphoma cells. These antibodies lead to cross linkage of CD24 
molecules and induction of apoptosis in a lipid raft dependant 
manner (39). 
Up to 90% of colorectal carcinomas show increased expression 
of CD24, found as early as, at the adenoma stage and  linked 
to prognosis in some studies (8). Similarly, many other 
gastrointestinal malignancies show over expression of CD24 
such as pancreatic, gastric, oesophageal cancers etc. (60, 64). 
In 2008 Sagiv et al. targeted colorectal and pancreatic cancer 
cells using two anti CD24 techniques i-e monoclonal anti-CD24 
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antibody and siRNA. They found growth inhibition and less 
severe malignant phenotype as a result of targeting CD24 using 
the above mentioned techniques (63). 
In 2011, a new and very interesting model to kill tumour cells 
with high CD24 expression was presented by Shapira et al. They 
conjugated a highly potent exotoxin (PE-38) with the CD24 
antibody (SWA11) with the help of ZZ domain (modified Fc 
binding protein from Staph. aureus). They showed the effective 
and selective killing of human colorectal cancer cells in mice by 
this immuno-conjugate. This coupled strategy to kill the tumour 
cells was more potent than using the unarmed mAb alone(65). 
 
Although these studies are quite promising, however, there are 
still few hurdles in translating these strategies into clinical trials. 
For example, the issue of immunogenicity posed by the murine 
components limits multiple cycle use of these treatments. 
Similarly, eventhough it is known that most adult cells do not 
express CD24 once differentiated, yet there are some normal 
cells including immune cells  that do express CD24 (7). Hence, 
targeting may also adversely affect these cells. Currently, 
strategies to overcome these hurdles are under investigations. 
 In sepsis: 
Besides a role in the development of tumours, another very 
significant and relatively newly identified role of CD24 is 
enabling dendritic cells to differentiate between Damage 
associated molecular patterns (DAMPs) and Pathogen 
associated molecular patterns (PAMPs). Chen and Yang Liu et 
al. (2009) have shown that CD24 and Siglec10 provides a 
negative feedback loop resulting in prevention of cytokine 
release when stimulation of TLR (Toll like receptors) takes place 
by DAMPs and not by PAMPs (21, 41). 
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The Paulson et al. (66) proposed that the sugars present on the 
CD24 molecule may be vital in mediating the above mentioned 
role and proposed the possibility of destruction of these sialic 
acid residues present extensively on CD24 by bacterial 
sialidases in the setting of sepsis .They showed that that sepsis 
was ameliorated when these sialidases were inhibited and this 
also required intact CD24-siglec axis as loss of CD24 or Siglecs 
both abrogated the effects of sialidases inhibitors in the 
treatment of sepsis (41, 66), Figure 7. 
 
Figure 7: Sialidase inhibitors DAMPen sepsis.(66) 
(a) Normally, DAMPs attenuate pro-inflammatory TLR signaling by forming a ternary complex with sialylated CD24 
and SiglecG/10. (b) During sepsis, bacterial sialidases cleave sialic acids on CD24, disrupting the 
CD24/SiglecG/10 inhibitory circuit and leading to enhanced cytokine production. (c) Sialidase inhibitors block the 
desialylation of CD24 that occurs during sepsis, preserving the Siglec inhibitory circuit and suppressing the 
inflammatory response. 
Such studies are promising  new strategies to combat sepsis 
and organ damage caused by drug toxicity by preserving the 
integrity of the CD24-Siglec axis (66, 67). 
Current controversies about role of CD24:  
 
Certain controversial aspects are found regarding the biology of 
CD24 in the current literature. These include features of stem-
ness, prognostic role and effects on cellular proliferation and 
certain signalling outcomes. Some possible explanations to 
these can be tissue specific and site specific glycosylation of 
CD24 and hence diverse signalling outcomes. 
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 Similarly, the location of CD24 can also be a potential reason 
and surface versus cytoplasmic or nuclear CD24 may have very 
different signalling outcomes. Yet another potential reason for 
discrepancies about CD24 was bought up by Kristiansen  et al. 
and that is the difference of antibodies used to detect CD24 
protein itself  (68). 
Their study compared the epitopes identified by three different 
CD24 antibodies i-e SN3b CD24, SWA-11, and ML-5. Both SWA-
11 and ML-5 bind to the core protein of CD24 whereas mAb 
SN3b does not identify the CD24 protein core itself; rather it 
binds to a glycan structure that decorates the CD24 molecule. 
However, this glycan is not present on all forms of CD24 and, 
possibly, more importantly, can be present on other yet 
unidentified molecules (68). 
This study was carried out using monoclonal antibody SWA11 
for the detection of CD24 and it was a kind gift from Prof Peter 
Altevogt.  
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Study Aims: 
 
Increasing literature points towards the significance of CD24 in 
human pathologies ranging from autoimmune diseases to 
malignancies. There are more than thirty different types of 
tumours associated with CD24 and the list is still growing. CD24 
has been linked to tumour pathogenesis, prognosis, and 
metastasis besides some promising therapeutic potential. 
However, much less is known about its signalling partners, and 
exact mechanisms leading to these diverse roles.  
The overall aim of this piece of work was to explore CD24 
biology a bit further. 
Specifically, in this study, we focussed on three aspects: 
 CD24 has been shown to regulate the differential 
response of immune cells when exposed to Damage 
Associated Molecular Patterns (DAMPs) versus Pathogen 
Associated Molecular Patterns (PAMPs). As the tumours 
also show both the high CD24 expression levels and 
release of DAMPs by the necrotic cells. We intended to 
explore the possibility of similar modulatory role of CD24 
in tumour cells when exposed to DAMPs. This was done 
using directional and non-directional cell motility and cell 
proliferation assays, after exposure to autologous DAMPs 
in colorectal cell lines with positive and negative 
expression of CD24. 
 We also aimed at exploring signaling relationship between 
CD24 and some tumour related molecules including Cten, 
ILK and FAK by performing co-transfections. We also 
sought to figure out functional relevance between these 
molecules by carrying out functional assays. 
 Glycosylation has been implicated as an important 
potential factor for CD24 associated cellular events. To 
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explore the significance of these glycosylation sites we 
attempted to mutate potential N-glycosylation sites in 
CD24 molecule using site-directed mutagenesis. 
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Cell Lines:  
 
Our lab had twenty six well established colorectal cancer cell 
lines. These were obtained from Molecular and Population 
Genetics Laboratory, London Research Institute, Cancer 
Research, London, UK. These cell lines were originally from 
ATCC®™ (American Type Culture Collection), the premier 
global biological materials resource and standards 
organization. 
The cell lines used in this study included SW620, HCT116, 
DLD1, RKO and SW480. As per regular protocol, all of these 
cell lines underwent regular checks for mycoplasma infection, 
as well as DNA fingerprinting in order to confirm the correct 
identity of the cell line against the most original stock of each 
particular cell line. 
 Moreover, the expression levels of CD24 in the above 
mentioned cell lines were analysed in the lab using real time 
PCR and the protein expression was verified by performing 
western blot for CD24 as well as by flow cytometry (See 
Appendix iii). 
A brief description of cell lines used in the current study along 
with salient molecular features is described below: 
SW620 (ATCC® CCL­227™): 
 
 Organism: Homo sapiens, human 
 Tissue: colon 
 Source: lymph node 
 Disease: Dukes' type C, colorectal adenocarcinoma. 
 Morphology: epithelial 
 Growth Properties: adherent. 
Genes expressed:  
carcinoembryonic antigen (CEA) 0.15 ng/10 exp6 
cells/10 days; transforming growth factor alpha; 
keratin; matrilysin, myc +; myb + ; ras +; fos +; sis +; 
p53 +; abl -; ros -; src -, blood type A; Rh+, The cells 
are negative for expression of CSAp (CSAp-) and colon 
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antigen 3, negative., The cells are positive for keratin by 
immunoperoxidase staining., The line is positive for 
expression of c-myc, K-ras, H-ras, N-ras, Myb, sis and 
fos oncogenes. 
 
SW480 (ATCC® CCL228™): 
 
 Organism: Homo sapiens, human 
 Tissue: colon 
 Disease: Dukes' type B, colorectal adenocarcinoma 
 Morphology: epithelial 
 Growth Properties: adherent 
 Genes expressed: 
carcinoembryonic antigen (CEA) 0.7 ng/10 exp6 cells/10 
days; keratin; transforming growth factor beta, myc +; 
myb + ; ras +; fos +; sis +; p53 +; abl -; ros -; src -, 
HLA A2, B8, B17; blood type A; Rh+, The cells are 
positive for keratin by immunoperoxidase staining., The 
line is positive for expression of c-myc, K-ras, H-ras, N-
ras, myb, sis and fos oncogenes. 
 
DLD1 (ATCC® CCL­221™): 
 
 Organism: Homo sapiens, human 
 Tissue: colon 
 Disease: Dukes' type C, colorectal adenocarcinoma 
 Cell Type: epithelial 
 Morphology: epithelial 
 Growth Properties: adherent 
Genes expressed: 
carcinoembryonic antigen (CEA) 0.5 ng/10 exp6 cells/10 
days; colon antigen 3; keratin, myc +; myb + ; ras +; 
fos +; sis +; p53 +; abl -; ros -; src -, blood type O, 
DLD-1 cells are positive for p53 antigen expression (the 
p53 antigen produced has a C -> T mutation resulting in 
Ser -> Phe at position 241)., The cells are positive for 
keratin by immunoperoxidase staining., The line is 
positive for expression of c-myc, K-ras, H-ras, N-ras, 
myb, sis and fos oncogenes. 
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HCT116 (ATCC® CCL­247™): 
 
 Organism: Homo sapiens, human 
 Tissue: colon 
 Disease: colorectal carcinoma 
 Morphology: epithelial 
 Growth Properties: adherent 
Genes expressed: 
The cells are positive for keratin by immunoperoxidase  
staining.HCT 116 cells are positive for transforming grow
th factor beta 1 (TGF beta 1) and beta 2 (TGF beta 2) 
expression. Carcinoembryonic antigen (CEA) 1 ng per 
106 cells per 10 days.  
 
RKO (ATCC® CRL­2577™): 
 Organism: Homo sapiens, human 
 Tissue: colon 
 Disease: Carcinoma 
 Morphology: epithelial 
Growth Properties: adherent 
 Genes expressed: 
RKO cells contain wild-type p53 but lack endogenous     
human thyroid receptor nuclear receptor (h-TRbeta1). 
 
 
 
Table 1: Status of significant oncogenes in the cell lines used (69). 
 
GENES SW620 SW480 DLD1 HCT116 RKO 
KRAS mutant mutant mutant mutant wild type 
BRAF wild type wild type wild type wild type mutant 
PI3K wild type wild type mutant mutant mutant 
P53 mutant mutant mutant wild type wild type 
NRAS wild type wild type wild type wild type wild type 
CD24 positive positive positive negative negative 
CTEN positive positive positive negative negative 
 
Cell cultures: 
 
The cells were cultured in Dulbecco's Modified Eagle's Medium 
(DMEM) (GIBCO®, Invitrogen, UK) containing 10% FBS 
(Invitrogen, UK), 100 units/ml penicillin, and 100µg/ml 
streptomycin (Invitrogen, UK). Cultures were maintained in a 
37°C incubator in a humidified atmosphere of 95% O2 and 5% 
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CO2. Cells were cultured ordinarily in T75 (75 cm2) culture 
treated flasks (Costar, UK) and were mostly adherent to the 
culture flask surface. For cell passaging, cells were allowed to 
grow to 90% confluence and then trypsinised in order to detach 
them from the surface of the tissue culture flask. The medium 
was removed from cells and the cells were washed twice with 
5ml of PBS (Sigma, USA). Following this, 1ml of trypsin-EDTA 
was added to the cells, the flask was placed in the incubator at 
37oC for 5min, after which, the cells could be seen to detach 
from the bottom of the flask. The cells were then re-suspended 
in 9mL of fresh medium, the FBS in the medium is important 
for inactivating the trypsin. The medium containing the cells 
was then plated into new flasks and the level of dilution of cell 
suspension to fresh plating medium was mostly kept at 1:10 
dilution. 
Transient forced expression of CD24 by transfection: 
 
Transfection: 
 
It is a robust technique that allows introduction of genetic 
material (DNA and double stranded RNA) of choice into the 
mammalian cells. It is a powerful technique used by the 
scientists to study the effects of genes of interest. This 
inserted DNA/ds RNA leads to expression, or production of 
proteins or altering the endogenous gene expression using 
the cellular machinery of the transfected mammalian cells. 
Transfection helps in studying functions of these genes and 
gene products. Currently a wide range of methodologies are 
commercially available for transfection using physical, 
chemical and biological approaches. 
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For successful transfection a nucleic acid, which carries a net 
negative charge under normal physiological conditions, must 
cross the cell membrane that also carries a net negative 
charge. A very popular approach in this regard is the use of 
Lipofectamine (chemical- transfection).  
Lipofectamine 2000 is a cationic liposome based reagent and 
it delivers great transfection efficiency leading to high levels 
of transgene expression in a range of mammalian cell types 
besides having a simple protocol. Lipofectamine 2000 
complexes with nucleic acid molecules, allowing them to 
overcome the electrostatic repulsion of the cell membrane 
and to be taken up by the cell (70, 71). 
  Stable versus transient transfection: 
 
The method of transfection into a cell can be transient or 
stable and both techniques offer varying benefits to scientists. 
In transient transfection, the transfected material enters the 
cell but does not get integrated into the cellular genome. In 
this method the gene expression changes can be studied in a 
window of 8 to 96 hours post-transfection.  This method is 
useful for short-term expression of genes or gene products, 
gene knockdown or small-scale protein production. 
On the other hand, in stable transfection, plasmid DNA 
successfully incorporates into the cellular genome and gets 
passed on to the future generations of the transfected cells.  
This method is less commonly used because of its complexity 
and time consumption. In this technique the plasmid DNA is 
designed to contain a gene that expresses antibiotic 
resistance in addition to the gene of interest. Continued 
antibiotic treatment of the transfected cells for a long-term 
results in the expansion of only the stably-transfected cells, 
while non-transfected/transiently transfected cells die off due 
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to the lack of antibiotic resistance. Stable transfection is 
mainly used for protein production on a large scale, research 
on long-term genetic regulations, extended pharmacology 
research or gene therapy. However, once successful it is quite  
useful and avoids huge variability of expression levels as seen 
with each repetition of transient transfections (70). 
 Time course stability of CD24:  
 
Regarding transient transfections, depending on the relative 
stability of the mRNA / protein expressed and the sensitivity 
of the assay system employed the expression profile can vary 
considerably. Hence it is important to optimise the 
transfection conditions as well as to know the time course 
stability of the protein under study. This is significant in order 
to correctly plan and interpret relevant experimental models. 
The expression plasmid CD24 - pcDNA3.1 was successfully 
constructed in our lab (see Appendix ix) and fully optimised 
to be used for transient forced expression of CD24 in cell lines 
having low or negative expression of CD24. In our lab settings 
peak CD24 expression levels were seen after 24 hours with 
significant protein levels maintained even after 72 hours post 
transfection (unpublished data). In current study we used the 
above time window (24-72 hours post transfection) for our 
experiments. 
  Methodology of transient transfection: 
 
The expression construct (CD24 - pcDNA3.1) was used to 
express CD24 in the low CD24 expressor cell line HCT116. 
Transfection was performed according to the 
Lipofectamine®2000 (Invitrogen) instructions manual. Briefly, 
one day before transfection 5 x 105 cells were plated in 2 ml 
of growth medium (DMEM) with 10 % FBS in 6-well plates 
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(volumes are adjusted according to plate size used). On the 
second day, cells were transfected when confluence reached 
between 60 and 90 %.Cells were serum starved (by keeping 
in DMEM only without FBS for two hours) before transfection. 
A total of 4.0µg/well of plasmid DNA or the control empty 
vector (pcDNA3.1) was diluted in 250µl Opti-MEM® I -Serum 
-reduced medium (Invitrogen) and mixed gently. 
Lipofectamine® 2000 (Invitrogen) was gently mixed before 
use, and then 10µl was diluted in 250 µl of Opti-MEM® I 
Medium and incubated for 5 minutes at room temperature. 
Subsequently, the diluted plasmid DNA was combined with 
the diluted Lipofectamine®2000, mixed gently and incubated 
for 20 minutes at room temperature. The complexes were 
lastly added to the cells containing 1.5 ml of fresh Opti-MEM® 
I -Serum - reduced medium and plates were rocked back and 
forth carefully and incubated at 37ºC in 5% CO2 incubator. 
Transfections were performed in triplicate. After 4-7 hours of 
transfection, the media was changed with fresh DMEM with 
20% FBS and 1% P/S. After 24 hours the cells were either (1) 
harvested for protein extraction and western blot (2) used 
directly for the relevant functional assays. 
Total RNA extraction: 
 
The RNeasy Mini Kit (Qiagen, Crawley, UK.) was used to extract 
total RNA from cultured cells. Cells were trypsinised as 
described for passaging, and then cells were pelleted. Pellets 
were re-suspended in 5mL of the medium, and counted using 
and automated cell counter (Bio-Rad, TC20™ Automated Cell 
Counter Model #1450102). The cells were aliquoted to get a 
maximum of 1 X 107 cells per aliquot, washed twice with PBS, 
re-suspended in 1ml PBS, transferred to a 1.5ml tube and spun 
for 5 min at 300xg. The supernatant was discarded and the 
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pellet was lysed with either 350μl or 600μl of RLT lysis buffer 
according to the starting number of cells  (< 5 X 106 cells were 
lysed in 350 μl, from 5 X 106 to 1 X 107 were cells lysed in 600 
μl). The cell suspension in the lysis buffer was further 
homogenised using QlAshredderTm spin columns (Qiagen, 
Crawley, UK) placed in a 2 ml collection tube, and centrifuged 
for 2 min at full speed. The lysate was then mixed with 70% 
ethanol and placed into a spin column with a silica membrane 
and centrifuged at 8000xg. for 15 sec. On-column DNase 
digestion was required for the elimination of genomic DNA 
contamination, to prepare the spin column, 350 μl Buffer RW1 
was added to the RNeasy spin column and centrifuge for 15 
seconds at  8000xg. 
To perform DNA digestion 10 μl DNase I stock solution was 
added to 70 μl Buffer RDD, then the DNase I incubation mix (80 
μl) was added directly to the RNeasy spin column membrane, 
and placed on the bench top (20–30°C) for 15 min. The 
membrane containing the RNA was washed once with 700 μl of 
RWI buffer, then twice with 500μl of RPE buffer (containing 
ethanol). After the last wash, the column was spun dry at 
8000xg. to remove the remaining traces of ethanol from the 
membrane. The RNA was then eluted in 30 μl of RNase free-
water. 
RNA/DNA quantification and quality check: 
 
To check the quantity and quality of the RNA, the 
spectrophotometer (NanoDropTM 1000 Spectrophotometer, 
Thermo Scientific) was blanked with RNase free water. The 
absorbance at 260nm and 280nm was measured. The measure 
of A260 gave the quantity of total RNA in μg. The ratio 
A260/A280 gave an estimation of the purity of the RNA 
(RNeasyt mini Handbook, Qiagen, Crawley, UK). A ratio of ~1.8 
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is commonly accepted as “pure” for DNA, and the ratio of ~2.0 
is generally accepted as “pure” for RNA. If the ratio is 
noticeably lower, in any case, it may point to the presence of 
protein, ethanol or other contaminants that absorb strongly at 
or near 280 nm. 
Synthesis of complementary DNA from RNA: 
 
In a 50μl reaction 400ng of random hexamers (Thermo 
Scientific AB gene Cat#12657375) were used (1μl per 
reaction). 5μg of RNA was diluted in dH2O (RNase, DNAse free 
water) for each sample to make a final volume of 21 µl. Samples 
were incubated at 70oC for 10 minutes (This denatures the RNA 
prior to allowing the random hexamers to anneal to the 
template strand). Samples were placed on ice for 5 minutes 
then pulse centrifuged to collect samples. While samples are on 
the ice, a Master Mix was made as described in Table 2.  Master 
Mix was then mixed by gentle pipetting and pulse centrifuge to 
collect contents.  29 μl of Master Mix were added to each RNA 
sample (making a total volume of 50 μl). These samples were 
incubated at 37oC for 1hr (This allows the Reverse Transcriptase 
enzyme (M-MLV Invitrogen cat#2802513) to synthesize the 
complementary DNA sequence to the template RNA strand from 
the added nucleotides). Finally, samples were incubated at 95oC 
for 10 minutes (This step will denature the enzyme, preventing 
it interacting in subsequent reactions). In order to exclude 
genomic DNA contamination, RT negative samples were made 
going through the same steps of reverse transcription except 
for adding the reverse transcriptase Table 3.  
 Without this enzymes, no cDNA is made, so when those 
samples are used for Q-PCR, if there is any amplification 
observed, it indicates the presence of genomic contamination in 
the RNA samples extracted. 
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Table 2: Master Mix made for the reverse transcription reaction. 
                                                     Master Mix.   
  
                                           1 reaction (μl).                   4 reactions (μl). 
5x First-Strand Buffer 10  40 
dNTP (10mM) 1.5  6 
DTT(0.1M) 5 20 
M-MLV-RT (200U/μl) 
enzyme (Invitrogen)       
2 8 
dH2O 10.5 42 
 
Table 3: Master mix made for the RT- negative reactions. 
                                                     Master Mix.   
  
                                           1 reaction (μl).                   4 reactions (μl). 
5x First-Strand Buffer  10  40 
dNTP (10mM) 1.5  6 
DTT(0.1M) 5 20 
dH2O 12.5 50 
 
Q-PCR: 
 
In order to look for comparative mRNA levels of Cten after 
CD24 forced expression, the following primers were used 
(MWG-Biotech AG). 
Table 4: Primers used for qPCR. 
Gene of 
interest. 
 Primer Sequence. Product 
size. 
Annealing 
temperature. 
 
HPRT.  
(NM_000194) 
 
Forward Primer 
5'AAATTCTTTGCTGACCTGCTG 3' 
 
122 
 
 
 
60˚C 
 
 
Reverse Primer 
5' TCCCCTGTTGACTGGTCATT 3' 
 
CD24. 
(NM_01323 0.2) 
Forward Primer  
5' ACCCACGCAGATTTATTCCA 3' 
 
110 
 
 
59˚C 
 
Reverse Primer 
5' CCTTGGTGGTGGCATTAGTT 3' 
 
Cten. 
(NM_032865) 
 
Forward Primer 
5' GCGTCTGCTCAGA ATCGAC  3' 
 
 
110 
 
 
 
56˚C 
 
Reverse primer 
5' GATGAGGAAGTGTCGGATGG 
3' 
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Set up of PCR reaction: 
All experiments were carried out in triplicate and the values 
of amplification were normalized to the house keeping gene 
Homo sapiens Hypoxanthine phosphoribosyl transferase 1 
(HPRT1) Table 4. The Brilliant SYBR® Green QPCR Master 
was purchased from Stratagene, UK. The final volume of each 
reaction was 10μl containing 5μl of 1X SYBR Green Master 
Mix (Stratagene, UK), 0.4 μl of each primer (final 
concentration: 250 nM), and 1μl of cDNA templates (2 ng/1 
μl) Table 5. Cycling conditions for the reactions were 1 cycle 
of denaturation for 10 minutes at 95˚C followed by 40 cycles 
of denaturation (30 Seconds at 95°C), annealing (60 Seconds 
at a temperature specific for the primer in use) and extension 
(30 Seconds at 72°C) in the thermal cycler (Mx3005PTM, 
Stratagene). Finally, the reactions were left for 1 cycle for 
120 seconds for the generation of a dissociation curve 
(divided as 1 minute denaturation at 95 °C, 30 seconds at 55 
°C, and 30 seconds at 95°C). The data for Q-PCR were 
analysed by the MxPro-QPCR software version 3.20 using the 
standard curve method. For each QRT-PCR experiment, a 
standard curve had to be generated for each target gene. 
Standard curves were generated using 10 fold serial dilutions 
of neat cDNA. The controls for QPCR experiments were “No 
template control (NTC)” reactions containing all the reagents 
excluding the DNA template, and RT- negative control to 
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analyse the possibility of genomic DNA contamination during 
the step of cDNA synthesis. 
 
Table 5: Master mix for qPCR . 
Components. X1  
Reaction (10μl). 
X 20  
Reactions. 
Master mix. 5 μl 100 μl 
Forward primer. 0.4 μl 8μl 
Reverse primer.  0.4 μl 8μl 
Water (PCR clean). 3.2 μl 64μl 
Template. Added separately 1μl each  
 
Western blot: 
Protein extraction: 
After aspiration of the media, the cells were washed with the 
appropriate volume of ice-cold 1X PBS according to the size 
of the flask or the plate in use. Cells were trypsinized and were 
transferred to a 1.5 ml eppendorf tube with media containing 
FBS. The tubes were centrifuged at maximum speed (200 x 
g) at 4 °C for 5 minutes and then washed twice with ice-cold 
1X PBS. The cell pellets were afterwards treated with ice-cold 
RIPA buffer (RadioImmuno Precipitation Assay) 
(Thermoscientific, UK, Cat. NO. 89901) (25mMTris-HCl pH 
7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS) with Halt Protease and Phosphatase Inhibitor 
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Cocktail, EDTA-free (100X) added as 1:100 concentration 
(Pierce, UK, Cat. NO. 78445). Tubes were incubated for 5 
minutes on ice. The eppendorf tubes were centrifuged at 
maximum speed (17,000 x g) at 4°C in BIOFUGE fresco 
machine for 20 minutes. The supernatant was collected, 
aliquoted into 0.5ml tubes and store at -20ºC. 
Protein quantification:  
For the purpose of equal loading in western blotting 
experiments, the concentration of total proteins in each of 
the cell lysates was quantified. The BCA Protein Assay Kit 
(Thermo Fisher Scientific Inc, Rockford, USA, Catalogue 
No.23225) was used according to the manufacturer’s 
instructions using the microplate procedure (see Appendix 
iv, Appendix v). The Spectrophotometer was used to 
measure the absorbance at 550 nm. The standard curve was 
made to calculate the amount of proteins in each sample by 
comparing the absorbance of each sample with those of the 
standard curve (see Appendix vi).  
SDS gel electrophoresis: 
Using the Bio-Rad gel system, SDS PAGE (4 % and 12 % 
were prepared whenever needed according to the target 
protein size) running gel was prepared (see Appendix vii), 
using the Biorad gel system. The glass plates (0.75mm) were 
set up in a casting frame to produce a good seal after they 
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were properly cleaned with mild detergent and air-dried with 
70% alcohol. A 10% SDS PAGE running gel was prepared and 
gently delivered into the plates up to a level that was 1cm 
below the wells so as to allow for a layer of stacking gel below 
the wells. After ensuring the resolving gel was set the 
prepared stacking gel was applied onto the resolving gel (see 
Appendix vii) and a 0.75 mm comb introduced carefully into 
the stacking gel. After polymerisation, the gel was transferred 
to the Biorad electrophoresis unit followed by the addition of 
1x Tris-glycine buffer (0.25M Tris, 1.92M Glycine, 1% SDS  
by GENEFLOW) electrophoresis buffer to cover the base and 
the top of the gel. The comb was then carefully removed.50 
µg of each protein sample were added to a 4X SDS loading 
buffer containing 5% β-mercaptoethanol. The samples were 
boiled at 95ºC for 5 minutes in a hotplate, subsequently, 
samples were transferred to ice for another 5 minutes after 
denaturation. After centrifuging for 1 minute at 17,000 x g, 
the samples were loaded into the wells and underwent 
electrophoresis for 60 minutes at 60 mA. A labelled size 
marker (rainbow marker) was used to measure the target 
protein size (Bio-Rad, UK). In the later part of the study, 
ready to use, pre-made SDS gels were also used for western 
blots (BIO-RAD Catalogue # 1611159, 4–20% Ready Gel® 
Tris-HCl Gel, 10 well, 50 µl). 
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Transfer to PVDF membranes: 
 
The resolving gel was equilibrated in a transfer buffer (0.25M 
Tris, 1.92M Glycine and 20% methanol) for 5 minutes. A 
Hybond-P PVDF (Polyvinylidene fluoride) membrane 
(Amersham Bioscience, Buckinghamshire, UK) was used for 
protein transfer and all equilibrations were done according to 
the manufacturer’s instructions. Following the formation of a 
transfer sandwich, the transfer of proteins was carried out 
using the semi-dry transfer unit (Bio-Rad, UK) at 0.8mA/cm2 
of membrane (64 mA for 2 gels). 
Immuno-detection: 
 
After transfer, the membranes were blocked with 5% non-fat 
dry milk/BSA in PBS/TBS containing 0.1% Tween20 for 1 
hour at room temperature and then incubated overnight at 
4ºC on a roller with the relevant antibody diluted to the 
optimal concentration in the same solution used for blocking 
the membranes. For the features and clones of antibodies 
used in this study see Table 6.  
For the purpose of checking the equality of loading, the 
monoclonal anti β-actin antibody (Sigma Aldrich, UK) was 
used at a dilution of 1:2000 against the ubiquitous β-actin 
protein. The blots were washed three times in PBS with 0.1% 
Tween20 (each washing for 5 mins) and then incubated for 1 
hour at room temperature with a horseradish peroxidase-
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linked secondary antibody. The secondary antibodies were 
from SIGMA; anti-mouse (A4416-SIGMA Aldrich, UK) or anti-
rabbit (A6154-SIGMA Aldrich, UK); the secondary antibodies 
were diluted in the same solution used for blocking. The blots 
were washed once again after secondary antibody incubation 
three times (for 5 mins each) in PBS with 0.1% Tween20 and 
the last wash was with PBS only. The immuno-reactive 
proteins were visualized with Enhanced Chemiluminescence 
detection kit (Super-signal West Pico Chemiluminescent 
Substrate, Thermoscientific, UK) and the ECL was kept on the 
blot for one to two minutes in dark and bands were visualised 
by exposure to X-ray film (Kodak UK). 
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Table 6 : Summary of antibodies used in the study. 
 
 
Antibody. Origin. 
Band 
size. 
Dilution 
Buffer. 
Blocking. 
(1 hour room temp 
/ overnight at 4˚C). 
Dilution. 
 
 
 
Washing. 
Except the last wash 
after secondary ab 
incubation (TBS 
alone ). 
 
Species. 
 
 
 
Secondary Ab type 
and dilution. 
(Both secondary 
antibodies raised in Goat). 
SIGMA ALDRICH 
1:10000 (1ul:10ml). 
E-cadherin. 
Cell signalling.  
24F10 
# 31955 
135 
KD. 
5% BSA in TBS 
with tween. 
 
5% BSA in 
TBS with 
tween. 
1:1000 
10µL:10mL 
TBS with tween. 
 
Rabbit. 
 
Anti rabbit IgG coupled with HRP, 
5% ,BSA in TBS with tween 1 
hour Room temperature (RT). 
N-cadherin. 
Abcam.  
Ab98952  
 
100KD. 
5% BSA in TBS 
with tween. 
 
5% BSA in 
TBS with 
tween. 
1:100 
30µL:3mL 
TBS with tween. 
 
Mouse.  
Anti mouse IgG coupled with HRP, 
5% BSA in TBS with tween1 hour 
RT. 
Snail( L70g2). 
Cell signalling. 
3895S 
29KD. 
5% BSA in TBS 
with tween. 
 
5% BSA in 
TBS with 
tween. 
1:1000 
10µL:10mL 
TBS with tween. 
 
Mouse. 
Anti mouse IgG coupled with HRP, 
5% BSA in TBS with tween1 hour 
RT. 
HSP90. 
Abcam. [E296] 
(ab32568) 
90KD. 
5% BSA in TBS 
with tween. 
 
5% BSA in 
TBS with 
tween. 
1:100 
30µL:3mL 
PBS with tween. 
 
Rabbit. 
Anti rabbit IgG coupled with HRP, 
5% BSA in TBS with tween1 hour 
RT. 
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Table 6 continued… 
 
Antibody.  Origin.  
Band 
size.  
Dilution 
Buffer. 
 
Blocking. 
(1 hour room temp 
/ overnight at 
4˚C). 
Dilution. 
 
 
Washing.  
Except the last wash 
after secondary ab 
incubation (TBS 
alone. 
Species.  
 
Secondary Ab type and 
dilution. 
(Both secondary 
antibodies raised in Goat). 
SIGMA ALDRICH 
1:10000 (1ul:10ml). 
FAK. 
Cell signalling. 
3285 
125KDa. 
5% BSA in PBS 
with tween. 
 
 
5% BSA in 
PBS with 
tween. 
 
1:500 
10µL:5 mL 
PBS with tween. 
 
Rabbit. 
Anti Rabbit IgG coupled with 
HRP,  5%, BSA in PBS with 
tween1 hour RT. 
ILK. 
 
Cell signalling. 
3862 
50KDa. 
5% BSA in PBS 
with tween. 
 
5% BSA in 
PBS with 
tween. 
 
1:500 
10µL:5 mL 
PBS with tween. 
 
Rabbit. 
Anti Rabbit IgG coupled with 
HRP, 5% BSA in PBS with tween1 
hour RT. 
 
Cten. 
Sigma TNS4. 
CLONE 3B8 
WHOO84951  
M1-100ug 
78KDa. 
5% milk in PBS 
with tween. 
 
5% milk in 
PBS with 
tween. 
1:1000 
10µL:10mL 
PBS with tween. 
 
Mouse. 
Anti Mouse IgG coupled with 
HRP, 5% milk in PBS with tween 
1 hour RT. 
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Table 6 continued……. 
Antibody.  Origin.   
Band 
size.  
Dilution 
Buffer. 
 
Blocking.  
(1 hour room temp 
/ overnight at 
4˚C). 
Dilution. 
 
Washing. 
 Except the last 
wash after 
secondary ab 
incubation (TBS 
alone.  
Species.  
 
Secondary Ab type and 
dilution. 
(Both secondary 
antibodies raised in Goat). 
 
SIGMA ALDRICH 
1:10000 (1ul:10ml). 
H3.  
Cell signalling. 
9715S 
18KDa. 
5% milk PBS 
with tween. 
 
5% milk PBS 
with tween. 
 
1:500 
10µL:5 mL 
PBS with tween. 
 
Rabbit. 
Anti Rabbit  IGg coupled with 
HRP, 5% milk in PBS with tween 
1 hour RT. 
HMGB1. 
Cell signalling. 
3935 
29KDa. 
5% BSA in PBS 
with tween. 
 
5% BSA in 
PBS with 
tween. 
1:1000 
10µL:10mL 
PBS with tween. Rabbit. 
Anti Rabbit IgG coupled with 
HRP, 5% BSA in PBS with tween1 
hour RT. 
 
β- actin. 
SIGMA CLONE. 
Ac-15  A1978-
200ul 
011M4812 
43KDa. 
5% milk in PBS 
with tween. 
 
5% milk in 
PBS with 
tween. 
1:2000 
5µL:10mL 
PBS with tween. 
 
Mouse. 
Anti Mouse IgG coupled with 
HRP, 5% milk in PBS with tween 
1 hour RT. 
SWA11 / 
CD24. 
Gift from Peter 
Altevogt. 
20-70 
KDa. 
3% milk PBS 
with tween. 
3% milk PBS 
with tween 
 
1:1 
3mL:3mL 
PBS with tween. 
 
Mouse. 
Anti Mouse IGg coupled with 
HRP,  5% milk in PBS with tween 
1 hour RT. 
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Cell migration assays: 
Trans-well migration assay:  
The cellular migratory capacities were tested using the trans-
well migration assay and the cellular wound healing assay. 
The trans-well migration assay uses a Boyden chamber, 24 
Trans-well inserts (Costar, Corning, NY, USA) with 6.5 mm 
diameter and polycarbonate membrane of 8-μm pore size. 
600µl of DMEM supplemented with 20% FCS was added to 
the lower chamber. In the upper chamber, 5 X 104 to 2 X 105 
cells (depending on the cell line type) were suspended in 
100µl of DMEM with 10% FCS. Migration was assessed after 
24 to 48 hours and single cells which had migrated through 
the membrane to the lower chamber were counted visually 
by an inverted microscope. Assays were performed in 
triplicate and on at least three different occasions. In order 
to reduce error, cells were counted by two observers at 
multiple occasions and found comparable counts by both.  
Wound healing Assay: 
 Cell migration was also measured using a cell wounding 
assay performed in 6-well plates. Cells were grown to 90 % 
confluency and then serum-deprived for 24 hours in serum-
free medium. A sterile 200 μl pipette tip was used to create 
three separate parallel scratches and migration of the cells 
across the wound line was assessed after 24 hours. 
Photographs were taken just after wounding(T=0) and after 
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24 hrs,  using a charge-coupled device (CCD) camera (Canon, 
Japan) attached to the inverted phase-contrast 
microscope(Zeiss, Germany)  at a magnification of 40x.The 
position of   each photograph  was noted  by the help of 
markings  made at the under surface of the culture plates .  
Migration of cells across the wound line was assessed 24 
hours after by using T Scratch software, this is feely available 
software and can be downloaded from.  
http://www.cse-lab.ethz.ch/software.html 
It reads the empty area in a picture and gives it as a 
percentage. The software enables a reliable and reproducible 
quantification of open areas (72). Assays were done in 
triplicate and repeated at least on three different settings. 
Methylene blue proliferation assay: 
For the purpose of comparing cell numbers between 
different experimental conditions, a time course 
proliferation assay was performed in 6-well plates and 
repeated in 24-well plates (Corning Incorporation, 
Coaster, UK). The number of cells seeded depended 
on the size of the plate in use thus, 1X104 cells were 
seeded in 24-well plates and 5 X 104 cells were 
seeded in 6 –well plates. After relevant cell 
treatments, cell numbers were measured as follows: 
medium was aspirated and cells were washed with 
PBS once and fixed at room temperature for 30 
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minutes with absolute methanol (1ml per well for 6-
well plates and 200 μl per well for 24-well plates). 
Subsequently, cells were allowed to air dry for 5 
minutes after tapping out of methanol. This was 
followed by staining with 1% methylene blue (1g 
methylene blue hydrate (Sigma, UK), and 100 ml 
distilled water) for 30 minutes at 37ºC. Next, the 
methylene blue was aspirated and wells were 
thoroughly washed three times with distilled water. 
Finally, the stain was eluted from the cells using 0.1% 
HCL in ethanol (1 ml in each well in a 6-well plates 
and 200μl per well for 24-well plates), and then 100µl 
of the eluent of each well was transferred into 96 well 
plate, and absorbance was measured at a wave 
length of 570nm using a plate reader (Lab systems, 
UK). Each experiment was performed in triplicate and 
repeated in at least three independent experiments. 
The spectrophotometric absorbance of methylene blue 
was measured at specified time points (24 hours, 72 
hours, and 5 days), the spectrophotometric reading is 
considered as reflective of cell number in each well. 
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Trypan blue exclusion assay for counting dead cells:  
Trypan blue is a vital stain that is used to selectively stain dead 
cells with a blue colour. Since live cells are very selective in 
the compounds that pass through their membrane, in a viable 
cell, trypan blue is not absorbed, and hence, cell is not 
coloured. However, trypan blue does cross the membrane of 
dead cells. The assay is used to compare the number of dead 
cells after different treatment conditions in culture and for 
counting viable cells. The cell suspension (prepared by 
trypsinisation of cells) was diluted with trypan blue (sigma 
Aldrich, UK, cat. no. t8154) in a 1:4 dilution (100µl) cell 
suspension added to 300 µl of trypan blue), the mix was 
incubated for 10 minutes at room temperature. 
 The haemocytometer was used to determine total cell counts 
and viable cell number (presumably cells floating in the 
medium are detached dead cells as CRC cell lines tested in 
our study are mostly adherent to culture plate surfaces). 
Each square of the haemocytometer, with cover-slip in place, 
represents a total volume of 0.1 mm3 and the cell 
concentration per ml is determined using the following 
calculations: cells per ml = the average count per square X 
dilution factor X 104. Total number of cells = cells per ml X 
the original volume of sample from which cell sample was 
removed. Assays were performed in triplicate and repeated 
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on three separate occasions. Data were analysed using Graph 
Pad Prism 6 software available at: www.graphpad.com 
 
Knock down of CD24: 
 
The protocol described in the Lipofectamine®2000 
manufacturer’s instructions manual was used for siRNA 
(small interfering RNA) transfection into the relevant cells. 
Briefly, 2x105 cells were seeded in 2ml DMEM media with 10 
% FBS and antibiotics (PS 1%) in 6-well plates (Corning) 
(volumes are adjusted according to plate size used). Cells 
were allowed to adhere for 24 hours prior to transfection. 
Cells were transfected when confluence reached between 40 
and 60 % at the time of transfection. The medium was 
aspirated and cells were washed with PBS and 2ml Opti- 
MEM®I was added to the cells.  
For each transfection sample, oligomer-Lipofectamine® 2000 
complexes were prepared as follows: 100 pico-mol Stealth 
siRNA oligomer i-e (5 μl) for CD24 was diluted in 250 μl Opti-
MEM® I Reduced Serum Medium (final concentration of 
siRNA when added to the cells is 50 nM), then mixed gently. 
10μl (or the optimized volume according to the gene of 
interest) of Lipofectamine®2000 was added to 250μl Opti- 
MEM® I, mixed gently and incubated for 5 minutes at room 
temperature. 
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 After 5 minutes, the diluted oligomer was combined with the 
diluted Lipofectamine®2000, mixed gently and then 
incubated for 20 minutes at room temperature. The 
oligomer-Lipofectamine®2000 complexes were added to each 
well containing cells and 250μl Opti- MEM® I (to make a final 
concentration of 50nm of the siRNA duplex), and mixed 
gently by rocking the plate back and forth. The media was 
changed after 4-6 hours by DMEM medium (with FBS 20 % 
and PS 1%), plates were incubated at 37ºC in 5% CO2 
incubator. Forty eight hours later, transfected cells were 
either (1) harvested for protein extraction and western blot 
(2) used directly for the relevant functional assays.  
The oligomers used in the study are listed in Table 11. 
Statistical Analysis: 
 
Statistical analysis was performed using the software GraphPad 
Prism version 6.00 for Windows (GraphPad Software, La Jolla 
California USA, www.graphpad.com).  All data are presented as 
mean ± standard error of the mean (SEM). Statistical 
significance between groups was evaluated using an unpaired 
two-tailed Student’s t-test and Two way ANOVA test. Mean 
differences were considered significant when was P≤ 0.05.  
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Introduction: 
 
Cells can be damaged either by pathogens or by lethal /sub-
lethal stimuli including physical stress, chemicals and thermal 
form of injury leading to innate immune system activation. It is 
known that the innate immune system recognises damaging 
stimuli by Pattern recognition receptors (PRRs). These include 
NOD like receptors (NLRs), Toll like receptors (TLRs), C-type 
lectin receptors (CLRs). These receptors interact with 
pathogens by detecting the conserved structural moieties 
present in the pathogens called Pathogen Associated Molecular 
Patterns (PAMPs). The exposure of cells to these PAMPs leads 
to a cascade of downstream events aiming at eradication and 
prevention of damage by the offending pathogen (73). 
 In contrast, cellular responses to damaging stimuli are not that 
clearly understood. The concept of “danger” was proposed 
about 25 years ago through observations that cellular damage 
results in disruption of the cellular membrane with release of 
endogenous molecules into the cellular microenvironment. The 
release of cellular contents together with damage induced 
degradation products from the extracellular matrix form what 
are known as Damage (or Danger) Associated Molecular 
Patterns (DAMPs) (21) Figure 8.  
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This is primarily the characteristic of necrotic cell death 
although now studies have shown that some apoptotic cells and 
phagocytes  also release DAMPs (73). 
The cell-derived DAMPs include cytoplasmic proteins (such as 
Heat Shock Protein (hsp90, and hsp70), nuclear proteins (such 
as high mobility group box 1(HMGB1), nucleic acids and 
metabolic products.  They can be detected by adjacent living  
cells and may provide signals, which, for example, help to 
initiate or maintain an immune response (73, 74).  
The mechanisms by which cells are able to detect DAMPs are 
unclear although a number of cell surface receptors have been 
described for specific DAMP molecules. Toll-Like Receptor (TLR) 
2 and 4, as well as Receptor for Advanced Glycation End 
products (RAGE) have been reported as receptors for 
HMGB1(75, 7). It is interesting that both DAMPs and PAMPs can 
interact with Toll like receptors (TLRs) and NOD-like receptors 
(NLRs) but the downstream response appears to be very 
different (7). 
 How this differential response was mediated remained a 
mystery till quite recently. CD24 emerged as a molecule that 
has been observed to physically interact with important DAMPs 
including HMGB1, HSP90 and HSP70. Siglecs are also recently 
identified ligands of CD24 as shown by co immunoprecipitation 
experiments by Chen et al. (41). 
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Figure 8: Release of DAMPs from necrotic cells to induce sterile inflammation .(76) 
They proposed a model where by TLR may be interacting with 
CD24 and members of the Siglec family of transmembrane 
proteins. In this model DAMPs, CD24 and Siglec molecules 
(Siglec G in mice, Siglec 10 in humans) form a tri-molecular 
complex.  CD24, through its interaction with Siglec, was 
proposed to inhibit the host response to tissue injury by 
modulating NF-kB activation(77). The extensive glycosylation 
of CD24 molecules can be the explanation of CD24’s ability to 
interact and form complexes with Siglecs and DAMPs (HMGB1 
and HSPs). 
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 These sites provide multiple binding sites that potentially can 
interact with multiple molecules simultaneously. This pathway 
imposed a significant negative feedback loop limiting 
inflammation and a high surge of cytokines when the cells are 
damaged by non-pathogenic stimuli. This was presented as a 
simple model by the same group as shown in the diagram below 
(21), Figure 9. 
   
Figure 9: Simplified model of CD24/Siglec/DAMP interaction. 
The model represents physiological pathway leading to  a differential response of 
cells to PAMPs and DAMPs mediated by tri- molecular complex formed by CD24/ 
Siglec/DAMPs leading to SHP-1 activation(21). 
To verify the hypothesis that CD24 plays a vital role in 
discriminating tissue response to DAMPs from PAMPs, Chen et 
al. induced damage in the mice liver cells by using the well-
known hepatotoxic drug i-e acetaminophen. Acetaminophen 
(N-acetyl-p-aminophenol [APAP]), also termed paracetamol, is 
one of the most commonly used experimental models of 
inducing acute liver cell damage in mice (78). The model is 
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highly reproducible and causes dose-dependent hepatotoxicity 
that can be induced by even single dose of APAP. They treated 
CD24 -/- mice with sub lethal dose (10mg/mouse) of 
acetaminophen (APAP) and observed that  a  dose that was well 
tolerated by wild type mice resulted in significantly reduced 
survival of  CD24 -/- mice compared to Wild type controls 
(death within 20 hours post treatment with APAP). They also 
detected significantly increased levels of inflammatory 
cytokines (including IL-6 and TNFα) and hepatic enzymes in 
CD24 deficient mice compared to Wild type group after APAP 
(Acetaminophen) treatment. These mice were rescued and 
showed decreased serum levels of cytokines and enzymes after 
treatment with HMGB1 blocking antibodies in the CD24 -/- 
group pointing towards HMGB1 to be the direct mediator of 
injury in the absence of CD24 (67).  
How this inhibitory effect of CD24 on the HMGB1 was mediated 
was unclear, as CD24 has no known signal transduction 
mechanism. Siglecs were looked up in this regard by Chen et 
al. based on the evidences that these cell surface receptors 
belonging to immunoglobulin super-family can recognize sialic 
acid-containing proteins. Siglecs have been considered as 
negative regulators of the immune system by virtue of presence 
of one or more cytosolic immune receptor tyrosine-based 
inhibitory motifs (ITIMs). They found direct interaction between 
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CD24 and Siglec 10 in mice by co-immunoprecipitation and flow 
cytometric analyses and hence provided evidence that CD24 
interacts directly with HMGB1 and Siglec molecules. Based on 
above findings they presented their tri-molecular model of 
CD24-Siglecs- HMGB1 as a loop that discriminates cellular 
response to danger versus pathogens(41). 
Very recently it has been proposed that pathogens lead to 
sepsis (there by causing excessive release of inflammatory 
cytokines and tissue damage) by breaking the above mentioned 
interaction. This is achieved by bacterial sialidases cleaving off 
CD24 sugar moieties. Inhibition of sialidases resulted in 
dampening of sepsis and is being explored as potential 
treatment option (66).  
This further emphasises the significance of glycosylation of 
CD24 and exploring these sugar sites was one of the targets of 
our study and will be discussed in detail. Within the 
gastrointestinal tract, there are a number of non-infectious 
inflammatory conditions in which there is likely to be a release 
of DAMPs.  Similarly, most solid malignancies are marked by 
necrosis and probable release of DAMPs in tumour and tissue 
microenvironment. Over the past decade, research has been 
undertaken to explore how this affects the adjacent cells and 
tissues.  
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Some studies have related these DAMPs to be important 
contributory factors in development of chronic diseases and 
even malignancies(79).  
 
 
 
Figure 10: Flow diagram of potential outcomes of tissue injury(79). 
The prototype DAMP presented in literature is HMGB1 (80). In 
2004 Rovere-Querini et al. showed that the supernatants of 
necrotic cells lead to dendritic cell maturation via HMGB1(81). 
The presence of HMGB1 in necrotic cell pellets, as well as 
supernatant from Hela cells when damaged by repeated freeze 
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thaw cycles, was shown by western blot and this naturally 
released HMGB1 had comparable effects to recombinant 
HMGB1(81). In 2006 Yang De et al. proposed a chemotactic role 
of DAMPs on dendritic cells at the site of injury (82). It was later 
shown that effects of DAMPs were not limited to immune cells - 
rather it was seen in a setting of macrophage/enterocyte co-
culture that necrotic macrophages (prepared by repeated freeze 
thaw) released DAMPs and these reduced enterocyte cell 
migration pointing towards the differential role of these 
substances on immune cells and epithelial cells (74). Another 
very recent study by Lotfi et al. demonstrated  that necrotic 
material from both normal as well as tumour cells (prepared 
from necrotic cell lysates from HCT116, CaCo2 ,COLO as well 
as from platelets and mesenchymal stem cells) promotes 
proliferation and trafficking of human mesenchymal stem cells 
(MSCs) (80). These effects were neutralised when HMGB1 
antibodies were used indicating it to be the common and major 
player released from these diverse cellular sources and quite 
interestingly the cellular response was similar irrespective of the  
source of DAMPs (80). 
Whilst much of the work on responsiveness to DAMPs has 
focused on inflammatory and immune cells, it is possible that 
DAMPs may also be detected by intestinal epithelial cells.  It has 
been shown that intestinal epithelial cells express Toll-like 
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receptors and RAGE and we have recently shown that 
expression of CD24 is up-regulated during active inflammation 
in epithelial cells in both Crohn’s disease and Ulcerative Colitis 
(26, 44). These diseases are characterised by extensive tissue 
necrosis followed by tissue healing.  For the latter to occur, 
epithelial cells must proliferate and migrate over damaged 
areas to restore epithelial continuity before re-modelling can 
begin. The above studies explored interactions between DAMPs 
released by immune cells acting on epithelial cells and vice 
versa but none of the studies tried to look up if dead epithelial 
cells can give messages to the remaining alive adjacent cells 
directly.  
Given that CD24 is linked to cellular properties like migration 
and growth and is increased in the setting of colorectal cancers 
and inflammatory bowel disease (26), we hypothesised that 
autologous DAMPs may influence epithelial cell functions. If so, 
DAMPs could cause alteration of cell motility and proliferation 
since these would be important in the healing process. We 
therefore, sought to investigate firstly whether or not colorectal 
carcinoma cells (epithelial cells) show any response to 
autologous DAMPs. Secondly, if any of these effects were 
mediated through CD24. 
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Materials and methods: 
Preparation of DAMPs: 
Colorectal carcinoma cell lines (HCT116/RKO/SW620/SW480 
and DLD1) were exposed to autologously derived DAMPs (i.e. 
derived from the same cell line) in order to prevent any possible 
activation due, for example, to cell line-specific growth factor 
production.  DAMPs were prepared following the protocol by 
Lotfi et al. and in accordance with the standard method (8, 35, 
37, 80, 83). Briefly, cells were grown to confluence, the tissue 
culture medium was aspirated and the cells were washed twice 
in Phosphate Buffered Saline (PBS, Sigma, USA).  After this, 
5ml of PBS was added to the cells which were then scraped off 
the flask with a scraper (Corning, UK). A single cell suspension 
was obtained by repeatedly pipetting the cells through a 10ml 
pipette tip. A total of 106 cells suspended in 1000µl of PBS were 
transferred into a 1.5ml eppendorf tube (Sigma Aldrich UK). 
The cells underwent four freeze-thaw cycles (consisting of 
freezing in dry ice for 5-7 minutes and thawing in a water bath 
at 37oC for 5-7 minutes) in order to release the DAMPs from the 
cells.  The tubes were centrifuged at 17,000 x g for 1 minute 
and the supernatant was collected in new tubes. The proteins 
in the supernatant were quantified, using the BCA Protein Assay 
Kit (Thermo Fisher Scientific Inc., Rockford, USA) in accordance 
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with the manufacturer’s instructions.  Western blots for HMGB1/ 
β-actin/ HSP90/ Histone 3 were performed on the supernatants 
as an indicator of cell lysis and for presence of DAMPs. Various 
concentrations of NCL (necrotic cell lysate) supernatant were 
tested in order to determine the optimal concentration for the 
DAMP stimulation experiments.  
Wound Healing Assays: 
Wound healing assays were performed in 6 well plates (Costa, 
UK).  Cells were grown to confluence in full medium and then 
starved for 24 hours in serum free medium.  A “wound” was 
created using a sterile 100µl pipette tip and the wells were 
supplemented with either autologously derived DAMPs to a final 
concentration of 0.08µg/µl of DAMPs or, for the controls, an 
equivalent volume of PBS.  Photographs were taken using a 
charge-coupled device (CCD) camera (Canon) attached to the 
inverted phase-contrast microscope at a magnification of 40x.  
Migration of cells across the wound line was assessed 24 hours 
after wounding using T Scratch  software (72).  The 
experiments were repeated four times at different occasions 
with each condition in triplicate with three wounds in each well. 
Transwell Migration Assays: 
Transwell cell migration assay was performed using a Boyden 
chamber containing a polycarbonate filter with an 8 µm pore 
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size (Costar, UK) as previously described (26).  Prior to the 
addition of cells, the Boyden chambers were incubated in 600µl 
serum free DMEM for one hour at 37oC.  This was removed and 
medium (600µl) supplemented with 20% FBS was added to the 
lower chamber.  A total of 105 cells were added into the upper 
chamber in 200µl of medium supplemented with 10% FBS.  In 
order to evaluate directional motility, medium in the lower 
chamber was supplemented with either autologously derived 
DAMPs to a final concentration of 0.08µg/µl of DAMPs or, for 
the controls, an equivalent volume of PBS.  
 Cell migration across the membrane was allowed to take place 
over a period of 8-12 hours depending on the cell line after 
which the chambers were removed.  The plates were incubated 
for a further two hours to allow migrating cells to settle down 
to the bottom of the wells and cells which had migrated to the 
bottom wells were counted by direct microscopy.  Cells were 
counted by two different experimenters for validation.  The 
experiments were conducted in triplicate and repeated three 
times.  
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Figure 11: Trans well migration. 
The Cells loaded in the upper chamber pass through the pores and are migrated to 
the bottom wells. These were counted by direct microscopy after allowing them to 
settle for two hours. 
Proliferation Assay: 
Presto-Blue® (PB) is a new, simple and extremely fast live 
assay. This assay is a commercially available, ready-to-use, 
water-soluble preparation. PrestoBlue® reagent contains a cell-
permeant compound (Resazurin) that is blue in colour and 
virtually non-fluorescent in solution. When added to media, 
PrestoBlue® reagent is rapidly taken up by cells. The reducing 
environment within viable cells converts PrestoBlue® reagent 
to an intensely red-fluorescent dye (Resorufin). This change 
can be detected by measuring fluorescence or absorbance. 
Conversion is proportional to the number of metabolically active 
cells and therefore can be measured quantitatively and hence 
can be used as a proliferation assay. Resazurin-based viability 
assays do not require cell lysis and hence, the same plates can 
be measured at different time points making is a very useful 
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assay to observe the effect of DAMPs on cellular proliferation 
over a course of 2-5 days. The experiment was performed 
according to the manufacturer’s protocol (Themo Fisher 
Scientific, UK, Cat # A-13261).  
Briefly, cells were exposed to autologous DAMPs at a 
concentration of 0.08ug/µl in full media (DMEM+10% FBS) and 
control cells were treated with equal volume of PBS in full 
media. Cells were seeded at a density of 2 × 10 4 cells/well in a 
24-well plate with each condition in triplicate.  
Cell proliferation was determined by incubation with 
PrestoBlue® master mix at 1 : 10 dilution (i-e 2.7ml DMEM+ 
300 µl of presto blue reagent). A total of 400 µl of this master 
mix was added to each well for 1 h at 37C° in the dark. 100 µl 
was added to each well of a 96 well plate (hence in triplicate 
from each well of 24 well plate). 
Three wells with master mix incubated with media but without 
the cells served as the “Blank”. The fluorescence intensity of 
the Resazurin product (Resorufin) was measured using Fluostar 
Optima® (BMG LabTech, Germany) at 530 nm (excitation 
wavelength) and 590 nm (emission wavelength). After each 
reading excess, Prestoblue® master mix was aspirated from 
the wells and cells were re incubated with either full media or 
full media with DAMPs as described above. Readings were taken 
at 0, 24, 48 and 72 h using three gains (500, 1000, and 1500). 
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The experiment was performed on three different cell lines and 
repeated on two separate occasions, with each condition in 
triplicate. 
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Results:  
It has already being shown by multiple studies that damage to 
cells by repeated freeze thaw cycles results in the breakdown 
of cell membranes. This leads to the formation of necrotic cell 
lysate (NCL) and it is generally taken as a natural source of 
DAMPs. As mentioned earlier, studies have shown  HMGB1 to 
be abundant ubiquitous DAMP common to various cell lysates 
tested (from necrotic macrophages, platelets, mesenchymal 
stem cells and colorectal cancer cells such as from HCT116 and 
COLO) in addition to other  DAMPs (80, 81). This approach is 
more helpful in our view, compared to some studies using only 
recombinant or purified single component, as this cellular lysate 
and the released contents are a closer reproduction of tissue 
microenvironment when the cells lysis occurs as a result of 
lethal tissue damage. 
Hence, we prepared our DAMPs by the above mentioned 
protocol. We performed western blot analysis on these lysates 
to ensure complete rupture of membranes and presence of 
DAMPs in that supernatant. Four antibodies were used: HMGB1 
is the prototype of DAMPs, present in the cell nucleus but acts 
as DAMP when released after cell lysis. HSP90 is also a specific 
DAMP itself present mostly in the cytoplasm, β-actin is a 
cytoplasmic protein and confirms the release of cytoplasmic 
contents, H3 is a nuclear protein and released only after 
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damage to nuclear membrane (hence all its accompanying 
contents). All antibodies were strongly positive Figure 12. 
 
Figure 12 : Western blot showing   DAMPs in supernatants (SW620). 
To ensure complete lysis of cells and thereby the release of DAMPs western blots were 
performed on supernatants from SW620. β-actin, Histone 3 (H3) , Heat shock protein 90 
(HSP90) and HMGB1 were immunoblotted. 
 
Figure 13: Western blot showing DAMPs in supernatants (DLD1 AND 
HCT116). 
DAMPs western blots performed on supernatants from DLD1 and HCT116. β-actin, Histone 3 
(H3) , Heat shock protein 90 (HSP90) and HMGB1 were immunoblotted (A). Densitometry bar 
graph (B). 
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Figure 14: Optimisation of supernatant conc. for functional assays. 
To know the optimum concentration of DAMPs (NCL) to be used in our functional assays, total 
protein conc. of the necrotic cell lysate was measured and taken as an indirect representation 
of amount of DAMPs in them. Various amounts ranging from 0.01 to 0.16 µg/µl were tested in 
transwell migration assay using SW620. Significant effects were seen at a concentration of 
0.08 µg/µl or above. Student t-test was used to analyse the data and a p value of ≤ 0.05 was 
considered significant. Conc. (concentration). 
 
We hypothesised that DAMPs may cause physiological changes 
in epithelial cells which can be related to cell motility and  
therefore, be relevant to both tissue healing (in the normal 
physiological context) and local tumour invasion (in the context 
of malignancy).  We did not know the likely nature of this effect 
(increasing or decreasing motility) nor the “dosage” required. 
We tested SW620 cells in transwell migration assays in order to 
find the optimal concentration of lysate to be used in the next 
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experiments. To achieve that we compared the motility of cells 
through the transwell membrane when exposed to increasing 
concentration of DAMPs in the bottom wells compared to media. 
The lower chambers of the wells were supplemented with 
DAMPs (NCL) in a concentration ranging from 0.001 to 0.1µg/µl.  
Compared to controls which were supplemented with PBS, a 
significant difference in motility was seen when cells were 
stimulated with DAMPs at a concentration of 0.08µg/µl and so 
we chose this concentration Figure 14. 
DAMPs inhibit both directional and non-directional motility: 
Our initial optimisation data showed that DAMPs were inhibiting 
cell motility in colorectal carcinoma cell lines (colonic epithelial 
cells).  In order to confirm that this was not a cell line-specific 
effect, we tested an additional 3 cell lines.  In order to analyse 
relevance of this effect to CD24, we selected two cell lines which 
had high expression of CD24 (DLD1 and SW620) and 2 cell lines 
which were negative for CD24 i.e. HCT116 and RKO. Analysis 
of CD24 expression levels has been done by our group 
previously analysing both mRNA and protein levels for CD24 in 
each cell line through qPCR, flow cytometry and western blots 
analyses (see Appendix iii). We also performed western blot 
to confirm CD24 expressions in these cell lines Figure 15. 
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Non directional cell motility was tested using wound healing 
assay and showed, in 3 out of 4 cell lines (RKO) tested, a 
significant inhibition of cell motility across the wound following 
exposure to DAMPs Figure 16. This effect was observed 
irrespective of CD24 expression in the cell lines, it indicated that 
CD24 may not be essential for a DAMPs response in colorectal 
cancer cell lines (colonic epithelial cells) Figure 17.  
Many studies have shown that DAMPs can act as chemo-
attractants for dendritic cells and thus we investigated whether 
they could modulate chemotaxis in epithelial cells. Transwell 
migration assays were performed with DAMPs added to the 
lower chamber.  Compared to PBS controls, the presence of the 
DAMPs significantly inhibited cell migration across the 
membrane in three out of four tested (again RKO did not show 
a statistically significant difference) Figure 18. The reasoning 
for the lack of significant response in RKO cell line could be due 
to the difference in genetic mutations amongst them. RKO lacks 
mutant Kras and carries mutant Braf and opposite is true for 
rest of the three cell lines Table 1. 
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Figure 15: Western blots of cell lines showing CD24 expression levels. 
 CD24 protein levels were tested in lysates from HCT116/DLD1/SW620 cell lines by using 
SWA11 mAb. β-actin was loading control. HCT116 is negative where as SW620 and DLD1 are 
strongly positive for CD24 (A). Densitometry bar graph (B). 
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Figure 16: DAMPs reduced cell migration across the wound. 
Representative images from colorectal carcinoma cell lines exposed to autologous DAMPs (0.08 
µg/µl) or media alone. Photographs were taken for T=0hrs and then after 24 hrs at same the 
point for each condition (image magnification X 40). For each condition at least six sets of 
photographs were taken along the wound. Open wound area of  the images was measured  
using T-scratch software(72). The experiment was repeated for each cell line in triplicate and 
on three different occasions.  
Magnification X 40 
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Figure 17: Wound healing assay in four colorectal cell lines. 
Wound healing assay was performed and analysed using T-scratch software and the percentage 
of wound closure after 24hrs of exposure to autologous DAMPs was calculated and compared 
to media in four colorectal cell lines. All values were expressed as ± SEM. DLD1 and SW620 are 
positive for CD24 and HCT116 and RKO are CD24 negative cell lines. These experiments were 
repeated thrice in triplicate at separate occasions. Student t-test was used to analyse the data 
and a p value of ≤ 0.05 was considered significant.  
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Figure 18: DAMPs inhibit directional motility as well in autologous cell lines. 
We performed transwell migration assay with DAMPs in the bottom wells as stimulus and 
observed that less number of cells migrated to the bottom wells having DAMPs as compared to 
media in both CD24 positive and negative cell lines. The effect was statistically significant in 3 
out of 4 cell lines. This effect was dose dependent with a minimum effective concentration of 
0.08µg/µl of DAMPs as shown by the optimization experiments. Cells migrated to the bottom 
wells after 8- 24hrs were counted by direct microscopy. Results were analysed using Graph pad 
prism version 6. These experiments were repeated thrice in triplicate at separate occasions. 
Results expressed as mean ± SEM and P-value of ≤ 0.05 were taken as significant. NS (not 
significant).  
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Mechanism of DAMPs inhibition of  epithelial cell motility:  
Next we tried to explore the possible mechanism leading to 
reduced cellular motility. In order to ascertain how DAMPs may 
be causing inhibition of cell motility, we tested SW620 by 
Western blot for expression of a panel of markers associated 
with Epithelial Mesenchymal Transition (EMT) including Snail, 
Cten, E-cadherin and N-cadherin.  Exposure to DAMPs led to a 
clear reduction in Snail, Cten and N-cadherin protein levels. 
However, the levels of E-cadherin remained quite similar. β-
actin was used as loading control Figure 19. 
DAMPs act independently of CD24: 
CD24 is a proposed DAMPs receptor in dendritic cells. Given our 
original observation of up-regulation of CD24 in epithelial cells 
in inflammatory bowel disease, we were prompted to 
investigate whether CD24 could also mediate the activity of 
DAMPs in non-immune cells. Our results on high and low 
expressing cell lines for CD24 suggested that CD24 was not 
essential to the DAMPs response.  In order to ascertain whether 
there was some contribution to the DAMPs response by CD24, 
we repeated the experiments following modulation of levels of 
CD24 by forced expression and knockdown. 
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Figure 19: DAMPs decrease cell motility by inhibiting epithelial mesenchymal  
transition. 
SW620 cells were exposed to DAMPs or media as a control for 24 hours and western blot was 
performed using a panel of motility markers including E-cadherin, N-cadherin, Cten and Snail, 
whereas β-actin was used as loading control (A). Densitometry bar graph (B). EMT (Epithelial 
mesenchymal transition). 
CD24 was knocked down in SW620 and the transwell migration 
experiments were repeated. Comparison of the PBS controls 
showed that, in agreement with our previous published data, 
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knockdown of CD24 resulted in an inhibition of cell motility. 
Comparison of the DAMPs stimulated cells, however, showed 
that there was no significant difference between cells 
transfected with CD24 siRNA versus luciferase controls Figure 
20. Thus, knockdown of CD24 could not rescue the inhibitory 
effects of DAMPs thereby suggesting again that CD24 was not 
modulating DAMPs response in colonic epithelial cells. The 
knock down was confirmed by western blot and gave typical but 
reduced smeary band in the knock down lane compared to 
scramble control Figure 21. 
 
Figure 20: Inhibition of transwell migration by DAMPs is not mediated through CD24. 
 Transwell experiment was performed after 48 hours of knockdown of CD24 in SW620 using 
CD24 si RNA and cells were then exposed to 0.08µg/µl DAMPs in the bottom well and migration 
was compared with media. Although CD24 knockdown resulted in inhibition of cell migration 
but DAMPs were once again showing significant inhibition of migration in both CD24 presence 
and absence (SC DAMPS vs KD CD24 DAMPS). Hence indicating, inhibition was not mediated 
by CD24. Results shown here are the means ± standard errors (SE) for three independent 
experiments. Data were analysed by Graph Pad prism6 using student t test and P≤0.05 as a 
significant p value. SC MEDIA (scramble control media), SC DAMPs (scramble control/luciferase 
SiRNA DAMPs), KD CD24 (Knock down CD24).  
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Figure 21: Western blot showing CD24 knock down. 
SW620 cells were transfected with either CD24 siRNA or Luciferase siRNA as control using 
Lipofectamine2000 reagent according to manufacturer guidelines. Cells were harvested for 
further transwell assay and immune blotting after 48 hours (A). Densitometry bar graph (B).  
SWA11Ab was used for CD24 and β-actin was loading control. KD (knock Down), SC 
(scramble control= Luciferase siRNA). 
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Figure 22: Forced expression of CD24 was confirmed by western blot. 
HCT116 cells were transfected with the CD24 expression vector and upregulation of 
CD24 was confirmed by using SWA11 mAb for CD24 and β-actin was used as 
loading control (A). Densitometry bar graph (B). 
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Figure 23: DAMPs inhibitory effect on motility appears independent of CD24. 
To analyse the effect of CD24 on the response of DAMPs .Wound healing assay was repeated 
by exposing cells to DAMPs in HCT116 cells after forced expressed with CD24 and wound 
closure was compared to controls. (Image magnification X 40) (A).Graph showing inhibition of 
cell motility by DAMPs and rescue of cell motility with CD24 forced expression but less marked 
in the presence of DAMPs (B).  
MEDIA 
DAMPs 
EMPTY VECTOR CD24 FORCED 
EXPRESSED 
A 
B 
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In accordance with the results of our previous experiments, it 
was observed that DAMPs were having inhibitory effects on 
motility. CD24 transfected cells showed rescue of migration 
with media, but less so in cells exposed to DAMPs Figure 23.  
These results, when taken together with knockdown 
experiments, suggest that the effect of DAMPs is to inhibit the 
motility of colorectal epithelial cells and this effect doesn’t 
appear to be mediated through CD24. 
DAMPs increase cell proliferation: 
An increase in mitotic activity is commonly seen in inflamed tissue and, 
in addition to changes in cell motility, it is an important component of the 
healing response.  We, therefore, investigated whether DAMPs could 
affect cell proliferation in SW620 / HCT116 and SW480. Stimulation of 
cells with DAMPs resulted in a significant increase in cell numbers .This 
was seen in both high and low expressers of CD24 Figure 24. 
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Figure 24: DAMPs induce significant increase in cellular proliferation. 
Effects of DAMPs on cellular growth were assayed by Presto Blue method. Three cell lines 
(SW620/SW480/HCT116) were exposed to autologous DAMPs and cell proliferation was 
measured at t=0, 24, 48 and 72 hrs and compared with media alone. The fluorescence intensity 
was measured at 530 nm (excitation wavelength) and 590 nm (emission wavelength). There 
was a significant difference (p≤0.001) in proliferation between cells exposed to media versus 
DAMPs but regardless of CD24. The experiment was repeated and was performed in triplicate 
but showed same results. Data were analysed by Graph Pad prism6 using Two way ANOVA 
Test, comparing each time point. 
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Discussion: 
There are many types of lethal pathological insult that can cause 
cell necrosis and spillage of cellular contents into the 
extracellular environment.  In order for damaged tissue to be 
repaired, new cells must proliferate and migrate into the 
damaged area in order to replace the damaged tissues.  It is 
not unreasonable therefore to conjecture that DAMPs may play 
a role in regulating the healing response.  Whilst DAMPs have 
been studied in lymphoid and dendritic cells, the effect of 
DAMPs on epithelial cells has been relatively ignored.  
Given solid tumours are marked by frequent necrosis and 
current research underscores the significance of tumour 
microenvironment in tumour progression and survival, some 
recent studies have explored the effects of DAMPs on 
mesenchymal stem cells and enterocytes. But none of the 
studies have explored if dying cancer cells could signal back to 
the autologous cancer cells. 
 In this study, therefore, we sought to examine the effect of 
DAMPs on autologous epithelial cell proliferation and motility. 
While most of the studies on DAMPs have used a single molecule 
as a representative of DAMPs (most commonly HMGB1), in our 
study, we used whole cell lysates as this is more reflective of 
the milieu found in tissue damage.  
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Both CD24 and DAMPs are believed to be increased in 
inflammatory bowel disease and the colorectal tumour 
microenvironment. We speculated firstly if DAMPs have any 
direct effect on epithelial cell proliferation and secondly if this 
effect is mediated through CD24 based on the fact both have 
been linked to cell proliferation in recent literature (56, 84, 85). 
Cell lines with different CD24 expression levels were tested for 
effects of DAMPs on cellular proliferation i.e. SW620 (high 
expresser of CD24), HCT116 (very low expresser) and SW480 
(negative for CD24). We found that proliferation was 
significantly increased in all three cell lines using the Presto Blue 
proliferation assay. This assay allows measurement of cell 
proliferation over repeated time points in the same wells. And 
the proliferation shows a marked increase compared to 
untreated controls with increasing time Figure 24. 
 Pistoia et al. have also shown an increase in  proliferation of 
mesenchymal stem cells (MSCs) by DAMPs and they proposed 
these MSCs in turn increase epithelial cell proliferation (84),  
whereas, we have found that DAMPs can directly stimulate cell 
proliferation as well. Our findings are quite similar to a very 
recent study by Kang et al. They also found increase in 
proliferation of pancreatic tumour cells by direct exposure to 
DAMPs (86). 
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 However as our experiments showed increased cell 
proliferation in both high expressing and negative cell lines for 
CD24, it seems the effect is not mediated via this molecule and 
may quite be through RAGE or Toll like receptors.  
Regarding effects of DAMPs on cell motility, intuitively we had 
expected DAMPs to stimulate cell motility.  However our data, 
obtained in four different cell lines and using 2 different types 
of assays (i.e. transwell migration and wound healing assays), 
have unequivocally shown that, in fact, DAMPs inhibit epithelial 
cell motility.  We have also shown that both general motility and 
chemotaxis are affected and that these effects are mediated 
through down-regulation of molecules such as Snail, N-cadherin 
and Cten whilst there was slight up-regulation of E-cadherin.  
These molecules are involved in epithelial–mesenchymal 
transition (EMT) and thus altered expression of these molecules 
raises the possibility of mesenchymal to epithelial transition 
(MET) as a consequence of DAMP activity.  Our data are 
supported by procedure Dai et al. who showed that HMGB1 
could inhibit cell motility and chemotaxis in enterocytes through 
TLR4 signalling which (which in turn led to increased focal 
adhesions (74).  
Many studies of the effects of DAMPs in leucocytes have shown 
that they act as chemo-attractants and that they stimulate cell 
migration (39, 68, 86, 87). Thus, it would seem that DAMPs act 
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to attract inflammatory cells to a site of injury whilst repelling 
immigration of epithelial cells.  It may be that, in the former 
case, the attraction of inflammatory cells helps to maintain the 
inflammatory reaction and limit the damaging stimulus.  
Inhibiting epithelial cell motility will delay healing but the 
DAMPs may be acting as signals which indicate that the context 
is not yet correct for healing to occur.  
We also found that the inhibitory effect of DAMPs on colonic 
epithelial cells was independent of CD24.  Migration in cells not 
expressing CD24 was inhibited and knock down of CD24 in 
SW620 (which expresses high levels of CD24) did not prevent 
the inhibition of motility.  Thus, CD24 does not appear to 
modulate cellular response to DAMPs in these cells in direct 
contrast to immune cells in which CD24 is thought to inhibit TLR 
activity and suppress inflammation. We reasoned that in 
contrast  to the experiments of  by Chen et al. (41)  we were 
trying to explore the  epithelial cells (colorectal carcinoma cell 
lines) which may have quite different glycosylation patterns and 
surface expression of molecules as compared to immune cells 
and hence  different interactions and signalling outcomes. It 
may be possible that epithelial CD24 does not interact with 
DAMPs and the results of Chen et al. may be specific to immune 
cells. Another  reason for this lack of modulation could be the 
absence of  Siglecs  in epithelial cells  as DAMPs may only 
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interact with CD24  by forming a tri-molecular complex as 
shown  in immune cells (88).  
The reasons for our observation of high expression of CD24 in 
the epithelial cells in active inflammatory bowel disease remain 
uncertain.  CD24 has been proposed to have a number of other 
functions such as maintenance of stemness (89)  and it may be 
that these are the reasons for up-regulation. 
In summary, we have shown that DAMPs can inhibit the motility 
of colonic epithelial cells possibly through the process of MET.  
They also affect proliferation in these cells and their activity is 
independent of CD24 expression. Further work is needed in 
order to identify the specific receptors for DAMPs in colonic 
epithelial cells and more sophisticated in vitro models are 
necessary to interrogate the relationship between the 
epithelium, inflammatory cells and substances in the tissue 
microenvironment.  
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Introduction: 
Given its unique structure, characteristic localisation and 
absence of any transmembrane domain for direct signalling, 
CD24 is very intriguing to researchers. Little is known about the 
mechanisms and signalling partners of this tiny molecule. 
Studies by Altevogt et al., Baumann et al. and Sagiv et al. have 
given some insight on potential signalling mechanisms and have 
attempted to explore possible therapeutic strategies (8, 35, 63, 
68, 90).  
Signalling Partners of CD24:            
In order to understand how this molecule works it is important 
to consider its structure, how it possibly affects nearby 
molecules, what are the molecules present in the vicinity and if 
any links between these can be found. Regarding CD24 we 
already know that it is heavily glycosylated and some of its 
interactions with its ligands are mediated via these sugars. In 
addition it has also been revealed that CD24 is present at 
specialised membrane areas called lipid rafts (also called 
Detergent resistant membranes DRM or Glycolipid enriched 
membranes GEM). These lipid rafts have special assemblies of 
molecules called focal adhesions. Molecular trafficking is shown 
to be tightly regulated at these sites with potentially significant 
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effects on cellular events  through unknown mechanisms (33). 
CD24 is a major component present in the lipid rafts and recent 
research has presented the notion that some of the functions 
attributed to this molecule may be linked to its presence at 
these docking sites. It is proposed that  functions might be 
orchestrated by affecting molecules present at focal adhesions 
(33). Here we briefly discuss some of the relevant structures 
and molecules that might help in understanding the signalling 
biology of CD24. 
Lipid Rafts: 
Over the last three decades, research has unveiled diversity 
amongst different parts of cellular membranes. Plasma 
membranes are now considered to be areas of dynamic 
assemblies of lipids and cholesterol and also harbour specialised 
docking sites called lipid rafts (rich in cholesterol and sphingo-
lipids) (91). This diversity and special assemblies suggest that 
membrane structure could be an important contributor to cell 
function and pathophysiology. The involvement of these 
domains in diverse cellular functions (e.g. growth factor 
signalling and membrane trafficking) and disease processes - 
including cancer, autoimmunity, and Alzheimer’s disease - has 
confirmed this potential and prompted an increased research in 
this area (91). CD24 being a GPI linked protein, is also shown 
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in recent research to be a significant contributor to trafficking 
across these. 
 
 
Figure 25: Schematic cartoon of lipid rafts showing GPI anchored proteins.(91) 
CD24 is proposed to be “gate keeper” of these lipid raft 
domains. Studies have shown trafficking of certain significant 
signalling molecules in and out of these lipid rafts to be 
monitored by CD24. These include β1 integrins (83) and CXCR 
in breast cancer (23, 92). 
Focal Adhesions: 
 
Focal adhesions were first identified in electron microscopic 
studies of cultured fibroblasts (93). These are specialised areas 
in the cell membranes that appear as focal plaques, dense spots 
or focal contacts seen on the ventral surfaces of the attached 
cells (93). Focal adhesions are large multiprotein complexes 
and they provide a structural connection between the actin 
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cytoskeleton inside the cell and the ECM (extra cellular matrix) 
components such as fibronectin and vimentin. This connection 
is via a family of specialised transmembrane receptors that are 
essential for the formation of focal adhesions and are known as 
Integrins (94).  
 
 
 
Figure 26: Schematic diagram illustrating a focal adhesion complex. 
Focal adhesions provide the transmembrane link between the extracellular matrix (ECM) and 
the actin cytoskeleton. Integrins are transmembrane heterodimeric receptors composed of α 
and β subunits. The extracellular domain of integrins interacts with the ECM while the 
cytoplasmic tail binds to cytoskeletal proteins. Focal adhesions are formed by diverse molecules. 
Tightly ordered recruitment of focal adhesion components, assembly and disassembly of focal 
contacts take place during cellular motility and adhesion (95). 
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Studies have revealed that these Focal adhesions also modulate 
numerous critical cellular events, besides just providing 
anchorage, including signal transduction for mediating vital 
cellular  events (96). In order to mediate a diverse range of 
signalling functions, focal adhesions have a special assembly of 
signalling molecules, including different protein kinases, 
phosphatases, their substrates, and various adapter 
proteins(93). 
Quite interestingly, focal adhesions are formed at specific 
membrane domains called lipid rafts also occupied by CD24. As 
mentioned earlier, studies have indicated a role of CD24 in 
bringing Integrins to these lipid rafts (83). In this section of the 
study we will be focussing on a few more molecules associated 
with these focal adhesions. The aim will be to explore if CD24 
mediates its role via any of these especially Cten, FAK and ILK. 
Integrins: 
One significant group of proteins, that are essential for 
maintaining the integrity of focal adhesions, are called 
Integrins. These are transmembrane receptors and structurally 
consist of obligate heterodimers. There are about 18 different 
types of α-subunits and 8 types of β subunits and lead to a 
range of receptor heterodimers that are thought to be 
associated with diverse and specific biological roles (97). 
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Integrins lack any intrinsic kinase activity. However, they have 
an assemblage of almost 50 proteins linked to their cytoplasmic 
tails including talin, paxillin, vinculin and alpha-actinin  and 
these, in turn,  interact with the actin cytoskeleton with in the 
cell (97). 
CD24 expression is shown to supports rapid cell spreading and 
strongly induces cell motility. Using a doxycycline-inducible 
system to express CD24, Baumann et al. found that CD24 
expression  activates  α3β1 and α4β1 integrins and thereby 
stimulates cell adhesion to fibronectin, collagens I/IV and 
laminins (33). 
C-src: 
In non-malignant cells, c-src kinase activity is tightly regulated. 
However many tumours are found to exhibit enhanced c-src 
kinase and this over expression is related to a poor prognosis. 
The kinase activity of c-src is known to play a significant role in 
the formation of focal adhesions and is shown to be through the 
phosphorylation of proteins such as FAK and paxillin (33). 
Very Recently Baumann et al, has shown a significant molecular 
link of CD24, focal adhesion complex and intact lipid rafts in 
breast cancer cells. CD24-increased c-src kinase activity that 
led to increased formation of focal adhesion complexes, 
enhanced phosphorylation of FAK and paxillin. Thereby 
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presenting that c-src is a CD24-activated mediator that 
promotes integrin-mediated adhesion and invasion and this was 
dependent on intact lipid rafts (33).  
Cten/TSN4: 
C-terminal tensin-like (Cten) is a member of the tensin gene 
family but lacks the N-terminus actin-binding domain. Its role 
in tumours is not very clear as yet and both anti-tumour and 
pro-tumour roles have been attributed to this molecule and 
these roles may well be tissue specific (98).  
The Cten gene translates for a complex protein which has 
multiple domains capable of interacting with several molecules 
which in turn play important roles in cell signalling. Significant 
domains of Cten include the Phospho-tyrosine binding domain 
(PTB) and Src homology domain (SH2). These domains help 
Cten to bind with the cytoplasmic tails of β integrin at  focal 
adhesions and also with the proteins containing 
phosphorylated tyrosine residues like Focal adhesion Kinase 
(FAK), ILK, p130Cas and P13 kinase (99). 
In colorectal cancer (CRC), up-regulation of Cten levels has 
been observed. Our group has found that increased expression 
of Cten results in increased cell migration (98). They also 
observed that the effect of Cten on cell migration and invasion 
was via modulation of downstream targets including down-
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regulation of E-cadherin and induction of epithelial to 
mesenchymal transition (EMT) (98). 
Not much is known about the regulation of Cten and our lab has 
already proposed EGFR_Kras-Cten signalling to be one of the 
pathways mediating this molecule. However this may not be the 
only loop regulating Cten (100). Many features indicated 
towards a potential link between Cten and CD24. Both Cten and 
CD24 are associated with increased cellular motility, 
invasiveness and adhesion. Akin to CD24, Cten is also 
upregulated early in the adenoma carcinoma sequence. 
Moreover, downstream targets for both molecules appear to be 
similar. As mentioned above,  Altevogt et al. showed CD24 to 
be regulating c-src and FAK as well as STAT3 (101). 
Comparable effects by CD24 on STAT3 were observed by Lee et 
al. indicating STAT3 was activated by CD24 via NANOG (102). 
On the other hand a recent study by Barbieri et al. has proposed 
STAT3 to be upregulating Cten and mediating increased tumour 
migration and invasiveness (102, 103). Once again pointing 
towards a potential signalling link between CD24 and Cten. 
FAK: 
FAK (Focal adhesion kinase) is a 125 kDa non-receptor and non-
membrane associated protein tyrosine kinase (PTK) discovered 
in the 1990s. It interacts with the cytoplasmic tails of Integrins 
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as well as other members of the focal adhesion protein complex 
such as paxillin (104-106). It is believed to be involved in many 
critical cellular events including adhesion, migration, 
proliferation and survival. It has been shown that FAK is over-
expressed in invasive and metastatic colon tumours at both the 
protein and the mRNA levels (107). The expression and 
phosphorylation of FAK have been shown to correlate with more 
invasive tumour phenotype by virtue of inducing epithelial to 
mesenchymal transformation. In addition, some studies have 
linked FAK and the response of tumour cells to chemotherapy 
(108). Studies have also shown regulation of FAK by CD24. 
Baumann et al.  have shown very recently (2011) that although 
the  total FAK protein levels remain the same after upregulation 
of CD24, phospho-FAK is increased along with augmented c-src 
kinase activity in breast cancer cells (33). We explored this 
relationship between CD24 and FAK to see if CD24 mediated 
cell motility was linked to FAK, by creating experimental 
conditions with high CD24 and simultaneously knocking down 
FAK protein.  
ILK: 
Integrin linked kinase (ILK) was discovered in 1996 and as the 
name suggests it is linked to the cytoplasmic tail of β1 and β3 
integrins. Quite similar to FAK, the presence of ILK at focal 
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adhesions allows it to play an essential role in the transduction 
of many biochemical signals that are triggered by cell-ECM 
interactions. These signals modulate diverse biological events, 
including cell survival, differentiation, proliferation, migration, 
invasion and angiogenesis (109-111).  
 It has been found that the C-terminal domain of ILK also 
interacts with actin-binding adaptor proteins, such as paxillin 
and parvins, which interact directly with the actin network, 
allowing ILK to bridge the effects of growth factors and extra 
cellular matrix (ECM) through growth factor receptors and 
transmembrane integrins to the actin cytoskeleton. This helps 
to regulate cytoskeletal re-organisation and cell migration 
processes (94). 
It has been found that ILK expression correlates significantly 
with tumour invasion, grade and stage, in colorectal carcinomas 
and many other malignancies, suggesting a role in tumour 
progression. It has also been described that ILK expression 
correlates with stimulation of the Akt pathway, down-regulation 
of E-cadherin and activation of β-catenin in human colon cancer 
(112-114). We explored this molecule regarding mediating 
CD24 associated motility. 
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Material and methods: 
Co-transfections : 
In order to assess the downstream signalling partners of CD24, 
we employed a system of simultaneous co-transfection of a 
CD24 expression vector together with a siRNA targeted to the 
gene of interest. This would be done in a cell line which is a low-
expressor of CD24 and would be followed by analysis of cell 
motility. In theory, forced expression of CD24 will induce cell 
motility and, if the gene of interest was important in mediating 
this function, then knockdown of that gene with siRNA should 
result in loss of cell motility. We tested Cten, ILK and FAK as 
potential mediators of CD24-induced cell motility.  Changes in 
protein levels were confirmed by western blots. Appropriate 
internal controls were used in each experiment. 
Briefly, 2x105 cells were seeded in 2ml DMEM media with 10 % 
FBS and antibiotics (PS 1%) in 6-well plates. Cells were allowed 
to adhere for 24 hours prior to transfection. Cells were 
transfected when confluence reaches between 50-60 % at the 
time of transfection. The medium was aspirated and cells were 
washed with PBS and 1.5ml Opti- MEM®I was added to the cells 
one hour before transfection. For each co-transfection sample, 
oligomer-Lipofectamine® 2000 complexes were prepared as per 
manufacturer guidelines (tabulated below).  100 pico-mol siRNA 
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oligomer for knock down and 4.0µg/well pcDNA 3.1CD24 
plasmid (see Appendix iii) for forced expression were diluted 
simultaneously in 250μl Opti-MEM® I Reduced Serum Medium 
and  mixed gently. 8.5μl (up to 15ul for some genes) of 
Lipofectamine® 2000 was added to 250μl Opti- MEM® I, mixed 
gently and incubated for 5 minutes at room temperature.  After 
5 minutes, the diluted oligomer/plasmid mixture was combined 
with the diluted Lipofectamine® 2000, mixed gently and then 
incubated for 20 minutes at room temperature. The 
oligomer/plasmid-Lipofectamine® 2000 complexes were then 
added to each well containing cells and Opti- MEM® I (to make 
a final concentration of 50nm of the siRNA duplex), and mixed 
gently by rocking the plate back and forth. The media was 
changed after 7 hours by 2ml of DMEM medium (with FBS 20 
% and PS 1%), plates were incubated at 37ºC in 5% CO2 
incubator. siRNA Luciferase and pcDNA3.1 plasmid were used 
as controls for co transfection. Forty eight hours later, 
transfected cells were 
 (1) harvested for protein extraction and western blot.  
 (2) used directly for the relevant functional assays. 
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Table 7:  Timings of Media Changes during co-tranfections. 
             Media changes during co transfections  
1 Seeding the cells. Full media (10% FBS in 
DMEM with 1%pencillin and 
streptomycin). 
2 1hour before 
transfection. 
Opti-MEM®  I. 
3 4-7 hours after 
transfection. 
Full media prepared with 
20% FBS. 
 
Table 8:  scaling concentrations for transfection components 
Culture 
vessel 
Vol. of 
plating 
media 
Vol. of 
dilution 
media 
DNA Lipofectamine® 
2000 
siRNA 
96 Well 100µl 2 x 25µl 0.2µg 0.5µl  
24 Well 500µl 2 x 50µl 0.8µg 2.0µl  
12 Well 1ml 2 x 100µl 1.6µg 4.0µl  
6 Well 2ml 2 x 250µl 4.0µg 10µl 100pmol 
60 mm 5ml 2 x 0.5ml 8.0µg 20µl  
10 cm 15ml 2 x 1.5ml 24µg 60µl  
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Calculations for Forced expression and Knock down: 
Manufacturer’s recommendation for DNA in a 6 well plate is 4 
µg / well of the plasmid. 
a. pcDNA3.1 (Empty  Vector).  
b. pcDNA3.1-CD24 (Vector for CD24).  
Manufacturer’s recommendation for siRNA in a 6well plate is 
100pmol / well. 
c. si RNA luciferase 1ul/well. 
d. siRNA cten   10µl/well. 
e. siRNA ILK   10µl/well. 
f. siRNA FAK  7.5µl/well. 
g. siRNA CD24  5µl/well.  
Table 9: Plate set up for co transfections using CD24 and Cten. 
 Control well  CD24 F/E  CD24 F/E 
WITH Cten 
KD 
 Cten KD 
pcDNA3.1empty 
vector 
 +  
siRNA luciferase 
pcDNA3.1CD24 
 
 + 
siRNA luciferase 
siRNA Cten 
 
+ 
pcDNA3.1CD24 
siRNA Cten 
 
+ 
pcDNA3.1Empty 
vector 
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Table 10: Plate set up for co transfections using CD24 and FAK/ILK.  
Control well  CD24 F/E  CD24 F/E 
WITH ILK KD 
 CD24 F/E 
WITH FAK 
KD 
pcDNA3.1empty 
vector 
 +  
siRNA luciferase 
pcDNA3.1CD24 
 
 + 
siRNA luciferase 
siRNA ILK 
 
+ 
pcDNA3.1CD24 
siRNA FAK 
 
+ 
pcDNA3.1CD24 
 
 
 
Table 11: Sequence of siRNAs used in co transfections and knock down. 
Cten NM032865 L AAGAGUAACUGUACCACGAGACCCG 
R UUCUCAUUGACAUGGUGCUCUGGGC 
ILK NM004517.2 L UUCUCCGUGUUGUCCAGCCACAGGC 
R GCCUGUGGCUGGACAACACGGGAGAA 
FAK NM005607 L GAUGUUGGUUUAAAGCGAU 
R AUCGCUUUAAACCAACAUC 
CD24 NM013230 L ACCACGCUUAGUUAUGACCUACGAA 
R UUCGUAGGUCAUAACUAAGCGUGGU 
 
Universal non targeting siRNA  
(Luciferase specific) 
L CAGUGUAGUAGUCGUUUC 
R GAAACGACUACUACACUG 
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Co-Immunoprecipitation: 
SW620 Cells from confluent flasks were trypsinized by adding  
2ml of Trypsin /EDTA for 5minutes to each flask, re-suspended 
in 8 mL of Dulbecco’s modified Eagle medium (DMEM) with 10% 
foetal bovine serum (FBS) and 1% penicillin/streptomycin 
(P/S).The suspension was centrifuged at 17,000xg. at room 
temperature for 5 minutes . The resulting cell pellet was washed 
with 1 mL phosphate-buffered saline (PBS) and the suspension 
was centrifuged at 17,000xg. at room temperature for 5 
minutes. 
 PBS was aspirated and the pellet was treated with ice-cold lysis 
buffer (100 µL RIPA buffer and 1 µL Halt™ Protease & 
Phosphatase Inhibitor Cocktail (100x), Thermo Scientific) for 15 
minutes. It was then centrifuged at maximum speed 
(17,000xg.) at 4 °C in BIOFUGE fresco machine. The 
supernatant (WCE= whole cell extract), was collected in 
eppendorf tubes and stored at -20ºC. 
Preclearing of  cell lysates was done by adding  20 µl  of 
suspended Protein A/G-agarose beads (Calbiochem) and  
Incubating at 4ºC for 30 minutes  followed by centrifugation at 
8000xg. for 5 min at 4ºC to remove the beads with non-
specifically bound proteins. Calculated by protein assay, 1mg of 
protein per IP was incubated with 2ul of CD24 antibody at 4˚C 
overnight.  
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The GFP antibody (iso-type control) and 10% sample input were 
used as negative and positive controls respectively. Then 20 µl 
of protein A/G beads were added to the negative controls and 
sample tubes only and incubated for 2 h at 4°C. Beads were 
precipitated by centrifugation at 8000xg. for 5 min at 4º C and   
washed 3 times with lysis buffer or PBS (less stringent). 
Laemmli buffer was added and beads were heated at 90C for 
three minutes and then spun for 1minute at full speed 
(17,000xg). 
After elution, the immunoprecipitates were run on SDS- PAGE 
gel (Bio-Rad Catalogue # 1611159, 4–20% Ready Gel® Tris-
HCl Gel, 10 well, 50 µl) and transferred to PVDF membrane by 
semi-dry technique (8volts for 1hour). The membrane was then 
western blotted using primary antibodies against Cten (1:1000 
and also tried 1:500) and SWA11 for CD24. The secondary 
antibody was a horseradish peroxidase-linked secondary 
antibody (Sigma Aldrich) anti-mouse IgG raised in goat. As a 
loading control β-actin (1: 2000) was used (see Table 6). 
The co-immuno-precipitated proteins were visualized with 
Enhanced Chemi-luminescence detection kit (Super signal West 
Pico Chemiluminescent Substrate, Thermoscientific, UK) and 
exposure to X-ray film (Kodak UK). To assess if the increased 
Cten after upregulation of CD24 was due to augmented Cten 
transcription. A qPCR was also performed on the cDNA, 
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extracted 48 hrs after transfection withCD24 expression vector 
in HCT116 cell line (Chapter 2: Materials and methods). 
Cyclohexamide assay (CHX assay): 
Cyclohexamide (CHX) is an inhibitor of protein biosynthesis in 
eukaryotic organisms. Cycloheximide interferes with the 
translocation step in protein synthesis (movement of two tRNA 
molecules and mRNA in relation to the ribosome) Treating cells 
with Cyclo-hexamide in a time-course experiment followed by 
Western blotting of the cell lysates for the protein of interest 
can give clues about its half-life. This is a helpful tool as it 
removes the new protein formation. And the decrease in protein 
levels with each passing time point indicates degradation.  The 
difference in the protein levels amongst CD24 transfected +CHX 
and control groups (transfected but no CHX) will be compared 
and if CD24 functions by reducing degradation of Cten, leading 
to improved Cten levels after transfection, it will be unaffected 
by CHX addition over the time points, whereas if increased Cten 
levels were due to increased production, the CHX treated wells 
will show lesser amount of protein compared to the non CHX 
group.  Hence using CHX assay and qPCR we tried to explore 
whether it is increased production or reduced degradation of 
Cten by CD24 that leads to increased Cten levels. 
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After 48 hours of forced expression with a CD24 expression 
vector, (according to protocol mentioned in materials and 
methods) Cells were divided into two groups and one group was 
exposed, to 100µg/ml cyclohexamide (from Sigma) for three 
time points 0, 8, 16 hours. Cell pellets were harvested at each 
time point and frozen for western blot confirmation later using 
both from cyclohexamide (CHX) exposed and media exposed 
control group. Western blots were performed SWA11 and Cten 
antibodies as per mentioned protocol in materials and methods 
chapter. 
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Results: 
CD24 levels were modulated by either by ectopic expression of 
CD24 in cell lines with low CD24 expression (HCT116, RKO) or 
gene knockdown by RNA interference in cell lines with high 
CD24 expression (SW620,DLD1, GP2D). 
Western blotting was used as a way to check the transfection 
efficiency and to confirm expression of the protein. The right 
size protein band ranging from 25kDa to 75kDa as well as 
having characteristic smeary pattern was detected using 
SWA11 antibody (detects the protein backbone of CD24) in all 
cell lines used. 
Verification of CD24 expression by plasmid vector: 
Upregulation of CD24 protein expression was confirmed by 
western blot, 48 hours post transfection of CD24 - pcDNA3.1. 
expression plasmid into HCT116 cells  (using Lipofectamine 
2000® based forced expression technique as described earlier 
in the material and methods chapter (Figure 27). 
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CD24 regulates Cten protein levels: 
The level of ectopic CD24 expression after transient transfection 
in HCT116 cells was compared to endogenous CD24 expression 
in SW620 cells by western blot analysis. We found a strong 
expression of CD24 after transfection that was similar to 
endogenously expressing cells. Upregulation of CD24 resulted 
in increased Cten protein Figure 28. 
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Figure 27: Selection of CD24 expression vector. 
 
In order to assess the efficacy of our CD24 expression vector (CD24-pcDNA3.1), transfection 
was performed in HCT116 cell line.PcDNA3.1Empty vector (annotated as Empty Vector) was 
used as vector control. Western blot was performed using Anti-CD24 antibody clone SWA 11. 
The house keeping protein β-actin was used as protein loading control. Both CD24 plasmids 
used (A, B) gave typical smeary pattern characteristic of CD24 protein ranging 25kDa to 75kDa 
(A).For further transfections and co-transfections CD24 plasmid B was used as it lead to better 
expression under similar conditions compared to plasmid A, although both lead to increased 
CD24 expression compared to empty vector. Densitometry bar graph (B). 
42kDa 
 
37-75kDa 
 A 
B 
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To further validate this regulation of Cten by CD24, SW620 
(high expressor of CD24) cells were used. CD24 was knocked  
down using siRNA for CD24 and Luciferase as negative control 
according to the protocol explained earlier for knock down of 
CD24 (Chapter 2:Materials and Methods). Protein levels were 
compared after 48 hours of transfection using western blots. 
And it was observed that knock down of CD24 protein resulted 
in concurrent reduction of Cten protein levels Figure 29. 
        
 
 
 
 
 
  
  
 
HCT116 was transfected with CD24 expression vector and levels of CD24 and Cten proteins 
were compared to empty vector (negative control) and SW620 (positive control) by western 
blot. CD24 forced expression resulted in increased protein levels of both CD24 and Cten 
compared to negative control (A). β-actin was used as protein loading control. Densitometry 
bar graph for CD24 protein levels (B). Densitometry bar graph for Cten protein levels (C).  
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Figure 28: CD24 causes upregulation of Cten.    
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Figure 29: Knock down of CD24 causes down regulation of Cten. 
In SW620 cell line CD24 was knocked down using siRNA for CD24 .The expression levels of 
CD24 and Cten proteins in knock down  wells (KD CD24) were compared to Luciferase 
control(Luci) 48 hours post transfection by western blot (A). β-actin was used as protein loading 
control. Knock down of CD24 protein resulted in decreased Cten protein levels. Densitometry 
bar graph for Cten and CD24 protein levels (B).                                      
CD24 does not physically interact with Cten:  
As CD24 is present in the lipid rafts and interacts with some 
proteins present at focal adhesions. Finding direct effects on 
Cten levels by up or down regulation of CD24 led us to analyse 
if these two molecules come in physical contact with each other 
as well. 
In order to explore protein- protein interactions one very 
popular technique is co-immunoprecipitation. This experiment 
is performed under non-denaturing conditions. Therefore, it’s a 
valuable tool to explore the protein interactions in near 
physiological conditions by virtue of keeping the post 
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translational modifications and conformation of proteins 
undisturbed by avoiding denaturation. In this technique the 
known protein (antigen) is termed the bait protein and the 
protein that it interacts with is called the prey protein. 
 To investigate this possibility we performed co-immuno-
precipitation technique using Cten and CD24 in SW620 cell line. 
Input lane was used positive control for CD24. GFP (Green 
fluorescent protein) immunoglobulin was used as intrinsic 
isotype control to rule out non-specific binding of the beads. IP 
Cten followed by the western blot with Cten was positive control 
for Cten.  
 
Figure 30: Investigation of physical interaction between CD24 and Cten 
proteins.   
 CD24 and Cten were co-immunoprecipitated from SW620 lysate. Input lane was the lysate 
alone (positive control). IP GFP lane was lysate with GFP Ig for isotype control (negative control) 
.IP Cten lane was the lysate with beads and Cten Ab to pull out Cten and its attached proteins. 
Western blot were performed on the lysates after IP Cten using CD24 (SWA11) and showed no 
CD24 protein being pulled out. Western blot with Cten Ab shows Cten protein (positive control). 
 
 
The presence of CD24 in the input lane indicates the presence 
of CD24 in the lysate, and absence of a band in IP GFP excludes 
nonspecific binding by the beads and antibodies, and absence 
of bands in IP Cten lane indicates that Cten does not IP with 
CD24. Whereas the presence of band in the Cten IP lane with 
western blot using Cten antibody indicate that the IP and the 
37-75kDa 78 kDa 
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antibodies both have worked Figure 30. Our lab (another PhD 
candidate) also performed reverse Co-IP using CD24 and Cten, 
however, she also could not find these two being pulled down 
together in reverse co-IP.  
However, this still does not rule out the presence of a signalling 
relationship between these two molecules. As there are certain 
limitations of co-IP technique itself that should also be kept in 
mind before making any final conclusions from co-IP results 
about protein-protein interactions.  
These limitations include.  
 The affinity of the individual antibodies also varies greatly 
depending upon a range of factors including 
concentrations of proteins in lysates, avidity of epitopes, 
stringency of buffers etc. and may also account for absent 
bands besides the prey protein being pulled down with 
the bait protein. Using suitable controls and optimising 
these variables, as well as reverse co-IP helps overcome 
some of these limitations. 
 Transient interaction between proteins may not be 
detected. Similarly the signals of low-affinity of protein 
interactions might not be detected.  
 The result of co-IP could not determine whether the 
interaction is direct or indirect, since the possibility of 
involvement of additional proteins could not be ruled out. 
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This might be the case in CD24 and Cten interactions as 
well. As the signalling may be mediated through 
intermediate signalling partners such as c-src or STAT3 
given few studies indicating that (101). 
CD24  appears to signal through Cten and this is functionally 
relevant: 
To further explore the possibility of a functional relationship 
between CD24 and Cten (as both appear to be mediating similar 
cellular properties in literature), we decided to create an 
experimental condition whereby CD24 was forcibly expressed in 
a negative cell line and Cten was simultaneously knock down. 
Cells were subjected to transwell motility assay 48 hours post 
co-transfections as described in methodology and harvested for 
western blot analysis. 
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This experiment validated our previous findings of increased cell 
motility caused by ectopic CD24 and indicated that Cten Knock 
down abrogated the effects of CD24 on cell motility in colorectal 
cancer cell line raising the possibility that CD24 might be 
signalling through Cten as hypothesised. 
Lysates from the above co–transfections were also subjected to 
western blots to confirm transfection efficiency and show 
changes in Cten and FAK levels. The data showed upregulation 
of Cten with ectopic expression of CD24. These experiments 
supported our hypothesis that CD24 signals through Cten and 
Figure 31: Transwell migration assay after co transfection with CD24 and 
Cten. 
Transwell migration was done 48hours after the co-transfection in HCT116  and cells 
migrated to the bottom well were counted by direct microscopy after 24 hours . There 
was significant increase  in cell migration as compared to empty vector and Luciferase 
control( EV/ Luciferase)  with CD24 overexpression (Luci /CD24+).However this migration 
was significantly reduced by the simultaneous knockdown of Cten  besides CD24 over 
expression(-Cten/CD24+). Similar reduction was observed with Cten knock down alone. 
The experiment was done in triplicate and analysed by Graph Pad prism using student T 
test and taking p ≤ 0.05 as significant. 
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there exists a functional relationship between CD24 and Cten 
as well. Indicating CD24 is upstream of Cten. 
 
 
 
 
These western blots also revealed that, in agreement with other 
studies, total FAK protein levels remained similar after CD24 
over expression. However, it appears that the down regulation 
of Cten by knock down reduced FAK protein, as published by 
our lab previously (115). These changes point towards the 
possibility that there may be indirect regulation of these kinases 
(FAK) by CD24 through Cten. Another possibility is that CD24 
Figure 32: Western blot for co transfections. 
Western blots represented in the first lane was lysate from cell co-transfected with PcDNA3.1 
empty vector and Luciferase siRNA duplexes (EV/Luci) serving as control with no 
endogenous CD24. Next lane was transfected with CD24-PcDNA3.1 expression vector and 
Luciferase siRNA duplexes (CD24+/Luci) and shows increased CD24 and concurrent increase 
in Cten levels induced by CD24 but FAK levels appeared similar. Next set comprised of 
ectopic expression CD24-PcDNA3.1 and simultaneous Knock down of Cten using Cten 
specific siRNA and it shows reduced Cten levels as well as decreased FAK protein levels 
besides ectopic CD24 expression. And final set of co-transfection involved PcDNA3.1 empty 
vector and Cten specific siRNA (EV/-Cten).Confirming again that reduced FAK was associated 
with knock down of Cten and not with CD24 expression(A). Densitometry bar graph (B). 
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might not be increasing the total amount of FAK protein but 
augmenting its activity by increasing its phosphorylation as 
indicated by a study on breast cancer cells by Baumann et al. 
(33). 
Results of qPCR and CHX- assay: 
 
 
Our forced expression and knock down data with CD24 and Cten 
suggested changes of the two proteins in concordance i-e CD24 
down regulation leads to reduced Cten protein levels and vice 
versa. The next question was what is the mechanism behind 
this regulation? Whether it is at transcriptional level i-e CD24 
leads to increased mRNA levels for Cten, thereby increased Cten 
protein or this occurs at a post transcriptional level. The answer 
to the first possibility could be found using qPCR on the cDNA 
from the cells with forced expression of CD24. If the qPCR 
showed increased nucleic acid levels for Cten, in addition to 
CD24, the mechanism operating would be increased 
transcription of Cten. 
The regulation of Cten by CD24 may well occur at a post 
transcriptional level i-e by increasing the half-life of Cten 
protein. To explore this possibility we used cyclohexamide assay 
on the cells with CD24 forced expression. This will stop the 
synthesis of new protein by the cellular machinery and hence if 
the protein levels of Cten still come up higher than the controls; 
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this will indicate that it’s not the increased production but 
reduced degradation of Cten by CD24. If this turns to be the 
case it will need further exploration whether CD24 mediates this 
effect by increased Cten stabilisation or reduced degradation by 
proteasomes.  
Unfortunately, the results of the qPCR analysis showed very 
close Ct values amongst controls with amplification even in the 
NTC wells. This indicated a contamination of the components of 
reaction mixture making the results unreliable. This required a 
fresh repeat of the experiment. As regards the CHX assay, as 
both of the proteins tested i-e CD24 and Cten were unknown 
for their half-life, it was found that the selected time points 
weren’t correct, as both the proteins, did not show any 
significant degradation even after 24 hours. The experiment 
needed a re plan as well regarding time points to be tested. 
Unfortunately, because of personal health and serious family 
issues, the study was disrupted and these experiments could 
not be repeated. 
CD24 mediates increased cell motility via FAK and ILK: 
Our data above show that CD24 is a positive regulator of Cten.   
In addition, the data (combined with previous data from our 
lab) show that Cten positively regulates ILK and FAK. We 
therefore, hypothesized that ILK and FAK may be common 
Chapter Four   CD24 Signalling.  
118 
 
downstream targets of CD24 and that CD24 mediated increase 
in cell motility is mediated through ILK and FAK. 
To explore this possible link we used co- transfection techniques 
to forcibly express CD24 and simultaneously knock down either 
ILK or FAK. This would create a condition whereby CD24 was 
present but ILK/FAK were depleted. These co-transfections 
were carried out in the RKO and HCT116 cell lines as both 
having very low expression of CD24 endogenously. The 
transfected cells were subjected to transwell cell migration 
assay to assess the effects on cell motility after 24- 48 hours 
post transfection. We tested whether there was any functional 
relevance between CD24.  
The cell line HCT116 was co-transfected with ILK-specific small 
interfering RNA and CD24-PcDNA3.1 expression vector 
(denoted as CD24+/ILK-) and the number of cells migrating to 
the bottom of the wells were counted after 24 hours and 
compared with control wells (CD24+/LUCI). 
It was observed that compared with cells co-transfected with 
control small interfering RNA (Luciferase= LUCI) and PcDNA3.1- 
Empty vector (EV) wells (in which neither CD24 nor ILK were 
altered) there was significant increase (p=0.04) in transwell cell 
motility in cells transfected with CD24 expression vector and 
control small siRNA Luciferase (CD24 +/LUCI), hence having 
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increased CD24 expression but no change to ILK) which was in 
accordance with previous findings. 
However, the knockdown of ILK resulted in abrogation of the 
effect of CD24 on cell migration (denoted as CD24+/ILK-).This 
was similar to our previous findings with Cten and it further 
strengthens the existence of signalling and functional 
relationship between CD24, Cten and ILK. (Figure 33). 
 
Figure 33: CD24 increases motility via ILK. 
Transwell migration was done 48hours after the co-transfection in HCT116   and cells migrated 
to the bottom well were counted after 24 hours. There was a significant increase in cell 
migration as compared to empty vector and Luciferase control (EV/LUCI) with CD24 
overexpression (CD24+/LUCI). However, this migration was significantly reduced by the 
knockdown of ILK   besides CD24 over expression (CD24+/ILK-). LUCI = Luciferase control. 
The p-value of ≤ 0.05 was taken as significant.   
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We next extended our investigation to be tested on another 
important signalling kinase namely Focal adhesion kinase. As 
this has also shown to promote cell migration and linked to play 
the main role in cancer metastasis either by phosphorylation 
and association with Src or interaction with PI3K and the 
adaptor molecule Grb7 as proposed by  Zhao and Guan (116). 
As FAK is linked to integrins and src as well by many recent 
studies mediating cancer cell migration and adhesion (117). 
Unpublished data from our lab also found that CD24 affects the 
phosphorylation of FAK. We tested if there exists a functional 
association between the two molecules. 
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Figure 34:  CD24 mediates cell motility via FAK and ILK in HCT116. 
Transwell migration was done 48hours after the co-transfection in HCT116 and cells migrated 
to the bottom well were counted after 24 hours. There was a significant increase (p=0.04) in 
cell migration as compared to empty vector and Scramble control (EV/LUCI) with CD24 
overexpression (LUCI/CD24+). However, this migration was significantly reduced by the 
simultaneous knockdown of both ILK and FAK besides CD24 over expression. The experiment 
was done in triplicate and analysed by Graph Pad prism using student T test and taking ≤0.05 
as significant p value. LUCI= Luciferase control siRNA. EV= Empty vector control. 
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Figure 35: CD24 has a functional relationship with FAK and ILK in RKO. 
Transwell migration was done 48hours after the co-transfection in RKO   and cells migrated to 
the bottom well were counted after 24 hours. There was a significant increase in cell migration 
as compared to empty vector and Luciferase control (EV/LUCI)   with CD24 overexpression 
(LUCI/CD24+). However, this migration was significantly reduced by the simultaneous 
knockdown of ILK   besides CD24 over expression (-ILK/CD24+). A similar reduction was 
observed with FAK knock down (FAK-/CD24+). The experiment was done in triplicate and 
analysed by Graph Pad prism using student T test and taking≤ 0.05 as significant p value. 
 
Co-transfections were performed as described above but 
including knock down of FAK and we tested these in two cell 
lines as shown in Figure 34 and Figure 35. This was 
interesting to find that both FAK and ILK knockdown led to 
abrogation of increased cell motility by CD24, raising the 
possibility of a common downstream pathway from CD24 
involving Cten, FAK and ILK.  
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Discussion: 
The interaction of cells with the extracellular matrix regulates 
many physiological and pathological outcomes. These 
interactions are accompanied by the recruitment of multiple 
cytoskeletal and regulatory proteins to focal adhesions involved 
in coordinating integrin mediated signal transduction associated 
with cell motility, gene expression and cell proliferation(118). 
It has been shown that CD24 promotes cell motility in a β1 
integrin-dependent manner and it is dependent on intact lipid 
rafts. It was observed in a study that blocking of β1 integrin 
interaction significantly reduced the migration of the CD24-
transfectants while it had no effect on the motility of the CD24-
negative control cells (83). 
It  was also further proposed by studies that CD24 leads to 
activation of c-scr (33) and STAT3(101). Quite interestingly, 
evidence emerged for Cten to be also activated by STAT3 and 
c-src besides activation by EGFR and Braf-Kras pathway (103). 
Cten was also linked to Wnt signalling pathway (119) that has 
a been shown to be the regulator of CD24 by our group 
(unpublished data). 
The presence of Cten at focal adhesions in association with 
integrins and focal adhesion kinases. And having similar 
downstream effects on cellular characteristics lead us to explore 
if CD24 has regulatory effects on Cten. And whether or not, 
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CD24 was mediating its effects on motility via Cten. Our 
experiments testing this hypothesis endorsed direct regulatory 
effect of CD24 on Cten and it has  been observed in our lab that 
both molecules go hand in hand in cell lines i-e the cell lines 
with high expression of CD24 also had high Cten (DLD1 and 
SW620) levels and vice versa (HCT116 and RKO). 
 
Figure 36: Schematic diagram for proposed link between CD24 and 
Cten/ILK and FAK. 
Cell motility and migration play an important role in tumour 
growth and metastatic spread and overexpression of FAK seem 
to enhance cell migration, whereas lack of FAK expression 
reduces cell migration (108). Our lab already showed Cten to 
be mediating cellular motility via ILK and down regulation of  E-
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cadherin (99). This study further extends that CD24 is upstream 
of Cten and motility is mediated both by FAK and ILK. Whether 
there exists a switch between ILK and FAK remains to be 
elucidated. 
Based on the experiments performed above and the published 
information in previous studies including by Baumann et al. 
(33). We propose here, that it appears that CD24 localises β-
integrins to lipid rafts, also leads to phosphorylation of c-src and 
STAT3 (101) that in turn leads to increased Cten levels. This 
causes activation and phosphorylation of FAK and ILK (33, 99) 
resulting in increased cellular motility as observed by our 
transwell migration assay Figure 36.  
Although this may not be the only signalling loop between these 
molecules as cellular machinery does harbour multiple 
interacting loops with overlaps. However, the evidence provided 
by the above experiments regarding CD24 and Cten regulation 
and the functional relationships between CD24, and FAK/ILK  
may also be  significant contributors to the biology of these 
molecules. 
 Despite the fact that the above co transfections did show clear 
trends, were performed in triplicate and repeated to produce 
similar results by another colleague for their project, yet the 
absence of supporting western blots undermine the strength of 
our arguments and is acknowledged as a limitation. An 
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equipment used for western blots was working sub-optimally, 
resulting in the lysates from the above transfections being 
wasted. This part of the project was then moved on to the next 
PhD student due to time constraint, he also found similar results 
with supportive western blots not only in colorectal but as well 
as in pancreatic cell lines (unpublished data).  
Nevertheless, the above data indicates that CD24 does not 
increase FAK protein levels, there is a possibility that CD24 
might enhance its function by increasing FAK phosphorylation 
as indicated in breast cancer cell lines (33) and should be 
sought further.  
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Chapter Five: Mutating N-glycosylation sites of CD24. 
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Introduction: 
 
N-Glycosylation of Proteins: 
Proteins undergo a wide variety of modifications after their 
synthesis and that is vital for the immense diversity in their 
structure and function found in cellular biology. One of the most 
common modifications is the addition of N-glycans (the sugars, 
which get attached to the proteins using the Nitrogen atom, 
present in the amide group of amino acids) to the newly 
synthesized proteins through a process called N-glycosylation. 
(120). 
N-glycosylation is a post- translational biochemical event in 
which a glycan (sugar moiety) is attached to a Nitrogen atom 
present in the amide part of the Asparagine amino acid. This 
process occurs within the endoplasmic reticulum and Golgi 
apparatus. 
Steps of glycosylation: 
O-glycosylation is also a stepwise process in which 
monosaccharides are first attached to the Oxygen atom 
present in the hydroxyl group of serine and threonine 
residues. The monosaccharides are then added  to the growing 
oligosaccharide chain during the later stages of protein 
synthesis in Golgi(121). 
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The addition of O-sugars  is thus, quite different from addition 
of GPI anchor and N-glycans to proteins, as both N-sugars and 
GPI anchor get attached to protein in pre-assembled form. N-
glycans (with GlcNAcβ–Asn bond), are transferred in a pre-
assembled dolichol-linked sugar chain to protein  after partial 
enzymatic trimming and is further extended by the addition of 
monosaccharides (121).  
These modifications of the N-glycan in the ER comprise 
sequential removal of glucose and α-1,2-mannosyl residues to 
produce oligomannose type glycans Figure 37. 
 
Figure 37: Steps of protein N-glycosylation(122). 
Proteins synthesised in the endoplasmic reticulum are N-glycosylated by attachment 
of pre-synthesized Dolichol-linked sugar chain. And this chain is further modified and 
elongated in Golgi apparatus for further maturation. 
Factors affecting   N-glycosylation : 
The N-glycosylation process uses the nitrogen atom of 
asparagine amino acid residues for attachment of sugars. The 
asparagine must be present in a specific Tri-peptide sequence 
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also called a sequon. The motif for N-glycosylation is Asn-X-
S/T where S is serine and T is threonine, whereas X is any other 
amino acid. Studies have shown a differential influence of X on 
N-glycosylation(123). For example, proline at position X 
appears to be an inhibitor of N-glycosylation whereas, threonine 
containing sequons are more prevalent sites of N-glycosylation 
as compared to serine sequons. Structural factors such as 
primary/secondary/ tertiary structure of a protein as well as 
position and adjacent sequence may also affect the 
glycosylation of consensus sequence. Hence, proteins having 
Asn-X-S/T motifs have potential N-glycosylation sites that 
may have variable glycosylation or might not be glycosylated at 
all (123-125).  
Yet another important level of regulation is by the enzymes 
involved in the glycosylation steps. Glycosyl hydrolases (GHs), 
glycosyl transferases (GTs) and nucleotide sugar transporters 
make up the ‘hardware’ of the pathway. These occur in the Golgi 
apparatus and are responsible for converting simple glycans like 
oligomannose, into a hybrid- and complex-type 
oligosaccharides. These glycan transforming enzymes can 
fluctuate amid different species, tissues and cell types and 
produce variable N-glycan structures. Making glycosylation a 
very dynamic process (126, 127). These GHs and GTs even 
have different substrate specificities and act sequentially. It is 
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also seen that these enzymes physically compete for the sugar 
substrate and hence  this can be one  additional reason of 
dissimilarity in glycosylation of same the protein amongst 
different tissues (127). Studies have linked dysregulation of 
these enzymes to important human diseases including oral 
cancer (120, 128). 
Functional Significance of N-Glycosylation: 
 
Protein glycosylation is seen in all eukaryotic cells. N-
glycosylation of proteins is very significant and in some cases 
essential for cell viability. A multitude of enzymes are involved 
in this process and genes for these enzymes are fairly 
conserved amongst species.  N-glycosylation is thought to help 
in important physiological processes such as folding of proteins, 
maintaining their stability, conformation, and localization to 
cellular and subcellular sites (124, 128, 129). There is growing 
evidence about the link between N-glycosylation regulating 
genes and cellular growth, proliferation and various aspects of 
the cell cycle (130). In addition, there are studies linking site 
specific N-glycans on proteins such as immunoglobulins and 
their function (127). However, this aspect of N-glycosylation 
has not been tested experimentally for most glycoproteins 
including CD24. 
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Cancers and N- Glycosylation: 
All mammalian cells are decorated with a variety of sugar 
moieties Figure 38 and it has been observed that changes in 
the cellular properties also affect these sugars. Neoplastic 
transformation is also found to alter the glycosylation pattern 
of tumour cells. Based on these observations certain 
carbohydrate structures have emerged as helpful tumour 
markers. Examples include MUC1/2, CEA, Ca19-9 etc. These 
glycoproteins are also being used as adjuvants in tumour 
diagnosis and for monitoring prognosis i-e MUC1/2 CEA etc. 
(131-133). 
A very recent study by Valeras et al. 2014 linked  disturbed N-
glycosylation of proteins like E-cadherin as a pathogenetic 
factor of oral cancer. They proposed that dysregulation of 
DPAGT1 (an enzyme involved in N-glycosylation of proteins 
including E-cadherin) leads to changes in intercellular 
interactions and cytoskeletal dynamics (120). 
Another study in 2015 by Sethi et al. did a comparison  of the 
N-glycome from colorectal carcinoma tissue and adjacent non 
tumour tissue and found N-glycoproteins signatures specific to 
colorectal tumours  and also associated with tumour stage 
(134). Similarly, Kapiro et al. found differences in the N-
glycome of colorectal adenomas and carcinomas and even 
found differences in glycosylation pattern between stage I, II 
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and III tumours (135). Current research is investigating 
potential ways of utilising these specific glycomic patterns in 
designing less invasive diagnostic tools and therapeutic 
possibilities in tumours expressing them and a few studies have 
already shown some promising results (63, 136, 137).
 
Figure 38: CD24 and common sugars on the human cell surface .Modified 
image (136). 
A figure representing major classes of sugars displayed on the cell surface. The 
CD24 molecule is heavily glycosylated with O and N-sugars and it is attached to the 
cell membrane via another glycol-conjugate i-e GPI- anchor. 
Post translational modification of CD24: 
CD24 was initially thought to be a haematological differentiation 
marker and only expressed on immune cells and embryonic 
tissue. Over the past 35 years, evidence continues to mount 
regarding the association of CD24 with a variety of benign and 
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malignant diseases (7). CD24 gene polymorphisms have been 
linked to risk of developing and in certain cases progression of 
autoimmune diseases including Multiple sclerosis, SLE, 
autoimmune thyroid disease, Giant cell arteritis etc. (44, 46). 
It was also found to be related with haematological 
malignancies but the list of tumours with an aberrant high 
expression of CD24 is growing larger with each passing year, 
having more than 22 solid malignancies being directly linked to 
this small molecule (62, 88, 138, 139). Most of these studies 
have shown a direct prognostic relevance of CD24 expression. 
While other studies showing the role of CD24 in tumour 
progression, growth, metastasis and even to be a marker of 
cancer stem cells (15, 37, 49, 51, 54, 90, 140). 
Over the past 30 years, most of the studies have focussed on 
the diagnostic and prognostic roles of CD24 but much less is 
still known about its exact biology, mechanism of action and 
signalling pathways. Poncet et al. analysed CD24 expression 
from developing human brain cells and in variety of neuronal 
tumours and found that expression of CD24 was 
transcriptionally regulated and RT-PCR showed the same 
transcript from various sources including haemopoietic, 
developing brain and tumour brain tissue. However, they found 
regulation at a post-transcriptional level as well. This was 
indicated by Western blot analysis of CD24, revealing 
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differential CD24 isoforms. These forms  vary with tissue site 
(hematopoietic versus nervous),  differentiation status and 
reflected variations in the extent of glycosylation, that is quite 
the case, with N-glycosylated proteins as described above 
(141). 
CD24 is quite interesting in the sense that more than half of its 
weight is because of extensive glycosylation making it similar 
to mucins (9). It is attached to the cell surface with the help of 
a GPI anchor. CD24 molecule has only 31 amino-acids in mature 
protein but 16 potential O glycosylation sites and two potential 
N-glycosylation sites (25), Figure 38. This results in a range of 
molecular weights of this protein, from as low as 25KDa to as 
high as 70KDa. This also gives a typical smeary pattern quite 
characteristic of this protein on the western blot (68). The 
process of CD24 glycosylation takes place in the endoplasmic 
reticulum and continues in Golgi apparatus and finally the fully 
glycosylated molecule is transported to the cell surface attached 
to an outer leaf of plasma membrane via GPI anchor Figure 
39. 
Only a few studies have tried to explore the glycosylation aspect 
of CD24. One study by Ohl et al. compared N-glycans from 
mouse brain and human cell lines and found few similarities 
(10). In 2009 Bleckmann et al.  used MALDI    (matrix- assisted 
laser-desorption ionization) and ESI (electrospray ionization ion 
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trap) mass spectrometry analysis of the N-linked glycans of 
CD24 (142). They found highly heterogeneous glycans, 
expressing distinct carbohydrate epitopes like 3-linked sialic 
acid, Lex or blood group H antigens, bi-secting N-
acetylglucosamine residues and N-acetyllactosamine repeats as 
well as high-mannose and hybrid type species (142). The same 
group also did an analysis of O glycans present in murine CD24 
and found important epitopes such as as 3-linked sialic acid, 
disialyl motifs, LeX, sialyl-LeX or HNK-1 units. Some of these 
sugar epitopes have been linked to quite significant cellular 
properties including cell-cell interaction, adhesion, migration 
etc. in the current glycobiology literature (126, 143). These 
studies hint towards the notion that variability of CD24 
glycosylation patterns could be a factor responsible for the 
broad spectrum of roles linked to this molecule (10, 144). To 
support this concept there are few examples onboard i-e this 
has been shown  that  sialyl Lex carbohydrate is essential for 
the CD24-mediated rolling of tumour cells on P-selectin (7, 59). 
Similarly, the interaction of CD24 with L1 depends on the 
presence of specific glycosylation pattern (α- 2,3- linked sialic 
acid residues) and this interaction  modulates neurite outgrowth  
(142). On the same note, Edwin Motari et al. in 2009 analysed 
in detail both N and O -sugars of recombinant CD24, the 
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glycoprotein’s oligosaccharides were released by chemical and 
enzymatic methods before their analysis by MALDI-TOF-MS. 
They found Neu5Acα-2,3/6Galβ-1,3GalNAc (sialyl-tumor 
antigen, sT), a cancer-associated carbohydrate, to be the most 
abundant sugar  linked with CD24. They suggested the 
possibility that CD24 might be the major font of this sugar 
epitope displayed commonly in cancers (145). This part of the 
study aimed at exploring the functional significance of N-
glycosylation sites present in CD24. 
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Figure 39 : GPI anchorage and glycosylation of CD24. (146) 
The illustration shows main events in the maturation of CD24, a GPI-anchored protein. Acquiring GPI anchor in the ER, a process during which a signal 
sequence is cleaved (at a consensus omega residue) and the GPI anchor is attached via a terminal ethanolamine phosphate to the C-terminal of CD24. The 
protein is heavily glycosylated and modified with both O and N- glycans and the process completes in Golgi, finally localizing the mature CD24 glycoprotein  
to the plasma membrane (146).
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Study hypothesis: 
N-sugars play a significant role in mediating the biological role 
of CD24. 
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Materials and methods:  
The ever-increasing quality of DNA proof-reading polymerases 
has facilitated numerous PCR-based approaches for mutating 
wild type DNA sequences. Several different approaches for site-
directed mutagenesis (SDM) have been suggested and 
successfully established although all vary regarding primer 
designs and characteristics, templates used, steps needed and 
enzymes used etc. Their success rates depend on multiple 
factors in each case. 
N-Glycosylation experiment plan: 
The motif for N-glycosylation is Asn-X-Ser/Thr, where X is any 
amino acid except Pro, Asp or Glu (38). We decided to replace 
asparagine (Asn) of CD24 with glutamine (Gln). Reasoning 
for selection of glutamine included the following: 
 Asparagine and glutamine both are polar amino acids. 
 Both are derived from acidic amino-acids (aspartic acid 
and Glutamic acid) having negatively charged side chains. 
 Both are structurally very similar, the only difference 
being presence of one extra methyl group in glutamine. 
 By replacing asparagine with glutamine, the N-
glycosylation site will be disabled at that specific point. 
However, O-glycosylation sites will not be affected by  
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these mutations as glutamine does not bind to O-glycans 
(123, 147, 148).  
So our aim was to mutate N-glycosylation sites of CD24 using 
site directed mutagenesis technique. The steps were as follows: 
Step 1: Identification of potential N-glycosylation sites. 
Step 2: Mutating Asparagine (N) with Glutamine (Q) using 
Site directed mutagenesis technique (by designing mutated 
primers). 
 ACC (Asn) -------- CAA (coding for glutamine) Gln.  
 AAT (Asn) -------- CAA (coding for glutamine) Gln. 
Step 3: Running PCR using these mutant primers to induce 
mutation of N-36 and N-52 sites along with appropriate 
controls. 
Step 4: Gel extraction and purification of PCR product. 
Step5: Dpn1 digestion of mutant PCR product to remove 
parental template DNA. 
Step 6: Ligation of mutant PCR product. 
Step 7: Transformation into E.coli for mutant plasmids to 
grow. 
Step 8: Mini-prep and Nano-drop to obtain mutant plasmids. 
Step9: Confirmation of presence of only required mutation by 
Gene sequencing analysis. 
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Step 10: Transfection of desired mutants into cell lines to 
assess the effects caused by these N-glycosylation mutant 
sites by performing functional studies and western blot 
analysis Figure 40. 
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Figure 40: Flow diagram showing the experimental plan for site directed 
mutagenesis. 
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CD24 Signal Peptide: 
  
CAGG  ATG  GGC AGA  GCA  ATG   GTG  GCC   AGG  CTC  GGG  CTG  
GGG  CTG   CTG   CTG CTG  GCA  CTG  CTC   CTA   CCC  ACG  CAG     
ATT  TAT  TCC  AGT   GAA   ACA  ACA  ACT GGA  ACT  TCA  AGT   AAC   
TCC   TCC  CAG   AGT ACT   TCC AAC   TCT  GGG   TTG GCC CCA  AAT  
CCA ACT AAT GCC ACC ACC AAG GCG GCT GGT GGT GCC CTG CAG 
TCA ACA GCC AGT CTC TTC GTG  GTC TCA CTC TCT CTT CTG CAT 
CTC TAC TCT TAA 
Consensus Sequence for N- glycosylation site: 
 
The motif for N-glycosylation is Asn-X-Ser/Thr,  where X is any 
amino acid except Pro, Asp or Glu (38). 
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Table 12: Codons and the corresponding amino-acid sequence for CD24 mature peptide. 
ATG GGC AGA GCA ATG    GTG   GCC    AGG CTC GGG CTG   GGG 
Methionine Glycine   Arginine   Alanine Methionine    valine Alanine Arginine Leucine Glycine Leucine Glycine 
CTG CTG CTG CTG GCA CTG CTC    CTA CCC ACG CAG ATT 
Leucine Leucine Leucine Leucine Alanine Leucine Leucine   Leucine Proline Threonine    Glutamine Isolucine 
TAT TCC AGT GAA ACA ACA ACT GGA ACT TCA AGT AAC*36 
Tyrosine Serine    Serine   Glutamic 
acid 
Threonine Threonine Threonine Glycine Threonine Serine      Serine Asparagine 
TCC TCC CAG AGT ACT TCC AAC   TCT GGG   TTG GCC CCA 
Serine Serine Glutamine Serine Threonine Serine Asparagine serine Glycine Luecine Alanine Proline 
AAT CCA   ACT AAT*52 GCC ACC ACC AAG GCG GCT GGT GGT    
Asparagine  Proline Threonine Asparagine Alanine Threonine Threonine Lysine Alanine Alanine Glycine Glycine 
GCC CTG CAG TCA ACA GCC AGT CTC TTC GTG GTC TCA 
Alanine Leucine Glutamine Serine Threonine Alanine Serine Leucine phenylalanine Valine Valine Serine 
CTC TCT CTT CTG CAT CTC TAC TCT         
Leucine Serine Leucine Leucine Histidine Leucine Tyrosine Serine         
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Site-directed mutagenesis is a technique that creates a 
mutation at a defined site. Changes to sequence can be made 
using PCR by simply including the desired change in the PCR 
primers. The identification and construction of new commercial 
polymerases and advances in oligonucleotide synthesis have 
dramatically increased its efficiency. The protocol is briefly 
shown in the flow chart Figure 41.    
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 Figure 41: Site directed mutagenesis flow chart: 
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Primer specifications for Site directed mutagenesis: 
Manual Primers: 
 
Our both mutant primer sets were designed manually keeping 
the following considerations. The forward and Reverse primers 
were back to back to each other in both cases. Following 
considerations were kept while designing these primers. 
 Only forward primer contained the mutation 
(AAC/AATCAA). 
 The mutant codon was kept in the middle of the forward 
primer with 12-15 bases on each side of the mutant codon 
to  anneal with the template strand. 
 GC content was between 35–65%. 
 Melting temperature (Tm) between 55–65°C. 
 The Tm difference between primers was limited to 2–3°C. 
The primer with the lower Tm dictated the annealing 
temperature used in the reaction. 
 To avoid dimerization of primers sequences were checked 
for sequence homology between themselves. 
We tried our best to follow as many steps we could to 
ensure good primer design but due to the constraints site-
directed mutagenesis imposes on the location of the 
primers, meeting all of these parameters is not always 
possible. 
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Phusion Site-Directed Mutagenesis Kit # F-541 was used for our 
mutagenesis experiments with an additional step of DpnI 
digestion to remove template DNA. 
Controls  of mutagenesis: 
Effective controls are an integral component of any 
mutagenesis experiment. The controls listed below were used 
to confirm each step in the process of making a site-specific 
mutation.  
PCR controls: 
 
Positive control— PCR containing a Template plasmid and wild 
type CD24 primers that would yield a wild type product was 
used as our positive control. 
Negative controls—We used one PCR with no template DNA to 
be used in transformation reaction, as a back ground template 
control. No amplification product should be detectable. If a 
product is amplified, one of the reagents is contaminated and 
must be replaced. 
We also used one PCR mix, with all of the PCR components, 
except polymerase. This will not produce any product and will 
only indicate the colonies produced by the template plasmid 
during transformation step. 
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Ligation controls: 
Negative control—was a reaction containing the positive  
control from the PCR product and deficient in ligase. Once 
transformed, this reaction will offer a clue of how much 
background was present in the experimental reaction. 
DpnI Digestion Controls: 
Negative control—undigested, supercoiled plasmid and no DpnI 
enzyme. This reaction will not digest the template plasmid and 
hence the colonies will be both from template plasmid and 
newly synthesized products of PCR. 
Transformation controls: 
 
The following were transformed into competent cells in parallel 
to the experimental sample:  
• PCR product positive control—Amplify the original plasmid 
using primers that do not introduce mutations to verify the 
experimental conditions will produce the expected product 
• Ligation positive and negative control—The positive 
ligation control should have 5–100 times more colonies than the 
negative ligation control.  
• DpnI positive and negative  
Control—the ratio of the number of colonies from the DpnI 
positive and negative control indicates the efficiency of the 
digestion. The negative control should have 5–100 times more 
colonies than the positive control. 
Chapter Five   N-Glycosylation. 
151 
 
Table 13: Primers  used in our site directed mutagenesis experiments.  
Gene of 
interest. 
           Primer Sequence. 
(All primers were purchased from 
    Eurofins MWG-Biotech AG). 
Annealing 
Temp. 
CD24 wild 
type primers. 
Forward primer  
5’CACCATGGGCAGAGCAATGGTGG 3' 
57 ˚C 
Reverse primer 
5’TTAAGAGTAGAGATGCAGAAGAG 3 ' 
57 ˚C 
CD24 N-36  
mutant 
primers. 
(manually 
designed) 
Forward Primer 
5” ACT TCA AGT CAATCC TCC CAG 3” 
(first) 
Did not 
work 
 
5’ACT TCA AGT CAA TCC TCC CAG AGT 
ACT3’(redesigned) 
63˚C 
Reverse Primer 
5’ TCC AGT TGT TGT TTC ACT GGA 3’ 
63˚C  
CD24 N-52 
mutant. 
Forward Primer 
5’AAT CCA ACT CAA GCC ACC ACC 3’ 
63˚C 
Reverse Primer 
5’ TGG GGC CAA CCC AGA GTT GGA3’ 
63˚C 
T7. 
Forward Primer 
5’ TAA-TAC-GAC-TCA-CTA-TAG-GG 3’ 
50˚C 
BGH. 
Reverse Primer 
5’ TAGAAGGCACAGTCGAGG 3’ 
54.8˚C 
CD24 N-36  
mutant. (SDM 
assist) 
Forward Primer#15 
5'CTTCAAGTCAGTCCTCCCAGAGT 3’  
59˚C 
Reverse Primer#40 
5' TGGGAGGACTGACTTGAAGTTCC 3’  
62˚C 
CD24 N-52 
mutant (SDM 
assist) 
 
Forward Primer#15 
5` ATCCAACTCAAGCCACCACCAAG 3` 
65˚C 
 
Reverse Primer#40 
5’GTGGTGGCTTGAGTTGGATTTGG3’ 
65˚C 
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Primer phosphorylation step: 
 
In order to phosphorylate the primers Thermo Scientific T4- 
Poly nucleotide Kinase (catalogue#EK0031) was used. And 
250pmol of the oligonucleotide were mixed with 5 µL of 10X 
reaction buffer A for T4 Polynucleotide Kinase and 5 µL of 10 
mM ATP. In the end 2 µL T4 Polynucleotide Kinase 10 U/µL was 
added and finally water was added to make up a final volume 
of 50 µL the reaction mix was incubated at 37°C for 30 minutes. 
T4 Polynucleotide Kinase was heat inactivated at 75°C for 10 
minutes.  
PCR reaction : 
 
Mutant primers for CD24 N glycosylation sites 36 and 52 were 
designed manually. The amplification primer pairs shown in 
Table 13 were purchased from (Eurofins MWG-Biotech AG) and 
subsequently diluted to a working concentration of 100pmol/μl. 
PcDNA3.1 CD24 plasmid DNA was used as our template. Above 
mentioned manually designed mutant primer sets were used, 
in a 50 µl PCR reaction using the Phusion Hot Start II High-
Fidelity DNA Polymerase (Thermo Scientific Cat. # F549L).  
Table 14 shows the PCR reaction components. The Phusion 
Hot Start II DNA Polymerase-mediated PCR amplification 
reaction was performed in thermal cycler (Perkin Elmer 
GeneAmp PCR system 2400), and allowed to run for 37 cycles 
with the following cyclic conditions, one cycle of 98°C for 2 
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minutes (initial denaturation), followed by 35 cycle of 98°C for 
1 minute (denaturation), 63°C for 30 seconds for both primer 
sets (annealing), 72°C for 2 minutes (extension). The final 
cycle was at 72°C for 10 minutes (final extension). PCR 
products were analysed using a 2% agarose gel to check for a 
single discrete band suitable for further steps. All PCR 
reagents, unless otherwise specified, were purchased from 
Roche Pharmaceuticals. 
 
Table 14: Components and concentrations of mutagenesis reaction. 
 
Choice of polymerase: 
 
The use of high-fidelity polymerases is preferred over Taq 
polymerase or other lower fidelity polymerases. High-fidelity 
polymerases decrease the number of PCR-induced errors such 
Component. 50 µL X 1 reaction. Final conc. 
Nuclease free H2O add to 50 µL  
5X Phusion HF Buffer * 10 µL 1X 
10 mM dNTPs 1 µL 200 µM each 
Forward primer** 2 µL 250nM 
Forward primer** 2 µL 250nM 
Phusion Hot StartII DNA 
Polymerase II (2 U/µL) 
0.5µL 0.02 U/µL 
Template (DNA 
(pcDNA3.1CD24plasmid) 1ng/ 
µL 
X 1 µL   
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as point mutations. Also, while using Oligonucleotide-directed 
Internal Mutagenesis technique it is essential to use a non-
strand-displacing polymerase such as Phusion® (Thermo 
Fisher, New England Biolabs), and to avoid strand-displacing 
polymerases (149, 150). These two considerations were kept in 
mind while choosing Phusion hotstart II DNA polymerase for our 
mutagenesis project. 
Gel extraction of PCR products: 
 
Electrophoresed DNA was visualised under ultraviolet light and 
appropriate bands (5.7kb) were excised from the gel using a 
clean scalpel. The PCR product  was then isolated from agarose 
gel using the QIAquick Gel Extraction system (QIAGEN, UK), 
following the manufacturer’s standard protocol. After weighing, 
the excised gel fragments containing the band of interest were 
dissolved in 3x volumes of Buffer QG (supplied with the Kit), 
then incubated at 50ºC for 10 minutes. After the gel slice had 
been dissolved completely, 1x gel volume of isopropanol 
(Sigma, USA) was added and mixed with the samples which 
were then washed with 750μl of Buffer PE (supplied with the 
Kit) to remove all traces of agarose and finally the DNA was 
eluted with 30μl of elution buffer.  
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Purification of PCR product: 
 
The gel extracted PCR products was purified using QIAquick PCR 
Purification Kit (Qiagen) cat # 28104 according to the 
manufacturer’s manual. In brief, one volume of PCR sample was 
added to 5 volumes of buffer PBI and mixed, then added to the 
QIA quick column and centrifuged for 60 seconds. The column 
was washed by adding 750 µL of buffer PE and centrifuged for 
60 seconds. DNA was eluted into a clean micro-centrifuge tube 
using 50µL of elution buffer. 
DpnI Digestion step: 
 
 
Add 1 μL of DpnI restriction endonuclease (Roche 
cat#10742970001) to the reaction mixture to remove the 
original plasmid DNA. Incubate at 37°C for 30 mins. 
 
Table 15: Components and concentrations of Digestion reaction. 
 
 
 
 
 
 
 
 
 
 
 
Digestion Reaction. 50 µL reaction. 
Restriction Endonuclease DpnI 
enzyme  10U/ µL   
1 µL 
10X Sure Cut buffer A( with Kit) 5 µL 
PCR product  3 µL ( 1.5ug DNA) 
Nuclease free Water 41 µL 
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Ligation step : 
 
To circularize the amplicon we used T4 DNA ligase (Invitrogen 
cat# 15224-07) and the reaction was carried out overnight  at 
4˚C.Heat inactivation of  T4 DNA ligase enzyme was done next 
morning for 10 mins at 65˚C. 
 
Table 16: Components and concentrations of Ligation reaction. 
 
 
 
 
 
 
 
 
 
Transformation of CD24 mutants: 
 
The mutant constructs from above reactions were 
transformed using NEB 5-alpha Competent E. coli (High 
Efficiency Cat# C2987P). Briefly, 10μl of above reactions 
were added into a vial of NEB 5-alpha Competent E.coli(50µl) 
and mixed gently, the reaction was then incubated on ice for 
30 minutes, the contents of the vial were heat-shocked for 
30 seconds at 42°C without shaking and were immediately 
transferred to ice for 5 minutes. 900μl of S.O.C. medium 
(Invitrogen, Cat# 15544-034) at room temperature were 
Ligation. 
 
10uL reaction 50uL reaction. 
5   X  T4   ligase 
buffer       
0.5 µL 2.5 µL 
T4  DNA ligase 
enzyme100U/ µL  
2 µL 10 µL 
PCR product 3 µL ( 1.5ug DNA) 3 µL 
Nuclease free Water 4.5 µL 34.5 
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added. The tube was tightly closed and shaken horizontally 
at 37°C for 1 hour. Tubes were spun at maximum speed for 
1 minute to form a pellet and 800μl of supernatant was 
discarded, pellet was re-suspended in the remaining SOC 
medium (see Appendix viiAppendix x) and 50μl from each 
transformation reaction was spread on a LB (Luria broth) 
agar plate containing the appropriate selection of antibiotic 
to allow propagation of bacteria containing the plasmid (i.e. 
100μg/ml ampicillin) and incubated overnight at 37°C. Plates 
with no polymerase control, undigested and un-ligated PCR 
products and cells alone were used as controls. 
Analysing Mutants for presence of required Mutations: 
 
24 hours after incubation on the LB agar plates, colonies were 
observed picked and cultured overnight in 5 ml of LB 
containing 100μg/ml ampicillin. The plasmid DNA was 
isolated from the 10 samples using the GenEluteTM Plasmid 
Miniprep Kit (Sigma Aldrich). In brief, 5 ml of an overnight 
recombinant, E. coli culture were pelleted by centrifugation 
at 17,000xg.  for 1 minute. The supernatant was discarded, 
and the pellet was completely re-suspended with 200μl of the 
re-suspension solution which is supplied with the kit. The 
contents were vortexed and pipetted up and down to 
thoroughly re-suspend the cells until homogeneous. The re-
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suspended cells were lysed by adding 200μl of the lysis 
solution, and the contents were immediately mixed by gentle 
inversion (6–8 times) until the mixture became clear and 
viscous. Subsequently, the neutralization/binding solution 
was added to the precipitate and the cell debris was pelleted 
by centrifuging at 17,000xg. for 10 minutes. Column 
preparation solution was then added to each mini-prep 
column and centrifuged at 17,000xg. for 1 minute. The lysate 
from the cells was added to a GenElute Miniprep Binding 
Column and centrifuged at 17,000xg. for 1 minute. After 
discarding the flow-through, a 750µl of wash solution was 
added to the column and centrifuged at 17,000xg. for 1 
minute. The flow-through was discarded and samples were 
centrifuged at maximum speed for 2 minutes. Finally, the 
plasmid DNA was eluted by adding 50µl of DNAase-RNAase 
free water to the column and centrifuged at 17,000xg. for 1 
minute. The quantity and purity of the eluted plasmid were 
checked by using NanoDrop ND-1000 Spectrophotometer. A 
ratio of 1.8 – 2.0 was considered an indication of relative 
purity. 
To confirm the presence of required mutations in N36 and 
N52 plasmids, 9 samples from each mutant plasmid DNA 
were sent to direct sequencing reaction. The T7 (forward) and 
BGH (Reverse) Vector primers were used for the sequencing. 
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The sequencing results were analysed using the Chromaslite 
software freely available at the web site 
http://www.technelysium.com.au/chromas_lite.html.  
 And Mega6 alignment soft ware also freely available at   
http://www.megasoftware.net/ 
HRM technique for identification of mutants: 
 
 
We also tried to detect the presence of mutant PCR products in 
our PCR reaction by using HRM (High Resolution Melting) that 
detects the presence of amplicons with different melting 
temperatures. As our mutant primers were not in 100% 
homology with the template they were expected to melt quicker 
than the parental DNA template similarly the hybrid products 
having one parental strand and one mutant strand will melt 
quicker compared to both wild type strands and hence giving 
different melting curves. 
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Figure 42:  Diagram indicating expected product sizes using T7 and BGH primers.  
 
 
 
 
Table 17 : HRM Reaction components. 
 
  
Components for HRM using  B7 and BGH primers 20 µl. 
 X1 X25 
Hot shot master mix.  10 250 
Template (mutant 
plasmids from mini 
preps). 
1 µl  to each  
T7 primer 250nM. 0.5 µl 12.5 
BGH primer 250nM. 0.5 µl 12.5 
Water. 6  150 
Lc green. 2 50 
  
T7 
  
CD24 
CD24 SITE   
BGH 
417bp 
247bp 170bp 
503bp 
72bp 
pcDNA3.1 
CD24 plasmid 
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HRM analysis: 
 
 
As HRM best detects the products that are between 300-500bp 
we decided to use T7pand BGH primers and the expected 
product size was 503bp Figure 42.  
The PCR reaction was in a final volume of 20 µl, which contained 
1xHotShot master mix, 1 primer pair with each primer at 250 
nM final concentration, 1x LC Green PLUS (Idaho Technology) 
and water to complete the total volume. The PCR products were 
transferred to Light Cycler capillaries (20 ml) (Roche).  
The products were melted in the HR-1 HRM instrument (Idaho 
Technology) at a rate of 0.38C/s, with a starting temperature 
of 68C, a final temperature of 98C and fluorescence data 
acquisition at 70-85C˚. The data had to be analysed using the 
HR-1 analysis tool custom software, and both derivative plots 
and difference plots would be generated after normalising and 
temperature shifting. The derivative and difference plots had to 
be visually inspected in order to separate out the mutants from 
the wild-type samples using a threshold of 4% difference in 
fluorescence. 
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Designing of new mutant primers using SDM assist software: 
 
 
As our primers were manually designed and did not give us the 
required mutants even on repeat PCR and sequencing.  We 
decided to redesign the primers using the specific software 
available for free to design the site directed mutagenesis 
primers. This software gave much precision and visual 
description of changes that are being introduced and allows the 
characteristics of the resultant primers to be automatically 
generated in a tabulated form (Figure 43). The features will 
be described in a bit detail under discussion section.  
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Figure 43: Screenshots of SDM-Assist while creating primers.  
(A)Dragging and dropping of glutamine  onto the Asparagine residues at position 36 leads 
to the formation of the target sequence and  Pressing the “Mutagenise” button opens a 
new window (B) that includes all possible nucleotide sequences derived from replacement 
of Asparagine to glutamine. The table highlights the mutated nucleotides in red and 
resulting palindromes which create a restriction site in green. (C)  The user has to choose 
one of the mutated sequences and presses the button “primerise” to get a list of potential 
primers and in our case we used #1 “CAA” mutation sequence to generate our primers 
and it gives list of possible primer sets with useful thermodynamic information  both for 
forward and reverse possible primer sets. 
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Results: 
 
The Mutant primers for CD24 N glycosylation site 36 and 52 
were designed manually as described above and were 
purchased from (Eurofins MWG-Biotech AG). They were 
subsequently diluted to a working concentration of 100pmol/μl. 
The primers were phosphorylated before use. 
And a temperature gradient PCR was run using a range of 
temperature 50C˚to 70C˚. 
 
  
Figure 44: N36 primer optimization. 
For N36 mutant primer set, in order to know the optimal 
annealing temperature, temperature gradient PCR (50C˚to 
70C˚) was performed and the products were run on the agarose 
gel. However, the gel electrophoresis showed the absence of 
any specific band in all the 11 Lanes and none of the tested 
annealing temperatures was able to produce a specific band of 
the correct size. Most lanes including NTC (last lane on the gel), 
instead showed a single band of approx. 100-150bp and most 
likely represented primer dimers (Figure 44).  
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As one of the reasons for no amplification can be wrong primer 
sequence, it was double checked for sequence homology with 
the template and only had one codon changed in the middle of 
the forward primer and the reverse primer was without any 
mutation. Also, primer concentration and extension 
temperature were all according to recommended settings. 
Another important reason for PCR failure is a suboptimal 
concentration of MgCl2 in the PCR reaction mix. To trouble shoot 
this possibility three additional concentrations of MgCl2 were 
tried including 2mm, 2.5mm and 3mm final concentration of 
MgCl2 in the temperature gradient PCR was set up but still with 
no amplification. Lastly, we also repeated the experiment was 
with Pfu polymerase by stratagene® but got no amplification 
Figure 44.  
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Figure 45: N36 primer optimization with added MgCl2. 
PCR optimization experiment was performed using three different concentrations of MgCl2 
(2mm, 2.5mm and 3mm) for N36 mutant primer. However, gel electrophoresis revealed that 
none of the concentrations could amplify the template at any temperature. Only primer dimers 
were observed including the NTC (no template control) lane. 
 
We decided to redesign our N-36 forward primer and in the 
redesigned primer six new complementary bases were included 
to improve the annealing of primers to the template. 
 
Figure 46: Temperature gradient for N36 Redesigned primer. 
Gel electrophoresis of PCR products from temperature gradient PCR using redesigned primer 
for N36 site showed specific single bands of the correct size for 6 of the tested temperature 
range (52˚C to 72 ˚C) and the annealing temperature of 63˚C was chosen for our next 
experiments. There was no amplification seen in NTC (no template control) lane. 
 
Chapter Five   N-Glycosylation. 
167 
 
The newly synthesized primers were tested for their optimal 
annealing temperature using a range of 52˚C to 72˚C in a 
gradient PCR reaction. The redesigned N36 primer product was 
run on agarose gel for electrophoresis and revealed discrete 
single bands at the required band size with 7 out of 12 
temperatures and with no band in NTC (no template control) 
lane thereby indicating no DNA contamination of PCR reaction 
(Figure 46).  
Similar to the first set we next aimed at sorting the optimal 
temperature for our N52 mutant primer pair using temperature 
gradient PCR and the recommended PCR settings as described 
in the materials and methods section. For this primer pair gel 
electrophoresis showed clean and specific bands at the 
expected band position in all of the temperatures tested (52˚C 
to 72˚C) but no band in negative control lane hence indicating 
no DNA contamination of reaction mix (Figure 47). 
 
Figure 47: N52 primer optimisation. 
Gel electrophoresis of PCR products from temperature gradient PCR using primer for the N52 
site. It showed specific single bands of the correct size for all of the tested temperature range       
(52˚C  to 72 ˚C) and the annealing temperature of 63˚C was chosen for our next experiments. 
There was no amplification seen in NTC (no template control) lane. 
 
 
In any PCR, too much or too little template can have a profound 
influence on the results. A reaction with too little template 
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typically produces weak or non-existent bands when the 
reaction is run on a gel. Too much template can suppress the 
PCR or result in the production of unwanted end products that 
may appear as smears on the gel. For most PCR-based 
applications, high-quality plasmid DNA is recommended to be 
used at a concentration of 1–10 ng. This was particularly 
important for these PCRs, as, these were aimed at mutagenesis 
and not just amplification of the template. 
 Hence, as the aim of these PCR reactions was not just an 
amplification of the product .This experiment actually aimed at 
making the mutant copies of the template using specific mutant 
primers so later we can remove the wild type Template DNA 
and use the mutant plasmids. It was important to know the 
optimal (minimal) amount of template DNA that would be 
sufficient to produce the mutant product as not only it would 
give better PCR product but also easier to clean out by DpnI 
enzyme digestion.  
To achieve that we decided to try different template plasmid 
concentrations for both N36 and N52 mutant primers and we 
also ran a positive control PCR using template plasmid and 
wildtype CD24 primers. We tried 1ng, 2ng, 500pg, 100pg and 
50pg of template plasmid concentrations and the products were 
ran on the agarose gel. For the mutant primer N36 best band 
was produced by the PCR having 1ng plasmid template and for 
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N52 mutant 2ng was the lane that showed brightest band 
(Figure 48/Figure 49). 
 
 
 
 
Gel electrophoresis of PCR products using varying concentration of template revealed that for 
the N36 template as low as 100pg gave a clean band but for N52 even 500pg gave a faint 
band. However, both of these mutant products gave a band of the same size as a wild type 
CD24 PCR positive control. Both NTC (no template control) lanes showed no product hence 
indicating the absence of contamination of PCR reaction mix. 
 
Our next step was to gel extract the mutant PCR product and 
the bands of the 1ng lane for N36 and the 2ng lane for N52 
mutant primer were excised under UV light for this purpose. 
The extracted PCR products were purified and then digested 
using DpnI enzyme. This enzyme selectively digests only the 
template DNA as it attacks the methylated sites. As only the 
DNA grown inside the bacteria (template plasmid) gets 
methylated whereas the fresh PCR products are non-
methylated the enzyme selectively digests these methylated 
DNA strands from parental template plasmid leaving in principle 
only the mutant PCR product. Appropriate controls were used 
at each experimental step as stated above. 
 
 
 
Figure 48: Template concentration optimisation. 
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Gel electrophoresis of PCR products using varying concentration of template revealed that for 
N36 template 2ng was too much and it gave a weaker band compared to sharp and bright 
seen in the 1ng lane. For N52 2ng gave the strongest band. Both NTC (no template control) 
lanes showed no product hence indicating the absence of contamination of PCR reaction mix. 
 
 
After the DpnI digestion, the mutant products were ligated 
using DNA-Ligase4 from Invitrogen® overnight. Finally, ligated 
products were transformed into NEB 5-alpha Competent E. coli 
(High Efficiency Cat# C2987P) for multiplication of the mutant 
plasmids produced. The procedure is described in detail above 
in the material and methods section.  
 
Following transformation combinations were performed  
Transformation outcomes for N36 mutant: 
 
1. Reaction mix without polymerase         Digested        Ligated          No colony. 
 
2. N36-Mutant PCR product                 Ligation alone               600 colonies. 
 
3. N36-Mutant PCR product       No ligation and No DpnI digestion        6 colonies. 
 
4. Cells alone without any PCR product            No colony. 
 
5. N36 -Mutant PCR product             Digested              Ligated            100 colonies.   
 
NT
 
N5
 
2ng 
N5
 
2ng 
N3
 
1ng 
N3
 
1ng 
NT
 
Figure 49: Template concentration optimisation. 
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Conclusions of transformation reactions: 
 
Transformation Reaction 1 was our negative control as only had 
template plasmid but no PCR product as no polymerase was 
added to the reaction and absence of colonies showed complete 
digestion of the template plasmid by DpnI enzyme. 
Transformation Reaction 2 was the control for the back ground 
as both the template and the mutant plasmid will be present in 
the reaction, being a  DpnI negative control it was expected to 
have 5-100 times more colonies compared to reaction 5. 
Transformation Reaction 3 was again as a control and showed 
back ground colonies produced by template plasmid. 
Transformation Reaction 4 Cells only was the control for 
contamination. As the agar media plates were made with 
ampicillin antibiotic, only the E.coli possessing Ampicillin 
resistance should be able to grow (E.coli transformed with 
plasmid vector because vector has ampicillin resistance gene). 
Transformation Reaction 5 was our expected mutant selecting 
setting as digestion was expected to remove all the template 
plasmid leaving a mutant product that was ligated for 
transformation and amplification inside E.coli. We selected 9 
clones from these for gene sequencing analysis of plasmids. 
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Transformation outcomes for N52 mutant: 
 
1. Reaction mixwithout polymerase             Digested              Ligated             No 
colony. 
 
2. N52-Mutant PCR product                 Ligation alone               200 colonies. 
 
3. N52-Mutant PCR product               No ligation and No DpnI digestion             No 
colony. 
 
4. Cells alone without any PCR product                 No colony. 
 
5. N52 -Mutant PCR product             Digested              Ligated             10 colonies. 
 
Conclusions: 
 
The N52 mutant transformations were analysed as well and in 
this case also, we got no growth in negative controls (Reactions 
1, 3 and 4), Transformation Reaction 2 was Ligation alone and 
hence was an indication of both template and mutant clones but 
gave fewer colonies compared to N-36 transformants. 
Transformation Reaction 5 we can only get 10 colonies this 
indicated a lower transformation efficiency compared to N-36. 
We selected 7 clones for further analysis by gene sequencing. 
Need for Gene Sequencing: 
 
Although as described above, prior to transformation in E. coli, 
digestion with DpnI (NEB, UK), an enzyme that degrades 
methylated DNA, was used to reduce the amount of wild type 
template. However, this digestion is often incomplete and 
traces of template result in recovery of wild type plasmids that 
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can only be distinguished from mutant DNA through 
sequencing. These transformants were selected using ampicillin 
selection and appropriate controls were used to help identify 
colonies with highest probabilities of mutant clones being 
present.  
Colonies were picked for each mutant primer and plasmids were 
extracted and quantified using mini-preps and nano drop as 
discussed above in materials and methods section. These were 
then sent for gene sequencing analysis using Universal priming 
sites present in our vector   i-e T 7p forward and BGH reverse, 
in order to ensure the presence of correct change at the 
intended site and absence of any non-specific mutations 
introduced during the mutagenesis process.  
Our wild type CD24 PCR product was a positive control. In order 
to analyse the effects of loss of specific N-glycosylation site 
(N36/ N52) and the resultant effects on the functionality of 
CD24 molecules, it was vital to analyse our mutant plasmids 
generated by site directed mutagenesis described above. 
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The clones fulfilling all of the three selection criteria mentioned 
below could only be used for next steps of the experimental 
plan.  
1) The presence of complete CD24 sequence in the mutant 
plasmid vectors. 
2) The presence of specific mutation i-e AACCAA for N-36 
mutant clone  and  presence of AATCAA at site 52 in 
the case of the N-52 mutant clone. 
3) The absence of undesired and non- specific mutation at 
any other site in the both mutant clones. 
 
More over gene sequencing will also help us in confirmation of 
the presence of CD24 gene in our wild type CD24 plasmid vector 
and absence of any mutations compared to the reference CD24 
sequence. 
As described above we used Chromas lite, Mega 6 alignment 
tool and BLAST 2 software from NCBI to analyse the gene 
sequencing results. It was observed that our wild type CD24 
plasmid had 100% homology with the CD24 reference gene 
from the NCBI library (cDNA clone MGC: 75043 IMAGE: 
5591617) and there were no gaps or mismatches present 
(Figure 50). The sequence of wild type CD24 also showed 
complete alignment with Reference CD24 sequence when 
analysed with Mega 6 alignment software (Figure 51). 
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Figure 50: BLAST 2 analyses of CD24 reference gene and WT CD24 clone 
The Chromaslite software was used to analyse the sequencing results of the CD24 pcDNA3.1 
plasmid using the T7 forward primer and BGH reverse primer. The results showed 100 % 
sequence similarity between the resultant sequences and CD24 coding sequence when aligned 
using the NCBI alignment tool. 
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Figure 51: Sequence alignment of CD24 reference gene and WT CD24.  
Mega6 alignment software was used to compare the sequence homology of our wild type CD24 
vector plasmid and CD24 reference gene from NCBI gene bank (Accession # BC064619.1).The 
analysis showed complete alignment. 
 
Sequence analysis of N36 mutant clones:    
 
As stated above the clones were examined to get a clone that 
fulfills all three criteria mentioned earlier in order enable us to 
study the distinctive outcomes of N-glycosylation site mutations 
at both of the sites respectively. 
The gene sequencing analysis of 9 clones for the N-36 site using 
Mega6 software revealed presence of CD24 gene sequence in 
the plasmids. Out of nine, 8 clones either had no mutation at 
the desired site or had undesired and nonspecific mutations. 
The required target mutation  i-e ACC-->CAA  at position 36 
was observed only in one clone i-e Clone 5,  however besides 
the presence of this specific mutation, there were extra 
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undesired mutations present along the sequence hence making 
it unfit for selection (Figure 52). 
Sequence analysis of N52 mutant clones: 
 
The Mega6 analysis  for N-52 mutant clones revealed a mixture 
of results. Few clones showing the fulfillment of two criteria i-e 
presence of CD24 gene in the plasmid vector,and absence of 
undesired mutations but unfortunately none of these clones had 
the required mutation at N-52 glycosylation site  (Figure 53). 
Three clones besides having no mutation at N-36 or N-52 site 
had missing ORF sequence of CD24 gene in them compared to 
the reference with some gaps (Figure 54). 
Hence, at this occasion, we could not select any clone for further 
experiments as none of these met the full criteria. 
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Figure 52: Mega6 alignment analysis of N-36 clones. 
Screen shot of alignment results using Mega 6 software for N-36 clones. These results were 
sequenced using a T7p primer. The clones were analysed for the presence of sequence 
homology to CD24 Reference sequence (row1).The N-glycosylation sites are marked in boxes. 
(A) analysis of the sequences  revealed misalignment and presence of unwanted changes 
instead of specifically required mutation. (B) Although the N-36 mutant primers were not 
expected to affect the N-52 site, sequencing showed disturbed sequence in all clones at the N-
52 site as well.  
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Figure 53: Mega6 analysis of N-52 Mutant clones. 
The gene sequencing analysis of 7 clones for N-52 , using Mega6 software, revealed presence 
of CD24 gene in the plasmid in all clones with no mutation at any site including the N-
glycosylation site  i-e AAC-->CAA  at position 36( site indicated in red box),this was the 
expected outcome of this primer set (A). 
However, all the clones also had exactly the same sequence compared to reference CD24 
including the N-glycosylation target mutation site i-e AAT-->CAA  at position 52( site indicated 
in the red box). And none of the clones showed the desired mutation that was expected to be 
generated by the mutant primers (B).  
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Figure 54: Screen shot of NCBI Blast2 of N-52 clone with CD24 ORF. 
The comparison shows (A) shorter sequence and presence of missing bases at position 77,78 
(encircled red). The remaining sequence had complete homology with the reference 
sequence.(B) Although the sequence showed 100% homology, only 95 bases from the ORF 
sequence  were present in the mutant plasmid.  
 
Results of HRM: 
 
No product was shown on HRM as the machine read MAX LED 
reached meaning 100% reading for LC green whereas it should 
actually decrease and should be ideally around 25%. No melting 
curve was generated by all samples. Products were also run on 
the agarose gel but no product was seen on the gel either, 
A 
B 
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indicating that the experiment didn’t work and needs 
optimisation. To overcome this the next possibility was to 
optimise the primers by repeating the PCRs using HF phusion 
enzyme (high fidelity) and temperature gradient. 
Unfortunately, because of personal health and family issues, the 
study got interrupted at that point and this could not be tried. 
SDM assist software designed primers: 
On resumption of the study we tried once more the PCRs and 
sequencing but still failed to get the required clones. On 
reanalysis of all potential reasons of failure one possibility 
turned up as our primers were manually designed and were 
back to back with each other, based on Inverse PCR principle 
thereby generating blunt ends which were ligated later as 
directed by Phusion protocol. Although our PCR worked with our 
manually designed primers and HF Phusion polymerase and 
products appear specific and gave transformation results that 
seemed promising but the gene sequencing analysis revealed 
the failure of specific mutagenesis and resulted in a mixture of 
random and undesired mutations. 
Hence, we next decided to try re-designing our primers, using 
software SDM-assist and the resultant primers are shown in 
Table 13  as mentioned above. 
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Discussion: 
 
This study aimed at mutating N-glycosylation sites present in 
CD24 molecule using site directed mutagenesis and to our 
knowledge will be the first study of its type. 
Site-directed mutagenesis is a valuable tool for introducing 
specific nucleotide mutations based on PCR. The identification 
and construction of new commercial polymerases and advances 
in oligonucleotide synthesis have dramatically increased its 
efficiency. Primers designed with mutations can introduce small 
sequence changes. This process has dramatically improved the 
speed and reduced the cost of mutagenesis experiments. 
Mutagenesis provides a useful method to study explicitly 
functions of different residues or glycans in proteins. This is not 
straightforward if we use the traditional methods such as 
chemical or enzymic modification or addition of glycosylation 
inhibitors (151).  
Many commercial kits are available for this purpose with few 
differences and most widely used ones are Quick ChangeTM by 
Stratagene and it uses overlapping mutant primers to introduce 
the change in the plasmid-based gene sequence.  
In this type of site-directed mutagenesis uses PCR primers 
designed to contain the desired change in the middle of the 
sequence .The PCR primer sequence simply replaces the 
original sequence. We used Phusion site directed mutated kit 
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that is another widely available tool using High fidelity 
polymerase II. 
It requires back to back primer set with one or both of the 
primers having the mutation at the centre of the 
oligonucleotide. Inverse PCR is used for mutating plasmids. 
These back-to-back primers amplify the whole plasmid and the 
linear product is then ligated back to the circular form.  
One potential reason for getting unwanted mutations could be 
the higher number of cycles  although  the estimated 
percentage of PCR products having an unwanted secondary 
mutation after 25 PCR cycles is only 5.5%(152). 
Despite the common view that DpnI digestion is adequate to 
exclude the wild type plasmid DNA, a detailed  study by Karnik 
et al. revealed that a rescue of 20-30% of un-mutated, wildtype 
plasmids after DpnI digest was inevitable and this could be one 
reason of getting the wild type clones in our N-52 primer set 
(150). 
Another possible reasoning was given for the failure of site 
directed mutagenesis efficiency is primer impurity and a 
comparative study by Acevedo et al.  showed that this played a 
critical role, with HPLC libraries enabling significantly higher 
yield on average than the ones, not HPLC purified but cleaned  
by conventional methods. However, the same study also 
showed that High fidelity Phusion hotstart II enzyme, that was 
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used in the current study, had the best outcome amongst the  
conventionally purified primers(153).  
While PCR for substitutions is a way to introduce a mutation, it 
is restricted by the fact that the mutation can only be introduced 
in the sequence covered by the primers rather than the 
sequence that is present between the primers. 
The guidelines given by Phusion site directed mutagenesis kit 
protocol for designing the primers were as follows:  
For generating point mutations, there can be either one 
mismatch/mutagenic primer or both forward and reverse may 
have the mutation. The length of the correctly matched 
sequence in the mutagenic primers should be in average 24−30 
nucleotides. The desired mutation should be in the middle of 
the primer with 10−15 perfectly matched nucleotides on each 
side. Complementarity between the primers should be avoided 
to prevent primer-dimer formation.  Similarly inverted repeats 
(self-complementarity) should be avoided.  The CG-content of 
the primer should be around 50%.And G's and C's at the 3'-end 
of the primers should be avoided(152). 
Although we tried to follow as much of the above as possible, 
however, meeting the criteria of avoiding G’s and C’s near ends 
wasn’t possible and the overall G C-content was around 47% in 
our manual primers. Trying to overcome these limitations 
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manually was cumbersome and time consuming hence, we 
decided to use a very helpful tool for redesigning our primers. 
SDM- ASSISST SOFTWARE: 
The SDM assist software provides an optimised strategy using 
partially overlapping primer pair which increases the likelihood 
of primer-template annealing over primer self-annealing. 
Although there are separate helpful web-based soft wares 
available both to design primers, SDM assist is unique as it 
allows the user to create all possible combinations of sequences 
encompassing the desired mutations. 
 The sequences can then be narrowed down to a single 
sequence that is used as the source for the downstream primer 
design. At the same time the program lists all physical 
properties of the DNA sequence that are relevant for optimal 
primer design such as melting temperature, the number of 
nucleotides exchanged, GC content and more. This feature 
alleviates the need to use a separate programme to choose the 
best option from the available primer combinations (154). 
The plug-in also provides the plasticity of specifying just the 
amino acid required for mutation. Since the genetic code allows 
some level of redundancy (e.g. serine can be represented by 
six different codons), the program displays all possible 
candidate sequences. 
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Once the DNA sequence is pasted it automatically gets 
translated into an amino acid sequence including a ruler for 
easier identification of target sites. Simple drag and drop 
feature permits selection of amino acid to be replaced with 
required one. In addition, right-click on any amino acid shifts 
through the different codons of that specific amino acid. This 
option provides the control to select specific codon to represent 
the amino acid. 
 Keeping the fact that SDM primers are long, it is vital to have 
the best possible thermodynamic characteristics (such as GC 
content, melting temperature etc.) to warrant that they would 
work successfully in an SDM reaction. And above mentioned 
features of SDM assist tool encouraged us to use it and the 
primers were designed and selected in very short span with 
promising success based on the selected feature and previous 
experimental studies(150). 
In brief new primers were successfully re-designed and these 
were partially overlapping primers (proposed to be better than 
both fully complementary primers and back to back primers in 
a recent study). They were shown to be compatible with 
Phusion site directed mutagenesis kit , but with an additional 
advantage of avoiding the requirement of Phosphorylation of 
primers and ligation step before transformation(150). 
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However because of time limitations, the project was handed 
over to the next Ph.D. candidate who have successfully 
obtained the mutant clones by using these SDM primers. And 
have found very interesting and significant outcomes by 
mutation of each of the N-glycosylation site, showing effects 
both on signalling and functional characteristics of the CD24 
molecule as hypothesised by this project. 
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General discussion: 
 
The yet unsolved mysteries of cancer pathogenesis, 
development and progression stand in the way of finding its 
cure. Intensive research is being carried out to uncover and 
hence target, the abnormal molecular mechanisms operating 
within the malignant cellular machinery. This molecular 
targeting approach appears promising as seen in some 
haematological and solid malignancies. 
CD24 molecule has relatively newer emergence on the scientific 
horizon. As an attribute to its significance, one finds this 
molecule in association with a diverse range of human 
pathologies including a growing list of cancers. 
CD24 also called Heat stable antigen was first discovered by 
springer et al. in 1978 in mice (155). Later  human CD24 was 
cloned in 1990 by Kay R et al. (6). The location of CD24 gene  
is agreed to be on chromosome 6q21 (156) and  exhibits an 
allelic polymorphism (Val to Ala exchange) (9). The CD24 
protein is encoded by a 243 base pair coding sequence and the 
mature peptide is just 27-31 amino acids (5, 6).  
In normal adult human tissues, CD24 is expressed on B cells, T 
cells, neutrophils, eosinophils, dendritic cells and macrophages. 
It is also seen on the epithelial cells, keratinocyte, muscle cells, 
pancreas, developing brain and stem cells (7).  
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In general, CD24 exhibits a higher expression on the progenitor 
cells and metabolically active cells with a gradual reduction in 
expression as the cell differentiates. It is not usually expressed 
on the adult human tissues. However, abnormal CD24 
overexpression has been documented in a large variety of 
human cancers including squamous cell carcinoma, breast 
carcinoma, colorectal carcinoma, renal cell carcinoma, bladder 
carcinoma, ovarian carcinoma, gliomas, non-small-cell lung 
cancer, prostate cancer and primary neuroendocrine 
carcinomas (7, 9, 13, 32, 36, 88, 157). Similarly, CD24 
polymorphisms are documented to be associated with the risk 
and  progression of autoimmune diseases, including multiple 
sclerosis, rheumatoid arthritis and systemic lupus 
erythematosus (SLE)(158). Ahmed et al. found  CD24 
upregulation in regenerative mucosa of both ulcerative colitis 
(UC) and Crohn’s Disease (CD)(26). These observations 
indicate its role in immune regulation as well as cancer 
pathogenesis. 
 Moreover, CD24 was recently demonstrated to be associated 
with a variety of Danger-associated molecular patterns 
(DAMPs). These DAMPs are intracellular components such as 
HMGB1, HSP70, HSP90 and cellular RNA etc., released during 
cellular injury and are found to interact with the Toll like 
receptors (TLRs). However it’s already known that the 
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Pathogen-associated molecular patterns (PAMPs) also interact 
with Toll-like receptors (TLRs) on innate immune cells to initiate 
protective immune responses. Whether the host is able to 
discriminate between DAMPs and PAMPs was not clear (41). 
Chen et al   found CD24 to interact with a variety of DAMPs, 
such as high mobility group box protein1, heat-shock proteins 
and nucleolins, they also observed CD24’s interaction with 
SiglecG (mouse)/ Siglec10 (human). They found that DAMPs 
interact with TLRs, CD24 and Siglecs leading to selective 
repression of the host immune response. Since the pathway 
does not affect the host response to pathogen-associated 
molecular patterns(PAMPs), they proposed that the CD24–
Siglec G pathway discriminates DAMPs from PAMPs (21, 
41).This pathway was also thought to contribute to the cancer 
immune escape hypothesis (158). 
 Considering these interactions of CD24 with DAMPs and taking 
into account that majority of tumours including colorectal 
carcinoma show considerable tissue necrosis and hence the 
release of DAMPs in the tumour microenvironment, we were 
intrigued to explore if CD24 also modulate tissue response to 
DAMPs in the setting of cancers. We tested our query by 
performing functional assays on the colorectal carcinoma cells 
after exposure to DAMPs in CD24 positive and negative cell 
lines. 
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Four colorectal cancer cell lines including SW620 and DLD1 
(+ve for CD24 expression) and HCT116 and RKO (-ve for CD24) 
were exposed to autologous necrotic cell lysates (DAMPs). The 
results of wound healing assay showed significant inhibition of 
colorectal cell migration by DAMPs but this was independent of 
CD24 status. Furthermore our trans-well assays also displayed 
reduced trans-well migration in majority of the cell lines 
independent of CD24 status after exposure to necrotic cell 
lysates. These results were supported by the knockdown and 
forced expression experiments as well. 
We also explored effects of DAMPs on cellular proliferation using 
autologous DAMPs in three colorectal cancer cell lines. Our 
results indicated a significant increase in cellular proliferation 
when exposed to DAMPs, irrespective of the CD24 status of the 
cell line. At an attempt to find the possible mechanism of 
inhibition of motility by DAMPs we exposed cells to DAMPs and 
these cells were analysed for the status of cellular motility 
mediators by western blots. We found down-regulation of 
molecules associated with increased motility including Cten, N-
cadherin and Snail in cells exposed to DAMPs. 
We suggested thereby that in epithelial cells, CD24 does not 
appear to modulate cellular response to DAMPs. However, 
DAMPs does show effects on epithelial cell migration and 
proliferation. We reasoned that in contrast  to the experiments 
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on immune cells (41)  we were trying to explore the  epithelial 
cells(colorectal carcinoma cell lines) which may have quite a 
different glycosylation compared to immune cells and may be a 
reason for  different interactions and signalling outcomes in 
different tissues. It may also be possible that epithelial CD24 
does not interact with DAMPs and the results of Chen et al. may 
be specific to immune cells. And the reason for this lack of 
modulation could be due to the absence of  Siglecs on epithelial 
cells that is the third prerequisite in the model presented by 
Chen et al. (88). 
Although many new aspects of CD24 biology have emerged 
since its discovery, it is still uncertain how it mediates its effects 
without a transmembrane domain and much less is known 
about its exact signalling partners. Aberrant activation of Wnt 
signalling pathway is very well known and is found  in almost 
80% of colorectal carcinomas(52, 159). 
The presence of TCF/LEF consensus sequences in promoter 
region  of CD24 suggests that it is target gene of Wnt signalling 
pathway  and a recent study by Ahmed et al. have shown the 
direct relationship between β-catenin and CD24 confirming 
thereby , CD24 as a target of Wnt signalling in colon (26).This 
association of CD24 and β-catenin has also being reported in 
hepatocellular carcinoma by Yang et al. (62). 
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Bauman et al.  showed that  CD24 ectopic expression in breast 
cancer cells resulted in increased proliferation rates and the 
activation of the a3β1 and a4β1 integrins, which induced binding 
to selectins, collagen, and laminin  thus increasing cell 
migration(33). 
Runz et al. showed that although  no β1 integrin localizes to 
lipid raft domains in CD24-negative cells, transfection of CD24 
induced the recruitment of  β1 integrin into these, cholesterol 
and sphingolipid-enriched, membrane domains. Moreover, they 
also showed that these CD24-transfectants increased both the 
invasiveness into a cushion of mixed collagens as well as the 
transmigration through a monolayer of endothelial cells (83). In 
another study by the same group, it was observed that in CD24-
positive cells, CXCR4 lost its association with lipid rafts, 
necessary for effective binding to its ligand SDF-1. This, in turn, 
resulted in a subsequent inhibition of downstream signalling, 
cell migration and invasion. Conclusively CD24 restricted the 
lipid raft localization of CXCR4 (23). Given that CD24 is a major 
GPI-anchored and lipid rafts associated protein in many cell 
types, it might , therefore, act as a general ‘‘gate-keeper’’ to 
lipid rafts. In an attempt to further explore the downstream 
targets of CD24, Baumann et al. in a very recent study found 
that CD24 interacts with and augments the kinase activity of c-
src, this happens within and was dependent upon intact lipid 
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rafts. CD24-augmented c-src kinase activity led to increased  
formation of focal adhesion complexes, accelerated 
phosphorylation of FAK and paxillin and consequently enhanced 
integrin-mediated adhesion(33). 
Another molecule that increases cellular characteristics quite 
similar to CD24 is Cten, also known as Tensin4. Recent research 
has shown Cten to bind with β integrin’s cytoplasmic tail and 
to be present within the focal adhesions. Cten is also 
demonstrated to be modulating proteins containing 
phosphorylated tyrosine residues like Focal adhesion Kinase 
(FAK), ILK, p130Cas and P13 kinase(99). We hypothesized 
that CD24 is signalling through Cten. We tested the hypothesis 
by performing forced expression and knock down experiments 
and also by carrying out co transfections. The results 
supported our hypothesis as Cten levels followed CD24 
expression levels and CD24 mediated cell motility was 
abrogated by knockdown of Cten. Our group has previously 
shown Cten to be mediating increased motility via ILK and we 
found that FAK and ILK were common downstream targets of 
both molecules as knock down of FAK or ILK both annihilated 
the effects of CD24 on motility. We observed there was no 
remarkable change in the protein levels of FAK by the change 
in CD24 levels, however, we did find that Cten affects FAK 
protein expression. Recent research has already shown an  
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increase in ILk levels by Cten (99) and that CD24 increases 
phosphorylation of FAK (33). Taken all these bits together, 
CD24 appears to increase cellular motility by recruiting β-
integrins to lipid rafts, increasing c-src phosphorylation and 
activation. This in turn leads to increased Cten levels and 
activation. The Cten increases protein kinases such as ILK and 
FAK and increases their activation via its SH2 (Src homology 
domain) and PTB (Phospho-tyrosine binding domain) domain, 
resulting in epithelial to mesenchymal transition and hence 
increased cellular motility as also shown by our group (98). 
The molecular weight of CD24 ranges from 30 to 70 kDa (5), 
most of its weight is due to extensive N- and O-linked 
glycosylation, as it has 16 potential O- and N-glycosylation 
sites. The extensive glycosylation renders to CD24  similarity to 
a mucin(7). Many studies have shown that glycosylation 
patterns vary widely between the tissues and these have been  
proposed as a factor responsible for the broad spectrum of roles 
linked to CD24 (160). There is evidence that fucosylated 
glycans present on CD24 enable CD24 to interact with P-
selectins on endothelial cell and platelet surfaces and help in 
cancer cell metastasis (12, 160). Similarly, in neuronal tissue, 
the interaction between L1 and CD24 depends on α2,3-sialic 
acid present on CD24, and this interaction  determines the cell 
type-specific promotion or inhibition of neurite outgrowth(18). 
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TAG-1 and Contactin (lectin-like molecules present in lipid rafts) 
were also found to interact with CD24 in cerebellar and dorsal 
root ganglion (DRG) neurons through Lewis x glycan present on 
CD24 (17).  
Another very recent evidence signifying role of sugars is the 
amelioration of sepsis by inhibition of bacterial sialidases. These 
bacterial sialidases result in the annihilation of interaction 
between CD24-siglec-DAMP complex and destroy the negative 
feedback mechanism for the release of interleukins and 
cytokines leading to sepsis (66). Moreover increasing research 
have proposed a role of N-glycans in cancers (161). 
The current study aimed at exploring the glycosylation aspect 
of CD24. We reasoned that being a heavily glycosylated 
molecule CD24 may also mediate its functions through its 
sugars as indicated by the studies above. Analysis of current 
information regarding the process of protein glycosylation and 
CD24 amino acid structure revealed two potential N-
glycosylation sites to be present in the CD24 molecule but 
multiple O-glycosylation sites. We decided to remove the sugars 
from these N-glycosylation sites by mutating the amino acid 
sequence required for the N-glycosylation to occur. Our aim was 
to construct mutant CD24 plasmids with both N-glycosylation 
sites mutated, individually as well as simultaneously. These 
mutant plasmids were then to be transfected in cancer cell lines 
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and analysed for their effects by performing relevant functional 
studies compared to the wild type CD24 plasmid. To achieve 
that, we selected Site-directed mutagenesis technique. Site-
directed mutagenesis (SDM) has proven itself as a quick reliable 
and relatively cheaper method to generate such point mutations 
and hence quite helpful to probe the function-structure 
relationship of proteins. There are other approaches available 
to remove the sugars from the molecules i-e using digestive 
enzymes that cleave off sugars or blocking the synthesis of 
these sugars by knocking down fucosyl-transferases. However 
for the current study, mutagenesis technique was preferred 
because it would allow us to mutate a particular N-glycosylation 
site using PCR and the resultant absence of N-sugar from that 
specific site only. This is not the case in enzymatic de-
glycosylation as that would remove N-sugars from all N-sugar 
sites. Similarly the knock down of fucosyl transferases will block 
synthesis of these glycans non-specifically. Once the clone with 
the desired mutation is obtained and verified via sequencing, 
these plasmids can be used easily in further experiments.  
Although our SDM technique didn’t work successfully in this 
attempt but the repeated attempt by the next Ph.D member 
was successful and is yielding interesting data that will help in 
our understanding of this molecule. 
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Conclusions: 
In summary the study aimed at investigating three aspects of 
CD24 biology including modulation effects of DAMPs response, 
signalling partners and structural significance of CD24. From 
our set of experiments we hereby conclude. 
 Autologous DAMPs have inhibitory effects on colorectal 
cancer cell lines and both directional and non-directional 
motility is inhibited as appreciated by transwell and 
wound healing assay. This inhibition appears to be 
independent of CD24 status and seems to be mediated by 
downregulation of molecules associated with increased 
motility including Cten, N-cadherin, and Snail. 
 As opposed motility, investigations involving three 
different colorectal cancer cell lines indicated an increase 
in cellular proliferation when exposed to autologous 
DAMPs and this effect was even more pronounced after 
48 hours of exposure. However, once again this appeared 
independent of CD24.  
 The study found CD24 to be having a direct regulatory 
effect on Cten protein levels and CD24 appears upstream 
of Cten. It was also observed that Cten, FAK, and ILK are 
indispensable for CD24 mediated increase of cell motility.  
 The last part of the study was aimed at mutating N-
glycosylation sites present in CD24 in order to see its 
Chapter Six  General Discussion. 
200 
 
functional and signalling impact on CD24 biology. We 
employed site-directed mutagenesis technique and 
although the attempt was not successful this time but still 
provides a valuable approach to explore the yet unclear 
mechanism of the functionality of this molecule. 
Potential strengths: 
 This was the first study exploring CD24 and DAMPs 
interaction in autologous colorectal cancer cells (epithelial 
cells). And it also explored if dead cancer cells could signal 
remaining alive cells directly. 
 Most experiments were carried out at least in three cell 
lines to avoid cell line specific effects in addition dual 
approach of knockdown and forced expression was also 
used to validate findings. 
 A dual approach of knockdown and ectopic expression 
was employed for studying the signalling relationships of 
CD24 supported by co-transfections. 
  This study has found the regulatory effect of CD24 on 
Cten levels and shown it to be functionally relevant as 
well. 
Study limitations: 
 Western blots were used in our study to compare and 
quantitate protein levels. Proteins have documented 
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molecular weights and appear as discrete single bands on 
the western blots. These bands are identified against a 
colour coded protein ladder with known molecular weights 
used as a marker. However, in case of CD24 the protein 
is heavily glycosylated with a variety of sugars attached 
to small amino acid backbone and produced a smear 
instead of a discrete band on the western blots with a size 
range from 37-75kDa.  
 Equal protein loading of all wells is vital in order to make 
sure that the differences appearing in different bands are 
actual dissimilarities of expression levels and not merely 
a result of unequal protein sample being used. One 
solution to that is to compare the lanes for a protein that 
is ubiquitously expressed by the cells and not affected by 
the experimental conditions.  β- actin protein (molecular 
weight 42kDa) is a common example used as loading 
control, as β-actin is ubiquitously expressed by all cell 
lines, is quite stable under most experimental conditions 
and expressed in high amounts. We also used β -actin as 
our loading control in our initial set of experiments (Figure 
15) we had to use parallel lanes on the same gel to detect 
β –actin because of overlapping molecular weight of CD24 
and β-actin. However, we acknowledge that this is not a 
true reflection of loading control. The issue was sorted in 
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the next set of experiments, where comparative 
quantification was needed, by stripping and re-probing 
technique. Whereby after detection of CD24 protein, the 
SWA11 antibody was stripped off and the membranes 
were re-blotted with β -actin antibody hence reflecting 
protein loading of the same wells. Another approach could 
be using Histone3 (molecular weight 19kDa) as loading 
control as oppose to b-actin which will allow cutting of 
membrane and simultaneous blotting of both CD24 and 
H3 instead of stripping and re-blotting. 
 The results of the DAMPs study will become more 
convincing if the effects on motility and proliferation by 
DAMPs (Necrotic cell lysates) could be reproduced by 
using purified DAMPs such as HMGB1. And if the reversal 
of effects could be shown by the addition of HMGB1 
blocking antibody. 
  Moreover, performing the experiments in a macrophage 
– epithelial coculture will be interesting to further clarify 
if the presence of Siglecs on macrophages will affect the 
response modulation of DAMPs by CD24. As it might be 
the case of completing the triad of CD24-Siglec-DAMPs 
to modulate cellular characteristics, as seen in immune 
cells. 
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 These experiments were performed in vitro and on cancer 
cell lines and this bear limitation of being not a true 
representation of in vivo conditions. 
 
 Due to personal health and family constraints, 
experiments exploring the mechanism of increased Cten 
protein levels by CD24 could not be repeated. So was the 
case with re-trial of mutating N-glycosylation 
experiments. 
Future Suggestions and Recommendations: 
 
 As mentioned earlier, it will be interesting to expand the 
DAMPs project to include co-culture technique with 
immune cells as actual tumour microenvironment 
consists of immune cells, necrotic cells mesenchymal and 
epithelial cells with potential effects on each other. 
Extending these experiments to animal models will be 
further helpful in validating study results. 
 Being heavily and differentially glycosylated, there is 
quite a possibility that CD24 performs so diverse 
functions albeit absence of a transmembrane domain, via 
these sugar moieties. Hence mutating its glycosylation 
sites is a very novel model. As it will indicate the specific 
effect and significance of each site. We started off with N-
glycosylation sites as there are only two potential sites for 
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N-glycosylation and more than16 O-glycosylation sites. 
The next Ph.D. student who took over this project has 
already found some interesting effects of mutating of both 
N-glycosylation sites individually. This can further be 
extended by creating a mutant having both mutations in 
one plasmid and also extending these to O-glycosylation 
sites. This study will provide novel information that has 
not yet attempted by any other group to our knowledge. 
 Another very interesting aspect of CD24 biology is its 
presence in lipid rafts. These lipid rafts are specialised 
areas of cell membrane highly enriched in cholesterol and 
sphingolipids. These detergent resistant membrane areas 
have been further characterised into different domains 
associated with signalling pathways, endocytosis and 
increasingly associated to be involved in multiple 
important cellular characteristics in recent literature. It 
has already being seen that CD24 mediates some of its 
functions by regulating trafficking of molecules in and out 
of these lipid rafts. However, the exact location of CD24 
and mechanism of this traffic regulation by CD24 is still 
unknown. We propose CD24 is present in Reggie 
microdomains that are independent of caveolin and 
dynamin domains and are identified by flotillin 2 proteins. 
This hypothesis is based on the studies in drosophila 
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indicating Reggie domains to be associated with Wnt 
signalling. Furthermore, in prostate cancer cells, that 
were caveolin1 and PTEN negative , lipid rafts  mediated 
effects through AKT and STAT3 and both of these 
molecules are linked to CD24 hence again pointing 
towards the possibility of CD24 being present in these 
domains. This could be explored further and will be an 
addition to the further understanding of CD24 biology. 
Study hypothesis: 
CD24 is present in Reggie microdomains (a subtype of 
lipid rafts) and flotillin 2 is involved in its signal 
transduction across the membrane. 
Possible Work plan for lipid rafts project: 
 
 Using Immunofluorescence for flottilin, caveolin and 
CD24 to see if they co- localize,  
 Co-immune-precipitation for CD24, caveolin, Flottilin2 
and CD24. 
 Investigate effects of blocking flotillin 2 / caveolin on 
CD24 localization, amount and its downstream targets 
(Cten/ FAK/Ilk/c-src/Snail). 
 Blocking Fllotilin-2 by antibodies in both CD24 positive 
and negative lines and performing functional assays and 
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to see if results are reversible by reversing F2 blockade 
will be interesting. 
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Appendix:  
 
Appendix i.             Brief Intro to CD24. 
CD24 antigen (small cell lung carcinoma cluster 4 antigen)  
CD24 molecule Synonyms : CD24A ; FLJ22950 ; FLJ43543 ; MGC75043 ; 
CD24 antigen;  
Locus ID: 100133941 Cytogenetic: 6q21    
RefSeq: BC064619.1, AAH64619 
RefSeq Size: 2180  
RefSeq ORF: 243 
[RefSeq, Jul 2008]. 
CD24 ORF sequence:  
NCBI RefSeq Nucleic | NM_013230 | XM_001725629 | Homo sapiens CD24 molecule 
(CD24), mRNA 
Appendix ii. CD24 (BC064619) Human cDNA. 
 
Clonehttp://www.origene.com/human_cdna/BC064619/SC126016.aspx 
 
CCCGGAGCCAGCGGTTCTCCAAGCACCCAGCATCCTGCTAGACGCGCCGCGCACCGACGG 
AGGGGACATGGGCAGAGCAATGGTGGCCAGGCTCGGGCTGGGGCTGCTGCTGCTGGCACT 
GCTCCTACCCACGCAGATTTATTCCAGTGAAACAACAACTGGAACTTCAAGTAACTCCTC 
CCAGAGTACTTCCAACTCTGGGTTGGCCCCAAATCCAACTAATGCCACCACCAAGGCGGC 
TGGTGGTGCCCTGCAGTCAACAGCCAGTCTCTTCGTGGTCTCACTCTCTCTTCTGCATCT 
CTACTCTTAAGAGACTCAGGCCAAGAAACGTCTTCTAAATTTCCCCATCTTCTAAACCCA 
ATCCAAATGGCGTCTGGAAGTCCAATGTGGCAAGGAAAAACAGGTCTTCATCGAATCTAC 
TAATTCCACACCTTTTATTGACACAGAAAATGTTGAGAATCCCAAATTTGATTGATTTGA 
AGAACATGTGAGAGGTTTGACTAGATGATGGATGCCAATATTAAATCTGCTGGAGTTTCA 
TGTACAAGATGAAGGAGAGGCAACATCCAAAATAGTTAAGACATGATTTCCTTGAATGTG 
GCTTGAGAAATATGGACACTTAATACTACCTTGAAAATAAGAATAGAAATAAAGGATGGG 
ATTGTGGAATGGAGATTCAGTTTTCATTTGGTTCATTAATTCTATAAGGCCATAAAACAG 
GTAATATAAAAAGCTTCCATGATTCTATTTATATGTACATGAGAAGGAACTTCCAGGTGT 
TACTGTAATTCCTCAACGTATTGTTTCGACAGCACTAATTTAATGCCGATATACTCTAGA 
TGAAGTTTTACATTGTTGAGCTATTGCTGTTCTCTTGGGAACTGAACTCACTTTCCTCCT 
GAGGCTTTGGATTTGACATTGCATTTGACCTTTTATGTAGTAATTGACATGTGCCAGGGC 
AATGATGAATGAGAATCTACCCCCAGATCCAAGCATCCTGAGCAACTCTTGATTATCCAT 
ATTGAGTCAAATGGTAGGCATTTCCTATCACCTGTTTCCATTCAACAAGAGCACTACATT 
CATTTAGCTAAACGGATTCCAAAGAGTAGAATTGCATTGACCGCGACTAATTTCAAAATG 
CTTTTTATTATTATTATTTTTTAGACAGTCTCACTTTGTCGCCCAGGCCGGAGTGCAGTG 
GTGCGATCTCAGATCAGTGTACCATTTGCCTCCCGGGCTCAAGCGATTCTCCTGCCTCAG 
CCTCCCAAGTAGCTGGGATTACAGGCACCTGCCACCATGCCCGGCTAATTTTTGTAATTT 
TAGTAGAGACAGGGTTTCACCATGTTGCCCAGGCTGGTTTCGAACTCCTGACCTCAGGTG 
ATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCTTGAGCCCCCGCGCCCAGC 
CATCAAAATGCTTTTTATTTCTGCATATGTTGAATACTTTTTACAATTTAAAAAAATGAT 
CTGTTTTGAAGGCAAAATTGCAAATCTTGAAATTAAGAAGGCAAAAATGTAAAGGAGTCA 
AAACTATAAATCAAGTATTTGGGAAGTGAAGACGAAGCTAATTTGCATTAAATTCACAAA 
CTTTTATACTCTTTCTGTATATACATTTTTTTTCTTTAAAAAACAACTATGGATCAGAAT 
AGCCACATTTGGAACACTTTTTGTTATCAGTCAATATTTTTAGATAGTTAGAACCTGGTC 
CTAAGCCTAAAAGTGGGCTTGATTCTGCAGTAAATCTTTTACAACTGCCTCGACACACAT 
AAACCTTTTTAAAAATAGACACTCCCCGAAGTCTTTTGTTCGCATGGTCACACACTGATG 
CTTAGATGTTCCAGTAATCTAATATGGCCACAGTAGTCTTGATGACCAAAGTCCTTTTTT 
TCCATCTTTAGAAAACTACATGGGAACAAACAGATCGAACAGTTTTGAAGCTACTGTGTG 
TGTGAATGAACACTCTTTTGCTTTATTCCAGAATGCTGTACATCTATTTTGGATTGTATA 
TTGTGTTTGTGTATTTACGCTTTGATTCATAGTAACTTCTTATGGAATTGATTTGCATTG 
AACACAAACTGTAAATAAAAAGAAATGGCTGAAAGAGCAAAAAAAAAAAAAAAAAAAAAA 
AAAAAAAAAAAAAAAAAAAA 
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Appendix iii. CD24 expression levels in colorectal carcinoma cell lines 
(Data from work done by previous PhD student on CD24). 
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Appendix iv. BCA protein assay Kit standard preparation guidelines. 
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Appendix v. BCA microplate procedure for protein quantification. 
 
Appendix vi. BCA standard curve for protein quantification. 
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Appendix vii. SDS Polyacrylamide gel recipe. 
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Appendix viii. pcDNA3.1D/V5-His-TOPO vector map: 
 
 
 
 
Appendix ix. Vector Map of His Topo Cloning vector 3.1. 
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Appendix x. SOC media Recipe. 
 
 
 
 
 
 
 
 
